U.S. patent application number 12/760638 was filed with the patent office on 2010-08-12 for hiv integrase inhibitors.
Invention is credited to Richard C.A. Isaacs, Linda S. Payne, Joseph P. Vacca.
Application Number | 20100204201 12/760638 |
Document ID | / |
Family ID | 37397115 |
Filed Date | 2010-08-12 |
United States Patent
Application |
20100204201 |
Kind Code |
A1 |
Vacca; Joseph P. ; et
al. |
August 12, 2010 |
HIV INTEGRASE INHIBITORS
Abstract
Tricyclic compounds of Formula I are inhibitors of HIV integrase
and inhibitors of HIV replication: ##STR00001## wherein bond a,
ring A, R.sup.1, R.sup.2 and R.sup.3 are defined herein. The
compounds are useful for the prophylaxis or treatment of infection
by HIV and the prophylaxis, treatment, or delay in the onset of
AIDS. The compounds are employed against HIV infection and AIDS as
compounds per se or in the form of pharmaceutically acceptable
salts. The compounds and their salts can be employed as ingredients
in pharmaceutical compositions, optionally in combination with
other antivirals, immunomodulators, antibiotics or vaccines.
Inventors: |
Vacca; Joseph P.; (Telford,
PA) ; Payne; Linda S.; (Lansdale, PA) ;
Isaacs; Richard C.A.; (Harleysville, PA) |
Correspondence
Address: |
MERCK
P O BOX 2000
RAHWAY
NJ
07065-0907
US
|
Family ID: |
37397115 |
Appl. No.: |
12/760638 |
Filed: |
April 15, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11920032 |
Nov 7, 2007 |
7741315 |
|
|
PCT/US2006/017369 |
May 5, 2006 |
|
|
|
12760638 |
|
|
|
|
60679431 |
May 10, 2005 |
|
|
|
Current U.S.
Class: |
514/211.04 ;
514/220; 514/230.2; 514/250; 514/293; 540/460; 540/488; 540/497;
544/101; 544/346 |
Current CPC
Class: |
C07D 471/14 20130101;
A61P 37/00 20180101; A61P 43/00 20180101; A61K 31/4375 20130101;
A61P 31/18 20180101; C07D 498/14 20130101; A61K 31/4353
20130101 |
Class at
Publication: |
514/211.04 ;
540/460; 514/293; 540/497; 514/220; 544/346; 514/250; 514/230.2;
544/101; 540/488 |
International
Class: |
A61K 31/553 20060101
A61K031/553; C07D 471/14 20060101 C07D471/14; A61K 31/4375 20060101
A61K031/4375; A61P 31/18 20060101 A61P031/18; A61K 31/551 20060101
A61K031/551; A61K 31/4985 20060101 A61K031/4985; A61K 31/5365
20060101 A61K031/5365; C07D 498/14 20060101 C07D498/14 |
Claims
1. A compound of Formula I, or a pharmaceutically acceptable salt
thereof: ##STR00085## wherein: bond in the ring is a single bond or
a double bond; R.sup.1 is C.sub.1-6 alkyl, R.sup.J, or C.sub.1-6
alkyl substituted with R.sup.J, wherein R.sup.J is CycA, AryA,
HetA, or HetP; R.sup.2 is H or C.sub.1-6 alkyl; R.sup.3 is: (1) H,
(2) halogen, (3) CN, (4) C.sub.1-6 alkyl, (5) C.sub.1-6 haloalkyl,
(6) C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, CN, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A,
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or OC(O)N(R.sup.A)R.sup.B, (7)
C(O)R.sup.A, (8) CO.sub.2R.sup.A, (9) C(O)N(R.sup.A)R.sup.B, (10)
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, (11) SR.sup.A,
(12) S(O)R.sup.A, (13) SO.sub.2R.sup.A, (14)
SO.sub.2N(R.sup.A)R.sup.B, (15) N(R.sup.A)R.sup.B, (16)
N(R.sup.A)C(O)R.sup.B, (17) N(R.sup.A)C(O)OR.sup.B; (18)
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, (19)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, (20)
N(R.sup.A)SO.sub.2R.sup.B, (21)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (22) OC(O)N(R.sup.A)R.sup.B,
or (23) Y--R.sup.K, wherein: Y is a single bond, C.sub.1-6
alkylene, O, O--C.sub.1-6 alkylene, C.sub.1-6 alkylene-O, C(O),
C(O)--C.sub.1-6 alkylene, C.sub.1-6 alkylene-C(O), C(O)--C.sub.1-6
alkylene-O, C(O)--C1-6 alkylene-O--C.sub.1-6 alkylene,
C(O)N(R.sup.A), C(O)N(R.sup.A)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O)N(R.sup.A), C.sub.1-6
alkylene-C(O)N(R.sup.A)--C.sub.1-6 alkylene, S(O), S(O).sub.2,
S(O)--C.sub.1-6 alkylene, S(O).sub.2--C.sub.1-6 alkylene, C.sub.1-6
alkylene-S(O), or C.sub.1-6 alkylene-S(O).sub.2; and R.sup.K is
CycB, AryB, HetB, or HetQ; or, as an alternative, when bond is a
double bond, R.sup.2 and R.sup.3 together with the carbon atoms to
which each is attached form: (i) a benzene ring which is optionally
substituted with a total of from 1 to 4 substituents wherein (a)
from zero to 4 substituents are each independently one of
substituents (1) to (25) as defined in part (i) of the definition
of AryA and (b) from zero to 2 substituents are each independently
one of the substituents (1) to (6) as defined in part (ii) of the
definition of AryA, or (ii) a 5- or 6-membered heteroaromatic ring
containing from 1 to 4 heteroatoms independently selected from N, O
and S, wherein the heteroaromatic ring is optionally substituted
with a total of from 1 to 3 substituents wherein (a) from zero to 3
substituents are each independently one of substituents (1) to (26)
as defined in part (i) of the definition of HetA and (b) from zero
to 2 substituents are each independently one of the substituents
(1) to (6) as defined in part (ii) of the definition of HetA; ring
A is a 5-membered, saturated or mono-unsaturated heterocyclic ring
containing in addition to the nitrogen shared with the
naphthyridine ring from 1 to 3 heteroatoms independently selected
from N, O, and S, wherein each S is optionally oxidized to S(O) or
S(O).sub.2; and wherein the saturated or mono-unsaturated
heterocyclic ring is optionally substituted with a total of from 1
to 6 substituents, wherein: (i) from zero to 6 substituents are
each independently: (1) halogen, (2) C.sub.1-6 alkyl, (3) C.sub.1-6
haloalkyl, (4) C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6
alkyl, O--C.sub.1-6 haloalkyl, CN, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A,
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, OC(O)N(R.sup.A)R.sup.B, or
OC(O)R.sup.A, (5) O--C.sub.1-6 alkyl, (6) O--C.sub.1-6 haloalkyl,
(7) oxo, (8) .lamda.C(R.sup.A)R.sup.B, (9) C(O)N(R.sup.A)R.sup.B,
(10) C(O)C(O)N(R.sup.A)R.sup.B, (11) C(O)R.sup.A, (12)
CO.sub.2R.sup.A, (13) SR.sup.A, (14) S(O)R.sup.A, (15)
SO.sub.2R.sup.A, (16) SO.sub.2N(R.sup.A)R.sup.B, or (17) OH, and
(ii) from zero to 2 substituents are each Z--R.sup.L, wherein: each
Z is independently a single bond, C.sub.1-6 alkylene, O,
O--C.sub.1-6 alkylene, C.sub.1-6 alkylene-O, C(O), C(O)--C.sub.1-6
alkylene, C.sub.1-6 alkylene-C(O), C(O)--C.sub.1-6 alkylene-O,
C(O)--C.sub.1-6 alkylene-O--C.sub.1-6 alkylene, C(O)N(R.sup.A),
C(O)N(R.sup.A)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O)N(R.sup.A), C.sub.1-6
alkylene-C(O)N(R.sup.A)--C.sub.1-6 alkylene, S(O), S(O).sub.2,
S(O)--C.sub.1-6 alkylene, S(O).sub.2--C.sub.1-6 alkylene, C.sub.1-6
alkylene-S(O), or C.sub.1-6 alkylene-S(O).sub.2; and each R.sup.L
is independently CycC, AryC, HetC, or HetR; each R.sup.A is
independently H or C.sub.1-6 alkyl; each R.sup.B is independently H
or C.sub.1-6 alkyl; CycA is a C.sub.3-8 cycloalkyl which is
optionally substituted with a total of from 1 to 6 substituents,
wherein: (i) from zero to 6 substituents are each independently:
(1) halogen, (2) CN (3) C.sub.1-6 alkyl, (4) OH, (5) O--C.sub.1-6
alkyl, (6) C.sub.1-6 haloalkyl, or (7) O--C.sub.1-6 haloalkyl, and
(ii) from zero to 2 substituents are each independently: (1) CycD,
(2) AryD, (3) HetD, (4) HetZ, (5) C.sub.1-6 alkyl substituted with
CycD, AryD, HetD, or HetZ, or (6) C(O)--HetZ or C(O)C(O)--HetZ;
CycB independently has the same definition as CycA; each CycC
independently has the same definition as CycA; AryA is an aryl
which is optionally substituted with a total of from 1 to 5
substituents, wherein: (i) from zero to 5 substituents are each
independently: (1) C.sub.1-6 alkyl, (2) C.sub.1-6 alkyl substituted
with OH, O--C.sub.1-6 alkyl, O--C.sub.1-6 haloalkyl, CN, NO.sub.2,
N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A,
CO.sub.2R.sup.A, SR.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A,
SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)CO.sub.2R.sup.B, N(R.sup.A)SO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, OC(O)N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, (3) O--C.sub.1-6 alkyl, (4)
C.sub.1-6 haloalkyl, (5) O--C.sub.1-6 haloalkyl, (6) OH, (7)
halogen, (8) CN, (9) NO.sub.2, (10) N(R.sup.A)R.sup.B, (11)
C(O)N(R.sup.A)R.sup.B, (12) C(O)R.sup.A, (13) C(O)--C.sub.1-6
haloalkyl, (14) C(O)OR.sup.A, (15) OC(O)N(R.sup.A)R.sup.B, (16)
SR.sup.A, (17) S(O)R.sup.A, (18) SO.sub.2R.sup.A, (19)
SO.sub.2N(R.sup.A)R.sup.B, (20) N(R.sup.A)SO.sub.2R.sup.B, (21)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (22) N(R.sup.A)C(O)R.sup.B,
(23) N(R.sup.A)C(O)N(R.sup.A)R.sup.B, (24)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, or (25)
N(R.sup.A)CO.sub.2R.sup.B, and (ii) from zero to 2 substituents are
each independently: (1) CycD, (2) AryD, (3) HetD, (4) HetZ, (5)
C.sub.1-6 alkyl substituted with CycD, AryD, HetD, or HetZ, or (6)
C(O)--HetZ or C(O)C(O)--HetZ; AryB independently has the same
definition as AryA; each AryC independently has the same definition
as AryA; HetA is a heteroaryl which is optionally substituted with
a total of from 1 to 5 substituents, wherein: (i) from zero to 5
substituents are each independently: (1) C.sub.1-6 alkyl, (2)
C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, CN, NO.sub.2, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
OC(O)N(R.sup.A)R.sup.B, N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, (3) O--C.sub.1-6 alkyl, (4)
C.sub.1-6 haloalkyl, (5) O--C.sub.1-6 haloalkyl, (6) OH, (7) oxo,
(8) halogen, (9) CN, (10) NO.sub.2, (11) N(R.sup.A)R.sup.B, (12)
C(O)N(R.sup.A)R.sup.B, (13) C(O)R.sup.A, (14) C(O)--C.sub.1-6
haloalkyl, (15) C(O)OR.sup.A, (16) OC(O)N(R.sup.A)R.sup.B, (17)
SR.sup.A, (18) S(O)R.sup.A, (19) SO.sub.2R.sup.A, (20)
SO.sub.2N(R.sup.A)R.sup.B, (21) N(R.sup.A)SO.sub.2R.sup.B, (22)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (23) N(R.sup.A)C(O)R.sup.B,
(24) N(R.sup.A)C(O)N(R.sup.A)R.sup.B, (25)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, or (26)
N(R.sup.A)CO.sub.2R.sup.B, and (ii) from zero to 2 substituents are
each independently: (1) CycD, (2) AryD, (3) HetD, (4) HetZ, (5)
C.sub.1-6 alkyl substituted with CycD, AryD, HetD, or HetZ, or (6)
C(O)--HetZ or C(O)C(O)--HetZ; HetB independently has the same
definition as HetA; each HetC independently has the same definition
as HetA; HetP is (i) a 4- to 7-membered, saturated or
mono-unsaturated heterocyclic ring containing at least one carbon
atom and from 1 to 4 heteroatoms independently selected from N, O
and S, where each S is optionally oxidized to S(O) or S(O).sub.2 or
(ii) a 6- to 10-membered saturated or mono-unsaturated, bridged or
fused heterobicyclic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, where each S is optionally
oxidized to S(O) or S(O).sub.2; and wherein the saturated or
mono-unsaturated heterocyclic or heterobicyclic ring is optionally
substituted with a total of from 1 to 4 substituents, wherein: (i)
from zero to 4 substituents are each independently halogen,
C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, oxo, C(O)N(R.sup.A)R.sup.B, C(O)C(O)N(R
C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A, S(O)R.sup.A,
SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B, and (ii) from zero
to 2 substituents are each independently CycD, AryD, HetD, or
C.sub.1-6 alkyl substituted with CycD, AryD, HetD; HetQ
independently has the same definition as HetP; each HetR
independently has the same definition as HetP; each CycD is
independently a C.sub.3-8 cycloalkyl which is optionally
substituted with from 1 to 4 substituents each of which is
independently halogen, C.sub.1-6 alkyl, OH, O--C.sub.1-6 alkyl, or
C.sub.1-6 haloalkyl; each AryD is independently phenyl or naphthyl,
wherein the phenyl or naphthyl is optionally substituted with from
1 to 5 substituents each of which is independently any one of the
substituents (1) to (25) as set forth above in part (i) of the
definition of AryA; each HetD is independently a 5- or 6-membered
heteroaromatic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein the heteroaromatic
ring is optionally substituted with from 1 to 4 substituents each
of which is independently any one of the substituents (1) to (26)
as set forth above in part (i) of the definition of HetA; each HetZ
is independently a 4- to 7-membered, saturated or mono-unsaturated
heterocyclic ring containing at least one carbon atom and from 1 to
4 heteroatoms independently selected from N, O and S, where each S
is optionally oxidized to S(O) or S(O).sub.2, wherein the saturated
or mono-unsaturated heterocyclic ring is optionally substituted
with from 1 to 4 substituents each of which is independently
halogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, oxo, C(O)N(R.sup.A)R.sup.B,
C(O)C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B; each
aryl is independently (i) phenyl, (ii) a 9- or 10-membered
bicyclic, fused carbocyclic ring system in which at least one ring
is aromatic, or (iii) an 11- to 14-membered tricyclic, fused
carbocyclic ring system in which at least one ring is aromatic; and
each heteroaryl is independently (i) a 5- or 6-membered
heteroaromatic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein each N is
optionally in the form of an oxide, or (ii) a 9- or 10-membered
bicyclic, fused ring system containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein either one or both
of the rings contain one or more of the heteroatoms, at least one
ring is aromatic, each N is optionally in the faun of an oxide, and
each S in a ring which is not aromatic is optionally S(O) or
S(O).sub.2.
2. (canceled)
3. A compound according to claim 1, or a pharmaceutically
acceptable salt thereof, wherein R.sup.1 is C.sub.1-6 alkyl
substituted with R.sup.J.
4. A compound according to claim 3, or a pharmaceutically
acceptable salt thereof, wherein R.sup.J is AryA or HetA.
5. A compound according to claim 1, or a pharmaceutically
acceptable salt thereof, wherein: R.sup.2 is H or C.sub.1-6 alkyl;
and R.sup.3 is H, C.sub.1-6 alkyl, C(O)N(R.sup.A)R.sup.B,
SO.sub.2N(R.sup.A)R.sup.B, or C.sub.1-6 alkyl substituted with
C(O)N(R.sup.A)R.sup.B or SO.sub.2N(R.sup.A)R.sup.B.
6. A compound according to claim 1, or a pharmaceutically
acceptable salt thereof, wherein the compound is a compound of
Formula IIb: ##STR00086## wherein W is O or N--R.sup.8; R.sup.6 and
R.sup.7 are each independently H, C.sub.1-6 alkyl, or C.sub.1-6
alkyl substituted with OH; and R.sup.8 is: (1) (2) C.sub.1-6 alkyl,
(3) C.sub.1-6 haloalkyl, (4) C.sub.1-6 alkyl substituted with OH,
O--C.sub.1-6 alkyl, N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, C(O)--N(R.sup.A)--C.sub.1-6
alkylene-OR.sup.B with the proviso that the N(R.sup.A) moiety and
the OR.sup.B moiety are not both attached to the same carbon of the
C.sub.1-6 alkylene moiety, S(O)R.sup.A, SO.sub.2R.sup.A,
SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A, or (5) Z--R.sup.L.
7. A compound according to claim 6, or a pharmaceutically
acceptable salt thereof, wherein R.sup.1 is: ##STR00087## the
asterisk * denotes the point of attachment of R.sup.1 to the rest
of the compound; V.sup.1 and V.sup.2 are each independently: (1) H,
(2) C.sub.1-4 alkyl, (3) OH, (4) O--C.sub.1-4 alkyl, (5) C.sub.1-4
haloalkyl, (6) O--C.sub.1-4 haloalkyl, (7) halogen, (8) CN, (9)
N(R.sup.A)R.sup.B, (10) C(O)N(R.sup.A)R.sup.B, (11) C(O)R.sup.A,
(12) C(O)OR.sup.A, (13) SR.sup.A, (14) S(O)R.sup.A, (15)
SO.sub.2R.sup.A, (16) N(R.sup.A)SO.sub.2R.sup.B, (17)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (18) N(R.sup.A)C(O)R.sup.B,
(19) N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, (20) HetD, (21) HetZ, or
(22) C(O)--HetZ, wherein HetD is a 5- or 6-membered heteroaromatic
ring containing a total of from 1 to 3 heteroatoms independently
selected from 1 to 3 N atoms, from zero to 1 O atom, and from zero
to 1 S atom, wherein the heteroaromatic ring is optionally
substituted with 1 or 2 substituents each of which is independently
C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl, halogen, CN,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A, HetZ is a 5- or 6-membered saturated heterocyclic
ring containing a total of from 1 to 2 heteroatoms selected from 1
to 2 N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the S
atom is optionally S(O) or SO.sub.2, wherein the saturated
heterocyclic ring is optionally substituted with from 1 to 2
substituents each of which is independently C.sub.1-4 alkyl, oxo,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, or
SO.sub.2R.sup.A, and with the proviso that when HetZ is attached to
the rest of the compound via the C(O) moiety, then HetZ is attached
to the C(O) via a ring N atom; or alternatively V.sup.1 and V.sup.2
are respectively located on adjacent carbons in the phenyl ring and
together form methylenedioxy or ethylenedioxy; and V.sup.3 is: (1)
H, (2) C.sub.1-4 alkyl, (3) O--C.sub.1-4 alkyl, (4) C.sub.1-4
haloalkyl, (5) O--C.sub.1-4 haloalkyl, or (6) halogen.
8. A compound according to claim 7, or a pharmaceutically
acceptable salt thereof, wherein the compound is of Formula IIId:
##STR00088## wherein: R.sup.2 and R.sup.3 are each independently H
or C.sub.1-4 alkyl; one of R.sup.6 and R.sup.7 is H, C.sub.1-4
alkyl, or C.sub.1-4 alkyl substituted with OH, and the other of
R.sup.6 and R.sup.7 is H or C.sub.1-4 alkyl; R.sup.8 is: (1) H, (2)
C.sub.1-4 alkyl, (3) C.sub.1-4 haloalkyl, (4) C.sub.1-4 alkyl
substituted with OH, O--C.sub.1-4 alkyl, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, S(O)R.sup.A,
SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A, (5) C.sub.1-4
alkylene-HetC, or (6) C.sub.1-4 alkylene-HetR; HetC is a 5- or
6-membered heteroaromatic ring containing a total of from 1 to 3
heteroatoms independently selected from 1 to 3N atoms, from zero to
1 O atom, and from zero to 1 S atom, wherein the heteroaromatic
ring is optionally substituted with 1 or 2 substituents each of
which is independently C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl,
halogen, CN, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A; HetR is a 5- or 6-membered saturated heterocyclic
ring containing a total of from 1 to 2 heteroatoms selected from 1
to 2N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the S
atom is optionally S(O) or SO.sub.2, wherein the saturated
heterocyclic ring is optionally substituted with from 1 to 2
substituents each of which is independently C.sub.1-4 alkyl, oxo,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, or
SO.sub.2R.sup.A; each R.sup.A is independently H or C.sub.1-4
alkyl; and each R.sup.8 is independently H or C.sub.1-4 alkyl.
9. A compound according to claim 8, or a pharmaceutically
acceptable salt thereof, wherein: bond in the ring is a single
bond; R.sup.2 and R.sup.3 are each independently H or CH.sub.3; one
of R.sup.6 and R.sup.7 is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2 or
(CH.sub.2).sub.1-3--OH, and the other of R.sup.6 and R.sup.7 is H
or CH.sub.3; R.sup.8 is: (1) H, (2) CH.sub.3, (3) CH.sub.2CH.sub.3,
(4) CH.sub.2CH.sub.2CH.sub.3, (5) CH(CH.sub.3).sub.2, (6)
CH.sub.2CH.sub.2CH.sub.2CH.sub.3, (7) C(CH.sub.3).sub.3, (8)
CH.sub.2CH(CH.sub.3).sub.2, (9) CH(CH.sub.3)CH.sub.2CH.sub.3, (10)
CF.sub.3, (11) CH.sub.2CF.sub.3, (12) (CH.sub.2).sub.2-4--U,
wherein U is OH, OCH.sub.3, N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A,
(13) (CH.sub.2).sub.1-4--V, wherein V is C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A, or
SO.sub.2N(R.sup.A)R.sup.B, (14) (CH.sub.2).sub.2-4-HetC, or (15)
(CH.sub.2).sub.2-4-HetR; HetC is a 5-membered heteroaromatic ring
selected from the group consisting of: ##STR00089## HetR is a 5- or
6-membered saturated heterocyclic ring selected from the group
consisting of: ##STR00090## the asterisk * in HetC and HetR denotes
the point of attachment to the rest of the molecule; each R.sup.A
is independently H or CH.sub.3; each R.sup.B is independently H or
CH.sub.3; V.sup.1 and V.sup.2 are each independently: (1) H, (2)
CH.sub.3, (3) CF.sub.3, (4) OH, (5) OCH.sub.3, (6) Cl, Br, or F,
(7) CN, (8) C(O)NH.sub.2, (9) C(O)NH(CH.sub.3), (10)
C(O)N(CH.sub.3).sub.2, or (11) SO.sub.2CH.sub.3; and V.sup.3 is H,
Cl, Br, F, CH.sub.3, or OCH.sub.3.
10. The compound according to claim 1, or a pharmaceutically
acceptable salt thereof, which is a compound selected from the
group consisting of:
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1,3-dimethyl-1,8,9,10-tetrahydroimi-
dazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione; and
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1,3,3-trimethyl-1,8,9,10-tetrahydro-
imidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione.
11. The compound according to claim 1, or a pharmaceutically
acceptable salt thereof, which is a compound selected from the
group consisting of:
2-[8-(3-chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-2,3,7,-
8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]-N,N-dimethylacet-
amide;
2-[8-(3-chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7-trioxo--
2,3,7,8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]-N-dimethyl-
acetamide;
2-[8-(3-chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7-tri-
oxo-2,3,7,8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]acetami-
de;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(2-hydroxyethyl)-3,3-dimethyl--
1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(3-hydroxypropyl)-3,3-dimethyl-1,-
8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(4-hydroxybutyl)-3,3-dimethyl-1,8-
,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(2-acetyloxypropyl)-3,3-dimethyl--
1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(3-acetyloxypropyl)-3,3-dimethyl--
1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1-(4-acetyloxybutyl)-3,3-dimethyl-1-
,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
8-(3-chloro-4-fluorobenzyl)-6-hydroxy-1,3-bis(2-hydroxyethyl)-3-methyl-1,-
8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione;
12. A pharmaceutical composition comprising an effective amount of
a compound according to claim 1, or a pharmaceutically acceptable
salt thereof, and a pharmaceutically acceptable carrier.
13. (canceled)
14. A method for the treatment of infection by HIV or for the
treatment of AIDS in a subject in need thereof, which comprises
administering to the subject an effective amount of the compound
according to claim 1, or a pharmaceutically acceptable salt
thereof.
15. (canceled)
Description
[0001] This application claims the benefit of U.S. Provisional
Application No. 60/679,431 (filed May 10, 2005), the disclosure of
which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention is directed to tricyclic analogs of
hydroxy polyhydro-2,6-naphthyridine dime compounds and
pharmaceutically acceptable salts thereof, their synthesis, and
their use as inhibitors of the HIV integrase enzyme. The compounds
and pharmaceutically acceptable salts thereof of the present
invention are useful for preventing or treating infection by HIV
and for preventing or treating or delaying the onset of AIDS.
BACKGROUND OF THE INVENTION
[0003] A retrovirus designated human immunodeficiency virus (HIV),
particularly the strains known as HIV type-1 (HIV-1) virus and
type-2 (HIV-2) virus, is the etiological agent of the complex
disease that includes progressive destruction of the immune system
(acquired immune deficiency syndrome; AIDS) and degeneration of the
central and peripheral nervous system. This virus was previously
known as LAV, HTLV-III, or ARV. A common feature of retrovirus
replication is the insertion by virally-encoded integrase of
+proviral DNA into the host cell genome, a required step in HIV
replication in human T-lymphoid and monocytoid cells. Integration
is believed to be mediated by integrase in three steps: assembly of
a stable nucleoprotein complex with viral DNA sequences; cleavage
of two nucleotides from the 3' termini of the linear proviral DNA;
covalent joining of the recessed 3' OH termini of the proviral DNA
at a staggered cut made at the host target site. The fourth step in
the process, repair synthesis of the resultant gap, may be
accomplished by cellular enzymes.
[0004] Nucleotide sequencing of HIV shows the presence of a pol
gene in one open reading frame [Ratner, L. et al., Nature, 313, 277
(1985)]. Amino acid sequence homology provides evidence that the
pol sequence encodes reverse transcriptase, integrase and an HIV
protease [Toh, H. et al., EMBO J. 4, 1267 (1985); Power, M. D. et
al., Science, 231, 1567 (1986); Pearl, L. H. et al., Nature, 329,
351 (1987)]. All three enzymes have been shown to be essential for
the replication of HIV.
[0005] It is known that some antiviral compounds which act as
inhibitors of HIV replication are effective agents in the treatment
of AIDS and similar diseases, including reverse transcriptase
inhibitors such as azidothymidine (AZT) and efavirenz and protease
inhibitors such as indinavir and nelfinavir. The compounds of this
invention are inhibitors of HIV integrase and inhibitors of HIV
replication. The inhibition of integrase in vitro and HIV
replication in cells is a direct result of inhibiting the strand
transfer reaction catalyzed by the recombinant integrase in vitro
in HIV infected cells. The particular advantage of the present
invention is highly specific inhibition of HIV integrase and HIV
replication.
[0006] The following references are of interest as background:
[0007] U.S. Pat. No. 6,380,249, U.S. Pat. No. 6,306,891, and U.S.
Pat. No. 6,262,055 disclose 2,4-dioxobutyric acids and acid esters
useful as HIV integrase inhibitors.
[0008] WO 01/00578 discloses 1-(aromatic- or
heteroaromatic-substituted)-3-(heteroaromatic
substituted)-1,3-propanediones useful as HIV integrase
inhibitors.
[0009] US 2003/0055071 (corresponding to WO 02/30930), WO 02/30426,
and WO 02/55079 each disclose certain
8-hydroxy-1,6-naphthyridine-7-carboxamides as HIV integrase
inhibitors.
[0010] WO 02/036734 discloses certain aza- and polyaza-naphthalenyl
ketones to be HIV integrase inhibitors.
[0011] WO 03/016275 discloses certain compounds having integrase
inhibitory activity.
[0012] WO 03/35076 discloses certain
5,6-dihydroxypyrimidine-4-carboxamides as HIV integrase inhibitors,
and WO 03/35077 discloses certain N-substituted
5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamides as HIV
integrase inhibitors.
[0013] WO 03/062204 discloses certain hydroxynaphthyridinone
carboxamides that are useful as HIV integrase inhibitors.
[0014] WO 04/004657 discloses certain hydroxypyrrole derivatives
that are HIV integrase inhibitors.
[0015] WO 2005/016927 discloses certain nitrogenous condensed ring
compounds that are HIV integrase inhibitors.
SUMMARY OF THE INVENTION
[0016] The present invention is directed to tricyclic analogs of
hydroxy polyhydro-2,6-naphthyridine dione compounds. These
compounds are useful in the inhibition of HIV integrase, the
prevention of infection by HIV, the treatment of infection by HIV
and in the prevention, treatment, and delay in the onset of AIDS
and/or ARC, either as compounds or their pharmaceutically
acceptable salts or hydrates (when appropriate), or as
pharmaceutical composition ingredients, whether or not in
combination with other HIV/AIDS antivirals, anti-infectives,
immunomodulators, antibiotics or vaccines. More particularly, the
present invention includes compounds of Formula I, and
pharmaceutically acceptable salts thereof:
##STR00002##
wherein: bond in the ring is a single bond or a double bond;
R.sup.1 is C.sub.1-6 alkyl, R.sup.J, or C.sub.1-6 alkyl substituted
with R.sup.J, wherein R.sup.J is CycA, AryA, HetA, or HetP; R.sup.2
is H or C.sub.1-6 alkyl;
R.sup.3 is:
[0017] (1) H, [0018] (2) halogen, [0019] (3) CN, [0020] (4)
C.sub.1-6 alkyl, [0021] (5) C.sub.1-6 haloalkyl, [0022] (6)
C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, CN, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A,
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or OC(O)N(R.sup.A)R.sup.B, [0023]
(7) C(O)R.sup.A, [0024] (8) CO.sub.2R.sup.A, [0025] (9)
C(O)N(R.sup.A)R.sup.B, [0026] (10) C(O)--N(R.sup.A)--C.sub.1-6
alkylene-OR.sup.B with the proviso that the N(R.sup.A) moiety and
the OR.sup.B moiety are not both attached to the same carbon of the
C.sub.1-6 alkylene moiety, [0027] (11) SR.sup.A, [0028] (12)
S(O)R.sup.A, [0029] (13) SO.sub.2R.sup.A, [0030] (14)
SO.sub.2N(R.sup.A)R.sup.B, [0031] (15) N(R.sup.A)R.sup.B, [0032]
(16) N(R.sup.A)C(O)R.sup.B, [0033] (17) N(R.sup.A)C(O)OR.sup.B;
[0034] (18) N(R.sup.A)C(O)N(R.sup.A)R.sup.B, [0035] (19)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, [0036] (20)
N(R.sup.A)SO.sub.2R.sup.B, [0037] (21)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0038] (22)
OC(O)N(R.sup.A)R.sup.B, or [0039] (23) Y--R.sup.K, wherein: [0040]
Y is a single bond, C.sub.1-6 alkylene, O, O--C.sub.1-6 alkylene,
C.sub.1-6 alkylene-O, C(O), C(O)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O), C(O)--C.sub.1-6 alkylene-O, C(O)--C.sub.1-6
alkylene-O--C.sub.1-6 alkylene, C(O)N(R.sup.A),
C(O)N(R.sup.A)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O)N(R.sup.A), C.sub.1-6
alkylene-C(O)N(R.sup.A)--C.sub.1-6 alkylene, S(O), S(O).sub.2,
S(O)--C.sub.1-6 alkylene, S(O).sub.2--C.sub.1-6 alkylene, C.sub.1-6
alkylene-S(O), or C.sub.1-6 alkylene-S(O).sub.2; and [0041] R.sup.K
is CycB, AryB, HetB, or HetQ; or, as an alternative, when bond is a
double bond, R.sup.2 and R.sup.3 together with the carbon atoms to
which each is attached form: [0042] (i) a benzene ring which is
optionally substituted with a total of from 1 to 4 substituents
wherein (a) from zero to 4 substituents are each independently one
of substituents (1) to (25) as defined in part (i) of the
definition of AryA and (b) from zero to 2 substituents are each
independently one of the substituents (1) to (6) as defined in part
(ii) of the definition of AryA, or [0043] (ii) a 5- or 6-membered
heteroaromatic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein the heteroaromatic
ring is optionally substituted with a total of from 1 to 3
substituents wherein (a) from zero to 3 substituents are each
independently one of substituents (1) to (26) as defined in part
(i) of the definition of HetA and (b) from zero to 2 substituents
are each independently one of the substituents (1) to (6) as
defined in part (ii) of the definition of HetA; ring A is a 5- to
9-membered, saturated or mono-unsaturated heterocyclic ring
containing in addition to the nitrogen shared with the
naphthyridine ring from 1 to 3 heteroatoms independently selected
from N, O, and S, wherein each S is optionally oxidized to S(O) or
S(O).sub.2; and wherein the saturated or mono-unsaturated
heterocyclic ring is optionally substituted with a total of from 1
to 10 substituents, wherein: [0044] (i) from zero to 10
substituents are each independently: [0045] (1) halogen, [0046] (2)
C.sub.1-6 alkyl, [0047] (3) C.sub.1-6 haloalkyl, [0048] (4)
C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, CN, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A,
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, OC(O)N(R.sup.A)R.sup.B, or
OC(O)R.sup.A, [0049] (5) O--C.sub.1-6 alkyl, [0050] (6)
O--C.sub.1-6 haloalkyl, [0051] (7) oxo, [0052] (8)
.dbd.C(R.sup.A)R.sup.B, [0053] (9) C(O)N(R.sup.A)R.sup.B, [0054]
(10) C(O)C(O)N(R.sup.A)R.sup.B, [0055] (11) C(O)R.sup.A, [0056]
(12) CO.sub.2R.sup.A, [0057] (13) SR.sup.A, [0058] (14)
S(O)R.sup.A, [0059] (15) SO.sub.2R.sup.A, [0060] (16)
SO.sub.2N(R.sup.A)R.sup.B, or [0061] (17) OH, and [0062] (ii) from
zero to 3 substituents are each Z--R.sup.L, wherein: [0063] each Z
is independently a single bond, C.sub.1-6 alkylene, O, O--C.sub.1-6
alkylene, C.sub.1-6 alkylene-O, C(O), C(O)--C.sub.1-6 alkylene,
C.sub.1-6 alkylene-C(O), C(O)--C.sub.1-6 alkylene-O,
C(O)--C.sub.1-6 alkylene-O--C.sub.1-6 alkylene, C(O)N(R.sup.A),
C(O)N(R.sup.A)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O)N(R.sup.A), C.sub.1-6
alkylene-C(O)N(R.sup.A)--C.sub.1-6 alkylene, S(O), S(O).sub.2,
S(O)--C.sub.1-6 alkylene, S(O).sub.2--C.sub.1-6 alkylene, C.sub.1-6
alkylene-S(O), or C.sub.1-6 alkylene-S(O).sub.2; and [0064] each
R.sup.L is independently CycC, AryC, HetC, or HetR; each R.sup.A is
independently H or C.sub.1-6 alkyl; each R.sup.B is independently H
or C.sub.1-6 alkyl; CycA is a C.sub.3-8 cycloalkyl which is
optionally substituted with a total of from 1 to 6 substituents,
wherein: [0065] (i) from zero to 6 substituents are each
independently: [0066] (1) halogen, [0067] (2) CN [0068] (3)
C.sub.1-6 alkyl, [0069] (4) OH, [0070] (5) O--C.sub.1-6 alkyl,
[0071] (6) C.sub.1-6 haloalkyl, or [0072] (7) O--C.sub.1-6
haloalkyl, and [0073] (ii) from zero to 2 substituents are each
independently: [0074] (1) CycD, [0075] (2) AryD, [0076] (3) HetD,
[0077] (4) HetZ, [0078] (5) C.sub.1-6 alkyl substituted with CycD,
AryD, HetD, or HetZ, or [0079] (6) C(O)--HetZ or C(O)C(O)--HetZ;
CycB independently has the same definition as CycA; each CycC
independently has the same definition as CycA; AryA is an aryl
which is optionally substituted with a total of from 1 to 5
substituents, wherein: [0080] (i) from zero to 5 substituents are
each independently: [0081] (1) C.sub.1-6 alkyl, [0082] (2)
C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, CN, NO.sub.2, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
OC(O)N(R.sup.A)R.sup.B, N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, [0083] (3) O--C.sub.1-6 alkyl,
[0084] (4) C.sub.1-6 haloalkyl, [0085] (5) O--C.sub.1-6 haloalkyl,
[0086] (6) OH, [0087] (7) halogen, [0088] (8) CN, [0089] (9)
NO.sub.2, [0090] (10) N(R.sup.A)R.sup.B, [0091] (11)
C(O)N(R.sup.A)R.sup.B, [0092] (12) C(O)R.sup.A, [0093] (13)
C(O)--C.sub.1-6 haloalkyl, [0094] (14) C(O)OR.sup.A, [0095] (15)
OC(O)N(R.sup.A)R.sup.B, [0096] (16) SR.sup.A, [0097] (17)
S(O)R.sup.A, [0098] (18) SO.sub.2R.sup.A, [0099] (19)
SO.sub.2N(R.sup.A)R.sup.B, [0100] (20) N(R.sup.A)SO.sub.2R.sup.B,
[0101] (21) N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0102] (22)
N(R.sup.A)C(O)R.sup.B, [0103] (23) N(R.sup.A)C(O)N(R.sup.A)R.sup.B,
[0104] (24) N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, or [0105] (25)
N(R.sup.A)CO.sub.2R.sup.B, and [0106] (ii) from zero to 2
substituents are each independently: [0107] (1) CycD, [0108] (2)
AryD, [0109] (3) HetD, [0110] (4) HetZ, [0111] (5) C.sub.1-6 alkyl
substituted with CycD, AryD, HetD, or HetZ, or [0112] (6)
C(O)--HetZ or C(O)C(O)--HetZ; AryB independently has the same
definition as AryA; each AryC independently has the same definition
as AryA; HetA is a heteroaryl which is optionally substituted with
a total of from 1 to 5 substituents, wherein: [0113] (i) from zero
to 5 substituents are each independently: [0114] (1) C.sub.1-6
alkyl, [0115] (2) C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6
alkyl, O--C.sub.1-6 haloalkyl, CN, NO.sub.2, N(R.sup.A)R.sup.B,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)CO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
OC(O)N(R.sup.A)R.sup.B, N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, [0116] (3) O--C.sub.1-6 alkyl,
[0117] (4) C.sub.1-6 haloalkyl, [0118] (5) O--C.sub.1-6 haloalkyl,
[0119] (6) OH, [0120] (7) oxo, [0121] (8) halogen, [0122] (9) CN,
[0123] (10) NO.sub.2, [0124] (11) N(R.sup.A)R.sup.B, [0125] (12)
C(O)N(R.sup.A)R.sup.B, [0126] (13) C(O)R.sup.A, [0127] (14)
C(O)--C.sub.1-6 haloalkyl, [0128] (15) C(O)OR.sup.A, [0129] (16)
OC(O)N(R.sup.A)R.sup.B, [0130] (17) SR.sup.A, [0131] (18)
S(O)R.sup.A, [0132] (19) SO.sub.2R.sup.A, [0133] (20)
SO.sub.2N(R.sup.A)R.sup.B, [0134] (21) N(R.sup.A)SO.sub.2O, [0135]
(22) N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0136] (23)
N(R.sup.A)C(O)R.sup.B, [0137] (24) N(R.sup.A)C(O)N(R.sup.A)R.sup.B,
[0138] (25) N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, or [0139] (26)
N(R.sup.A)CO.sub.2R.sup.B, and [0140] (ii) from zero to 2
substituents are each independently: [0141] (1) CycD, [0142] (2)
AryD, [0143] (3) HetD, [0144] (4) HetZ, [0145] (5) C.sub.1-6 alkyl
substituted with CycD, AryD, HetD, or HetZ, or [0146] (6)
C(O)--HetZ or C(O)C(O)--HetZ; HetB independently has the same
definition as HetA; each HetC independently has the same definition
as HetA; HetP is (i) a 4- to 7-membered, saturated or
mono-unsaturated heterocyclic ring containing at least one carbon
atom and from 1 to 4 heteroatoms independently selected from N, O
and S, where each S is optionally oxidized to S(O) or S(O).sub.2 or
(ii) a 6- to 10-membered saturated or mono-unsaturated, bridged or
fused heterobicyclic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, where each S is optionally
oxidized to S(O) or S(O).sub.2; and wherein the saturated or
mono-unsaturated heterocyclic or heterobicyclic ring is optionally
substituted with a total of from 1 to 4 substituents, wherein:
[0147] (i) from zero to 4 substituents are each independently
halogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, oxo, C(O)N(R.sup.A)R.sup.B,
C(O)C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B, and
[0148] (ii) from zero to 2 substituents are each independently
CycD, AryD, HetD, or C.sub.1-6 alkyl substituted with CycD, AryD,
HetD; HetQ independently has the same definition as HetP; each HetR
independently has the same definition as HetP; each CycD is
independently a C.sub.3-8 cycloalkyl which is optionally
substituted with from 1 to 4 substituents each of which is
independently halogen, C.sub.1-6 alkyl, OH, O--C.sub.1-6 alkyl, or
C.sub.1-6 haloalkyl; each AryD is independently phenyl or naphthyl,
wherein the phenyl or naphthyl is optionally substituted with from
1 to 5 substituents each of which is independently any one of the
substituents (1) to (25) as set forth above in part (i) of the
definition of AryA; each HetD is independently a 5- or 6-membered
heteroaromatic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein the heteroaromatic
ring is optionally substituted with from 1 to 4 substituents each
of which is independently any one of the substituents (1) to (26)
as set forth above in part (i) of the definition of HetA; each HetZ
is independently a 4- to 7-membered, saturated or mono-unsaturated
heterocyclic ring containing at least one carbon atom and from 1 to
4 heteroatoms independently selected from N, O and S, where each S
is optionally oxidized to S(O) or S(O).sub.2, wherein the saturated
or mono-unsaturated heterocyclic ring is optionally substituted
with from 1 to 4 substituents each of which is independently
halogen, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, O--C.sub.1-6 alkyl,
O--C.sub.1-6 haloalkyl, oxo, C(O)N(R.sup.A)R.sup.B,
C(O)C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A,
S(O)R.sup.A, SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B; each
aryl is independently (i) phenyl, (ii) a 9- or 10-membered
bicyclic, fused carbocyclic ring system in which at least one ring
is aromatic, or (iii) an 11- to 14-membered tricyclic, fused
carbocyclic ring system in which at least one ring is aromatic; and
each heteroaryl is independently (i) a 5- or 6-membered
heteroaromatic ring containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein each N is
optionally in the form of an oxide, or (ii) a 9- or 10-membered
bicyclic, fused ring system containing from 1 to 4 heteroatoms
independently selected from N, O and S, wherein either one or both
of the rings contain one or more of the heteroatoms, at least one
ring is aromatic, each N is optionally in the form of an oxide, and
each S in a ring which is not aromatic is optionally S(O) or
S(O).sub.2.
[0149] The present invention also includes pharmaceutical
compositions containing a compound of Formula I or a
pharmaceutically acceptable salt thereof. The present invention
further includes methods for the treatment of AIDS, the delay in
the onset of AIDS, the prophylaxis of AIDS, the prophylaxis of
infection by HIV, and the treatment of infection by HIV.
[0150] Other embodiments, aspects and features of the present
invention are either further described in or will be apparent from
the ensuing description, examples and appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[0151] The present invention includes compounds of Formula I above,
and pharmaceutically acceptable salts thereof. These compounds and
their pharmaceutically acceptable salts are HIV integrase
inhibitors (e.g., HIV-1 integrase inhibitors).
[0152] A first embodiment of the present invention (alternatively
referred to herein as "Embodiment E1") is a compound of Formula I,
or a pharmaceutically acceptable salt thereof, wherein ring A is a
5- to 9-membered, saturated or mono-unsaturated heterocyclic ring
containing in addition to the nitrogen shared with the
naphthyridine ring from 1 to 3 heteroatoms independently selected
from N, O, and S, wherein each S is optionally oxidized to S(O) or
S(O).sub.2; and wherein the saturated or mono-unsaturated
heterocyclic ring is optionally substituted with a total of from 1
to 6 substituents, wherein: [0153] (i) from zero to 6 substituents
are each independently: [0154] (1) halogen, [0155] (2) C.sub.1-6
alkyl, [0156] (3) C.sub.1-6 haloalkyl, [0157] (4) C.sub.1-6 alkyl
substituted with OH, O--C.sub.1-6 alkyl, O--C.sub.1-6 haloalkyl,
CN, N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A,
CO.sub.2R.sup.A, C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with
the proviso that the N(R.sup.A) moiety and the OR.sup.B moiety are
not both attached to the same carbon of the C.sub.1-6 alkylene
moiety, SR.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A,
SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)CO.sub.2R.sup.B, N(R.sup.A)SO.sub.2R.sup.B,
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)N(R.sup.A)R.sup.B, or OC(O)N(R.sup.A)R.sup.B, [0158]
(5) O--C.sub.1-6 alkyl, [0159] (6) O--C.sub.1-6 haloalkyl, [0160]
(7) oxo, [0161] (8) .dbd.C(R.sup.A)R.sup.B, [0162] (9)
C(O)N(R.sup.A)R.sup.B, [0163] (10) C(O)C(O)N(R.sup.A)R.sup.B,
[0164] (11) C(O)R.sup.A, [0165] (12) CO.sub.2R.sup.A, [0166] (13)
SR.sup.A, [0167] (14) S(O)R.sup.A, [0168] (15) SO.sub.2R.sup.A, or
[0169] (16) SO.sub.2N(R.sup.A)R.sup.B, and [0170] (ii) from zero to
2 substituents are each Z--R.sup.L, wherein: [0171] each Z is
independently a single bond, C.sub.1-6 alkylene, O, O--C.sub.1-6
alkylene, C.sub.1-6 alkylene-O, C(O), C(O)--C.sub.1-6 alkylene,
C.sub.1-6 alkylene-C(O), C(O)--C.sub.1-6 alkylene-O,
C(O)--C.sub.1-6 alkylene-O--C.sub.1-6 alkylene, C(O)N(R.sup.A),
C(O)N(R.sup.A)--C.sub.1-6 alkylene, C.sub.1-6
alkylene-C(O)N(R.sup.A), C.sub.1-6
alkylene-C(O)N(R.sup.A)--C.sub.1-6 alkylene, S(O), S(O).sub.2,
S(O)--C.sub.1-6 alkylene, S(O).sub.2--C.sub.1-6 alkylene, C.sub.1-6
alkylene-S(O), or C.sub.1-6 alkylene-S(O).sub.2; and [0172] each
R.sup.L is independently CycC, AryC, HetC, or HetR; and all other
variables are as originally defined (i.e., as defined in the
Summary of the Invention).
[0173] A second embodiment of the present invention (Embodiment E2)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is R.sup.J or C.sub.1-6 alkyl substituted
with R.sup.J; and all other variables are as originally defined or
as defined in Embodiment E1
[0174] A third embodiment of the present invention (Embodiment E3)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is C.sub.1-6 alkyl substituted with
R.sup.J; and all other variables are as originally defined or as
defined in Embodiment E1.
[0175] A fourth embodiment of the present invention (Embodiment E4)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is C.sub.1-4 alkyl substituted with
R.sup.J; and all other variables are as originally defined or as
defined in Embodiment E1.
[0176] A fifth embodiment of the present invention (Embodiment E5)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is (CH.sub.2).sub.1-2R.sup.J or
CH(CH.sub.3)--R.sup.J; and all other variables are as originally
defined or as defined in Embodiment E1.
[0177] A sixth embodiment of the present invention (Embodiment E6)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is CH.sub.2--R.sup.J; and all other
variables are as originally defined or as defined in Embodiment
E1.
[0178] A seventh embodiment of the present invention (Embodiment
E7) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein R.sup.J is AryA or HetA; and all other
variables are as originally defined or as defined in any one of the
preceding embodiments.
[0179] An eighth embodiment of the present invention (Embodiment
E8) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein R.sup.J is phenyl, naphthyl,
2,3-dihydrobenzo-1,4-dioxinyl, benzo-1,3-dioxolyl, quinolinyl,
isoquinolinyl, cinnolinyl, or quinazolinyl, any of which is
optionally substituted with a total of from 1 to 4 substituents,
wherein: [0180] (a) from zero to 4 substituents are each
independently: [0181] (1) C.sub.1-6 alkyl, [0182] (2) O--C.sub.1-6
alkyl, [0183] (3) C.sub.1-6 haloalkyl, [0184] (4) O--C.sub.1-6
haloalkyl, [0185] (5) OH, [0186] (6) halogen, [0187] (7) CN, [0188]
(8) N(R.sup.A)R.sup.B, [0189] (9) C(O)N(R.sup.A)R.sup.B, [0190]
(10) S(O)R.sup.A, [0191] (11) SO.sub.2R.sup.A, [0192] (12)
N(R.sup.A)SO.sub.2R.sup.B, [0193] (13)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0194] (14)
N(R.sup.A)C(O)R.sup.B, or [0195] (15)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, and [0196] (b) from zero to 2
substituents are each independently HetZ or C(O)--HetZ, [0197]
wherein HetZ is a 5- or 6-membered saturated heterocyclic ring
containing a total of from 1 to 2 heteroatoms selected from 1 to 2
N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the S atom
is optionally S(O) or SO.sub.2, wherein the saturated heterocyclic
ring is optionally substituted with from 1 to 2 substituents each
of which is C.sub.1-4 alkyl, oxo, C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, or SO.sub.2R.sup.A, [0198] and with
the proviso that when HetZ is attached to the rest of the compound
via the C(O) moiety, then HetZ is attached to the C(O) via a ring N
atom; and all other variables are as originally defined or as
defined in any one of the preceding embodiments.
[0199] A ninth embodiment of the present invention (Embodiment E9)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is CH.sub.2--R.sup.J; is as defined in
Embodiment E8; and all other variables are as originally defined or
as defined in Embodiment E1.
[0200] A tenth embodiment of the present invention (Embodiment E10)
is a compound of Formula I, or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is:
##STR00003##
the asterisk * denotes the point of attachment of R.sup.1 to the
rest of the compound; V.sup.1 and V.sup.2 are each independently:
[0201] (1) H, [0202] (2) C.sub.1-4 alkyl, [0203] (3) OH, [0204] (4)
O--C.sub.1-4 alkyl, [0205] (5) C.sub.1-4 haloalkyl, [0206] (6)
O--C.sub.1-4 haloalkyl, [0207] (7) halogen, [0208] (8) CN, [0209]
(9) N(R.sup.A)R.sup.B, [0210] (10) C(O)N(R.sup.A)R.sup.B, [0211]
(11) C(O)R.sup.A, [0212] (12) C(O)OR.sup.A, [0213] (13) SR.sup.A,
[0214] (14) S(O)R.sup.A, [0215] (15) SO.sub.2R.sup.A, [0216] (16)
N(R.sup.A)SO.sub.2R.sup.B, [0217] (17)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0218] (18)
N(R.sup.A)C(O)R.sup.B, [0219] (19)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, [0220] (20) HetD, [0221] (21)
HetZ, or [0222] (22) C(O)--HetZ, [0223] wherein [0224] HetD is a 5-
or 6-membered heteroaromatic ring containing a total of from 1 to 3
heteroatoms independently selected from 1 to 3 N atoms, from zero
to 1 O atom, and from zero to 1 S atom, wherein the heteroaromatic
ring is optionally substituted with 1 or 2 substituents each of
which is independently C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl,
halogen, CN, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A, [0225] HetZ is a 5- or 6-membered saturated
heterocyclic ring containing a total of from 1 to 2 heteroatoms
selected from 1 to 2 N atoms, zero to 1 O atom, and zero to 1 S
atom, wherein the S atom is optionally S(O) or SO.sub.2, wherein
the saturated heterocyclic ring is optionally substituted with from
Ito 2 substituents each of which is independently C.sub.1-4 alkyl,
oxo, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, or
SO.sub.2R.sup.A, [0226] and with the proviso that when HetZ is
attached to the rest of the compound via the C(O) moiety, then HetZ
is attached to the C(O) via a ring N atom; or alternatively V.sup.1
and V.sup.2 are respectively located on adjacent carbons in the
phenyl ring and together form methylenedioxy or ethylenedioxy;
and
V.sup.3 is:
[0226] [0227] (1) H, [0228] (2) C.sub.1-4 alkyl, [0229] (3)
O--C.sub.1-4 alkyl, [0230] (4) C.sub.1-4 haloalkyl, [0231] (5)
O--C.sub.1-4 haloalkyl, or [0232] (6) halogen; and all other
variables are as originally defined or as defined in Embodiment
E1.
[0233] An eleventh embodiment of the present invention (Embodiment
E11) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein R.sup.1 is CH.sub.2--R.sup.J; and kJ is
4-fluorophenyl or 3-chloro-4-fluorophenyl; and all other variables
are as originally defined or as defined in Embodiment E1.
[0234] A twelfth eleventh embodiment of the present invention
(Embodiment E12) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein R.sup.2 is H or C.sub.1-6 alkyl;
and R.sup.3 is H, C.sub.1-6 alkyl, C(O)N(R.sup.A)R.sup.B,
SO.sub.2N(R.sup.A)R.sup.B, or C.sub.1-6 alkyl substituted with
C(O)N(R.sup.A)R.sup.B or SO.sub.2N(R.sup.A)R.sup.B; and all other
variables are as originally defined or as defined in any one of the
preceding embodiments.
[0235] A thirteenth embodiment of the present invention (Embodiment
E13) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 and R.sup.3 are each independently H
or C.sub.1-4 alkyl; and all other variables are as originally
defined or as defined in any one of the preceding embodiments.
[0236] A fourteenth embodiment of the present invention (Embodiment
E14) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein R.sup.2 and R.sup.3 are both H; and all other
variables are as originally defined or as defined in any one of the
preceding embodiments.
[0237] A fifteenth embodiment of the present invention (Embodiment
E15) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein ring A is:
##STR00004##
wherein each R* is independently: (1) H, (2), C.sub.1-6 alkyl, (3)
C(O)R.sup.A, (4) SO.sub.2R.sup.A, (5) CO.sub.2R.sup.A, or (6)
C.sub.1-6 alkyl substituted with OH, O--C.sub.1-6 alkyl,
N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A,
CO.sub.2R.sup.A, C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with
the proviso that the N(R.sup.A) moiety and the OR.sup.B moiety are
not both attached to the same carbon of the C.sub.1-6 alkylene
moiety, S(O)R.sup.A, SO.sub.2R.sup.A, SO.sub.2N(R.sup.A)R.sup.B,
N(R.sup.A)C(O)R.sup.B, N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A;
Q is O or C(R.sup.A)R.sup.B; and the 's denote the points at which
ring A is attached to the remainder of the naphthyridine ring with
which it is fused; and all other variables are as originally
defined or as defined in any one of the preceding embodiments.
[0238] A sub-embodiment of Embodiment E15 is a compound of Formula
I, or a pharmaceutically acceptable salt thereof, wherein each R*
is independently: (1) H, (2), C.sub.1-6 alkyl, (3) C(O)R.sup.A, (4)
SO.sub.2R.sup.A, or (5) CO.sub.2R.sup.A; and ring A, Q and all
other variables are as defined in Embodiment E15.
[0239] A sixteenth embodiment of the present invention (Embodiment
E16) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein each R.sup.A and R.sup.B is independently H
or C.sub.1-4 alkyl; and all other variables are as originally
defined or as defined in any one of the preceding embodiments.
[0240] A seventeenth embodiment of the present invention
(Embodiment E17) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each R.sup.A and R.sup.B is
independently H or C.sub.1-3 alkyl; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments.
[0241] An eighteenth embodiment of the present invention
(Embodiment E18) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each R.sup.A and R.sup.B is
independently H or methyl; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments.
[0242] A nineteenth embodiment of the present invention (Embodiment
E19) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein bond in the ring is a single bond; and all
other variables are as originally defined or as defined in any one
of the preceding embodiments.
[0243] A twentieth embodiment of the present invention (Embodiment
E20) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein CycA, CycB, and CycC are each independently a
C.sub.3-7 cycloalkyl which is optionally substituted with from 1 to
2 substituents each of which is independently C.sub.1-4 alkyl,
O--C.sub.1-4 alkyl, phenyl, or benzyl; and all other variables are
as originally defined or as defined in any one of the preceding
embodiments. In an aspect of this embodiment, CycA, CycB, and CycC
are each independently cyclopropane, cyclobutane, cyclopentane, or
cyclohexane, any of which is optionally substituted with methyl or
phenyl; and all other variables are as originally defined or as
defined in any one of the preceding embodiments.
[0244] A twenty-first embodiment of the present invention
(Embodiment E21) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each aryl (i.e., the aryl
incorporated into the definitions of AryA, AryB, and AryC) is
independently selected from the group consisting of phenyl,
naphthyl, tetrahydronaphthyl (tetralinyl), indenyl, anthracenyl, or
fluorenyl; and all other variables are as originally defined or as
defined in any one of the preceding embodiments. In an aspect of
this embodiment, each aryl is independently selected from the group
consisting of phenyl and naphthyl. In another aspect of this
embodiment, each aryl is phenyl.
[0245] A twenty-second embodiment of the present invention
(Embodiment E22) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each heteroaryl (i.e., the
heteroaryl incorporated into the definitions of HetA, HetB, and
HetC) is independently selected from the group consisting of
pyrrolyl, pyrazolyl, thienyl, furanyl, imidazolyl, triazolyl,
tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl,
thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl (or pyridyl),
pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, benzofuranyl,
indolyl, indazolyl, naphthyridinyl, isobenzofuranyl,
benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl,
quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl,
2,3-dihydrobenzo-1,4-dioxinyl
##STR00005##
and benzo-1,3-dioxolyl
##STR00006##
and all other variables are as originally defined or as defined in
any one of the preceding embodiments. In an aspect of this
embodiment, each heteroaryl is independently a 5- or 6-membered
heteroaromatic ring selected from the group consisting of pyrrolyl,
pyrazolyl, thienyl, furanyl, imidazolyl, triazolyl, tetrazolyl,
oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl,
thiadiazolyl, pyridinyl (or pyridyl), pyrazinyl, pyrimidinyl, and
pyridazinyl.
[0246] A twenty-third embodiment of the present invention
(Embodiment E23) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein HetP and HetQ are each
independently a 4- to 7-membered, saturated heterocyclic ring
containing from 1 to 3 heteroatoms independently selected from N, O
and S, where each S is optionally oxidized to S(O) or SO.sub.2;
wherein the heterocyclic ring is optionally substituted with from 1
to 4 substituents each of which is independently halogen, C.sub.1-4
alkyl, C.sub.1-4 haloalkyl, O--C.sub.1-4 alkyl, O--C.sub.1-4
haloalkyl, oxo, C(O)N(R.sup.A)R.sup.B, C(O)C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, SR.sup.A, S(O)R.sup.A,
SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B; and all other
variables are as originally defined or as defined in any one of the
preceding embodiments. In an aspect of this embodiment, HetP and
HetQ are each independently selected from the group consisting of
azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl,
thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl,
pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl,
tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl,
thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl,
tetrahydrothiopyranyl, and dioxanyl.
[0247] A twenty-fourth embodiment of the present invention
(Embodiment E24) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each CycD is independently a
C.sub.3-7 cycloalkyl which is optionally substituted with from 1 to
2 substituents each of which is independently C.sub.1-4 alkyl,
O--C.sub.1-4 alkyl, phenyl, or benzyl. In an aspect of this
embodiment, each CycD is independently cyclopropane, cyclobutane,
cyclopentane, or cyclohexane, any of which is optionally
substituted with methyl or phenyl; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments.
[0248] A twenty-fifth embodiment of the present invention
(Embodiment E25) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each AryD is independently phenyl
which is optionally substituted with from 1 to 3 substituents each
of which is independently (1) C.sub.1-4 alkyl, (2) OH, (3)
O--C.sub.1-4 alkyl, (4) C.sub.1-4 haloalkyl, (5) O--C.sub.1-4
haloalkyl, (6) halogen, (7) CN, (8) N(R.sup.A)R.sup.B, (9)
C(O)N(R.sup.A)R.sup.B, (10) C(O)R.sup.A, (11) C(O)OR.sup.A, (12)
SR.sup.A, (13) S(O)R.sup.A, (14) SO.sub.2R.sup.A, (15)
N(R.sup.A)SO.sub.2R.sup.B, (16)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (17) N(R.sup.A)C(O)R.sup.B, or
(18) N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B; and all other variables
are as originally defined or as defined in any one of the preceding
embodiments.
[0249] A twenty-sixth embodiment of the present invention
(Embodiment E26) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each AryD is independently phenyl
which is optionally substituted with from 1 to 3 substituents each
of which is independently (1) C.sub.1-4 alkyl, (2) C.sub.1-4
haloalkyl, (3) OH, (4) O--C.sub.1-4 alkyl, (5) halogen, (6) CN, (7)
C(O)NH.sub.2, (8) C(O)NH(C.sub.1-4 alkyl), (9) C(O)N(C.sub.1-4
alkyl).sub.2, or (10) SO.sub.2--C.sub.1-4 alkyl; and all other
variables are as originally defined or as defined in any one of the
preceding embodiments. In an aspect of this embodiment, the 1 to 3
substituents are each independently selected from the group
consisting of CH.sub.3, CF.sub.3, OH, OCH.sub.3, Cl, Br, F, CN,
C(O)NH.sub.2, C(O)NH(CH.sub.3), C(O)N(CH.sub.3).sub.2, or
SO.sub.2CH.sub.3.
[0250] A twenty-seventh embodiment of the present invention
(Embodiment E27) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each HetD is independently a 5- or
6-membered heteroaromatic ring independently selected from the
group consisting of pyrrolyl, pyrazolyl, thienyl, furanyl,
imidazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl,
oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, thiadiazolyl,
pyridinyl (or pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl, and
triazinyl; wherein the heteroaromatic ring is optionally
substituted with from 1 to 3 substituents each of which is
independently (1) C.sub.1-4 alkyl, (2) OH, (3) O--C.sub.1-4 alkyl,
(4) C.sub.1-4 haloalkyl, (5) O--C.sub.1-4 haloalkyl, (6) halogen,
(7) CN, (8) N(R.sup.A)R.sup.B, (9) C(O)N(R.sup.A)R.sup.B, (10)
C(O)R.sup.A, (11) C(O)OR.sup.A, (12) SR.sup.A, (13) S(O)R.sup.A,
(14) SO.sub.2R.sup.A, (15) N(R.sup.A)SO.sub.2R.sup.B, (16)
N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, (17) N(R.sup.A)C(O)R.sup.B, or
(18) N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B; and all other variables
are as originally defined or as defined in any one of the preceding
embodiments.
[0251] A twenty-eighth embodiment of the present invention
(Embodiment E28) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each HetD is independently a 5- or
6-membered heteroaromatic ring independently selected from the
group consisting of the heteroaromatic rings set forth in
Embodiment E27, wherein the heteroaromatic ring is optionally
substituted with from 1 to 3 substituents each of which is
independently (1) C.sub.1-4 alkyl, (2) C.sub.1-4 haloalkyl, (3) OH,
(4) O--C.sub.1-4 alkyl, (5) halogen, (6) CN, (7) C(O)NH.sub.2, (8)
C(O)NH(C.sub.1-4 alkyl), (9) C(O)N(C.sub.1-4 alkyl).sub.2, or (10)
SO.sub.2--C.sub.1-4 alkyl; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments. In an aspect of this embodiment, the 1 to 3
substituents are each independently selected from the group
consisting of CH.sub.3, CF.sub.3, 011, OCH.sub.3, Cl, Br, F, CN,
C(O)NH.sub.2, C(O)NH(CH.sub.3), C(O)N(CH.sub.3).sub.2, or
SO.sub.2CH.sub.3.
[0252] A twenty-ninth embodiment of the present invention
(Embodiment E29) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each HetD is independently a 5- or
6-membered heteroaromatic ring containing a total of from 1 to 3
heteroatoms independently selected from 1 to 3 N atoms, from zero
to 1 O atom, and from zero to 1 S atom, wherein the heteroaromatic
ring is optionally substituted with 1 or 2 substituents each of
which is independently C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl,
halogen, CN, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A; and all other variables are as originally defined
or as defined in any one of the preceding embodiments.
[0253] A thirtieth embodiment of the present invention (Embodiment
E30) is a compound of Formula I, or a pharmaceutically acceptable
salt thereof, wherein each HetZ is independently a 4- to
7-membered, saturated heterocyclic ring containing from 1 to 3
heteroatoms independently selected from N, O and S, where each S is
optionally oxidized to S(O) or SO.sub.2; wherein the heterocyclic
ring is optionally substituted with from 1 to 4 substituents each
of which is independently halogen, C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, O--C.sub.1-4 alkyl, O--C.sub.1-4 haloalkyl, oxo,
C(O)N(R.sup.A)R.sup.B, C(O)C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A,
CO.sub.2R.sup.A, SR.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A, or
SO.sub.2N(R.sup.A)R.sup.B; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments. In an aspect of this embodiment, each HetZ is
independently a saturated heterocyclic ring selected from the group
consisting of azetidinyl, piperidinyl, morpholinyl,
thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl,
isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl,
tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl,
hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl,
diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl,
wherein the ring is optionally substituted with from 1 to 2
substituents each of which is independently C.sub.1-4 alkyl or
oxo.
[0254] A thirty-first embodiment of the present invention
(Embodiment E31) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein Y is a single bond,
(CH.sub.2).sub.1-2, O, O--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--O, C(O), C(O)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O), C(O)--(CH.sub.2).sub.1-2--O,
C(O)--(CH.sub.2).sub.1-2--O--(CH.sub.2).sub.1-2, C(O)N(R.sup.A),
C(O)N(R.sup.A)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O)N(R.sup.A),
(CH.sub.2).sub.1-2--C(O)N(R.sup.A)--(CH.sub.2).sub.1-2, S(O),
S(O).sub.2, S(O)--(CH.sub.2).sub.1-2,
S(O).sub.2--(CH.sub.2).sub.1-2, (CH.sub.2).sub.1-2--S(O), or
(CH.sub.2).sub.1-2--S(O).sub.2; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments.
[0255] A thirty-second embodiment of the present invention
(Embodiment E32) is a compound of Formula I, or a pharmaceutically
acceptable salt thereof, wherein each Z is independently a single
bond, (CH.sub.2).sub.1-2, O, O--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--O, C(O), C(O)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O), C(O)--(CH.sub.2).sub.1-2--O,
C(O)--(CH.sub.2).sub.1-2--O--(CH.sub.2).sub.1-2, C(O)N(R.sup.A),
C(O)N(R.sup.A)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O)N(R.sup.A),
(CH.sub.2).sub.1-2--C(O)N(R.sup.A)--(CH.sub.2).sub.1-2, S(O),
S(O).sub.2, S(O)--(CH.sub.2).sub.1-2,
S(O).sub.2--(CH.sub.2).sub.1-2, (CH.sub.2).sub.1-2--S(O), or
(CH.sub.2).sub.1-2--S(O).sub.2; and all other variables are as
originally defined or as defined in any one of the preceding
embodiments.
[0256] A first class of the present invention (alternatively
referred to herein as "Class C1") includes compounds of Formula IIa
and IIb and pharmaceutically acceptable salts thereof:
##STR00007##
wherein: bond in the ring is a single bond or a double bond;
R.sup.1, R.sup.2 and R.sup.3 are each as originally defined above
or as defined in any one of the preceding embodiments; n is an
integer equal to zero, 1, 2, or 3;
W is O or N--R.sup.8;
R.sup.4 is:
[0257] (1) H, [0258] (2) C.sub.1-6 alkyl, or [0259] (3) C.sub.1-6
alkyl substituted with OH or OC(O)R.sup.A; each R.sup.5 is
independently: [0260] (1) H, [0261] (2) C.sub.1-6 alkyl, [0262] (3)
C.sub.1-6 alkyl substituted with OH, [0263] (4) OH, or [0264] (5)
--R.sup.L; each R.sup.9 is independently H or C.sub.1-6 alkyl;
alternatively, R.sup.5 and R.sup.9 attached to the same ring carbon
atom together form oxo or .dbd.C(R.sup.A)R.sup.B; R.sup.6 and
R.sup.7 are each independently H, C.sub.1-6 alkyl, or C.sub.1-6
alkyl substituted with OH; and
R.sup.8 is:
[0264] [0265] (1) H, [0266] (2) C.sub.1-6 alkyl, [0267] (3)
C.sub.1-6 haloalkyl, [0268] (4) C.sub.1-6 alkyl substituted with
OH, O--C.sub.1-6 alkyl, N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, C(O)--N(R.sup.A)--C.sub.1-6
alkylene-OR.sup.B with the proviso that the N(R.sup.A) moiety and
the OR.sup.B moiety are not both attached to the same carbon of the
C.sub.1-6 alkylene moiety, S(O)R.sup.A, SO.sub.2R.sup.A,
SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A, or [0269] (5)
Z--R.sup.L; [0270] wherein R.sup.A, R.sup.B, Z and R.sup.L are each
as originally defined above.
[0271] It is understood that n=0 means a 5-membered ring with a
direct bond between the ring N atom shared with the naphthyridine
ring and the ring carbon to which R.sup.4 is attached
[0272] A subclass of the first class (alternatively referred to as
"Subclass SC1-1") includes compounds of Formula IIa and IIb, and
pharmaceutically acceptable salts thereof, wherein R.sup.1 is as
defined in Embodiment E10; and all other variables are as
originally defined Class C1.
[0273] A second class of the present invention (Class C2) includes
compounds of Formula IIa' and IIb' and pharmaceutically acceptable
salts thereof:
##STR00008##
wherein: R.sup.4 is H or C.sub.1-6 alkyl; each R.sup.5 is
independently H or C.sub.1-6 alkyl; R.sup.6 and R.sup.7 are each
independently H or C.sub.1-6 alkyl; and
R.sup.8 is:
[0274] (1) H, [0275] (2) C.sub.1-6 alkyl, [0276] (3) C.sub.1-6
haloalkyl, [0277] (4) C.sub.1-6 alkyl substituted with
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A,
C(O)--N(R.sup.A)--C.sub.1-6 alkylene-OR.sup.B with the proviso that
the N(R.sup.A) moiety and the OR.sup.B moiety are not both attached
to the same carbon of the C.sub.1-6 alkylene moiety, S(O)R.sup.A,
SO.sub.2R.sup.A, or SO.sub.2N(R.sup.A)R.sup.B, or [0278] (5)
Z--R.sup.L; and all other variables are as originally defined in
Class C1.
[0279] A subclass of the second class (Subclass SC2-1) includes
compounds of Formula IIa' and IIb', and pharmaceutically acceptable
salts thereof, wherein W is O, NH, or N--C.sub.1-6 alkyl; and all
other variables are as originally defined in the second class.
[0280] Another subclass of the second class (Subclass SC2-2)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein W is O, NH, or N--C.sub.1-4
alkyl; and all other variables are as originally defined in the
second class.
[0281] Another subclass of the second class (Subclass SC2-3)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein W is O; and all other variables
are as originally defined in the second class.
[0282] Still another subclass of the second class (Subclass SC2-4)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein W is NH or N--C.sub.1-4 alkyl;
and all other variables are as originally defined in the second
class.
[0283] Still another subclass of the second class (Subclass SC2-5)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein W is NH or N--C.sub.1-3 alkyl;
and all other variables are as originally defined in the second
class.
[0284] Still another subclass of the second class (Subclass SC2-6)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein W is NH or N--CH.sub.3; and all
other variables are as originally defined in the second class.
[0285] Still another subclass of the second class (Subclass SC2-7)
includes compounds of Formula IIa' and IIb', and pharmaceutically
acceptable salts thereof, wherein Z is a single bond,
(CH.sub.2).sub.1-2, O, O--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--O, C(O), C(O)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O), C(O)--(CH.sub.2).sub.1-2--O,
C(O)--(CH.sub.2).sub.1-2--O--(CH.sub.2).sub.1-2, C(O)N(R.sup.A),
C(O)N(R.sup.A)--(CH.sub.2).sub.1-2,
(CH.sub.2).sub.1-2--C(O)N(R.sup.A),
(CH.sub.2).sub.1-2--C(O)N(R.sup.A)--(CH.sub.2).sub.1-2, S(O),
S(O).sub.2, S(O)--(CH.sub.2).sub.1-2,
S(O).sub.2--(CH.sub.2).sub.1-2, (CH.sub.2).sub.1-2--S(O), or
(CH.sub.2).sub.1-2--S(O).sub.2; and all other variables are as
originally defined in the second class or as defined in any of the
preceding subclasses of the second class.
[0286] A third class of the present invention (Class C3) includes
compounds of Formula IIIa, IIIb, IIIc, and IIId and
pharmaceutically acceptable salts thereof:
##STR00009##
wherein: bond in the ring is a single bond or a double bond;
R.sup.2 and R.sup.3 are each independently H or C.sub.1-4
alkyl;
R.sup.4 is:
[0287] (1) H, [0288] (2) C.sub.1-4 alkyl, or [0289] (3) C.sub.1-4
alkyl substituted with OH or OC(O)R.sup.A; R.sup.5a is H, C.sub.1-4
alkyl, OH or -HetR; R.sup.9a is H or C.sub.1-4 alkyl;
alternatively, Rya and R.sup.9a together form oxo; R.sup.5b is H,
C.sub.1-4 alkyl, or OH; R.sup.9b is H or C.sub.1-4 alkyl; R.sup.5c
is H, C.sub.1-4 alkyl, or C.sub.1-4 alkyl substituted with OH;
R.sup.9c is H or C.sub.1-4 alkyl; alternatively, R.sup.5c and
R.sup.9c together form .dbd.CH.sub.2; with the proviso that when
one of R.sup.5a, R.sup.5b and R.sup.5c is other than H or C.sub.1-4
alkyl, then the other two of R.sup.5a, R.sup.5b and R.sup.5c is H
or C.sub.1-4 alkyl; one of R.sup.6 and R.sup.7 is H, C.sub.1-4
alkyl, or C.sub.1-4 alkyl substituted with OH, and the other of
R.sup.6 and R.sup.7 is H or C.sub.1-4 alkyl;
R.sup.8 is:
[0289] [0290] (1) H, [0291] (2) C.sub.1-4 alkyl, [0292] (3)
C.sub.1-4 haloalkyl, [0293] (4) C.sub.1-4 alkyl substituted with
OH, O--C.sub.1-4 alkyl, N(R.sup.A)R.sup.B, C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A,
SO.sub.2N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A, [0294] (5) C.sub.1-4
alkylene-HetC, or [0295] (6) C.sub.1-4 alkylene-HetR; HetC is a 5-
or 6-membered heteroaromatic ring containing a total of from 1 to 3
heteroatoms independently selected from 1 to 3 N atoms, from zero
to 1 O atom, and from zero to 1 S atom, wherein the heteroaromatic
ring is optionally substituted with 1 or 2 substituents each of
which is independently C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl,
halogen, CN, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A; HetR is a 5- or 6-membered saturated heterocyclic
ring containing a total of from 1 to 2 heteroatoms selected from 1
to 2N atoms, zero to 1 O atom, and zero to 1 S atom, wherein the S
atom is optionally S(O) or SO.sub.2, wherein the saturated
heterocyclic ring is optionally substituted with from 1 to 2
substituents each of which is independently C.sub.1-4 alkyl, oxo,
C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, or
SO.sub.2R.sup.A; each R.sup.A is independently H or C.sub.1-4
alkyl; each R.sup.B is independently H or C.sub.1-4 alkyl; and
V.sup.1, V.sup.2 and V.sup.3 are as defined in Embodiment E10.
[0296] As an example of the proviso for R.sup.5a, R.sup.5b and
R.sup.5c in Class C3, when R.sup.5a is OH or -HetR or when R.sup.5a
and R.sup.9a together form oxo, then R.sup.5b and R.sup.5c are each
independently H or C.sub.1-4 alkyl.
[0297] A fourth class of the present invention (Class C4) includes
compounds of Formula IIIa' and IIId' and pharmaceutically
acceptable salts thereof:
##STR00010##
wherein: bond in the ring is a single bond or a double bond; n is
an integer equal to zero, 1, 2 or 3; V.sup.1 and V.sup.2 are each
independently: [0298] (1) H, [0299] (2) C.sub.1-4 alkyl, [0300] (3)
OH, [0301] (4) O--C.sub.1-4 alkyl, [0302] (5) C.sub.1-4 haloalkyl,
[0303] (6) O--C.sub.1-4 haloalkyl, [0304] (7) halogen, [0305] (8)
CN, [0306] (9) N(R.sup.A)R.sup.B, [0307] (10)
C(O)N(R.sup.A)R.sup.B, [0308] (11) C(O)R.sup.A, [0309] (12)
C(O)OR.sup.A, [0310] (13) SR.sup.A, [0311] (14) S(O)R.sup.A, [0312]
(15) SO.sub.2R.sup.A, [0313] (16) N(R.sup.A)SO.sub.2R.sup.B, [0314]
(17) N(R.sup.A)SO.sub.2N(R.sup.A)R.sup.B, [0315] (18)
N(R.sup.A)C(O)R.sup.B, [0316] (19)
N(R.sup.A)C(O)C(O)N(R.sup.A)R.sup.B, [0317] (20) HetD, [0318] (21)
HetZ, or [0319] (22) C(O)--HetZ, [0320] wherein [0321] HetD is a 5-
or 6-membered heteroaromatic ring containing a total of from 1 to 3
heteroatoms independently selected from 1 to 3 N atoms, from zero
to 1 O atom, and from zero to 1 S atom, wherein the heteroaromatic
ring is optionally substituted with 1 or 2 substituents each of
which is independently C.sub.1-4 alkyl, OH, O--C.sub.1-4 alkyl,
halogen, CN, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, C(O)OR.sup.A, or
SO.sub.2R.sup.A, [0322] HetZ is a 5- or 6-membered saturated
heterocyclic ring containing a total of from 1 to 2 heteroatoms
selected from 1 to 2 N atoms, zero to 1 O atom, and zero to 1 S
atom, wherein the S atom is optionally S(O) or SO.sub.2, wherein
the saturated heterocyclic ring is optionally substituted with from
Ito 2 substituents each of which is independently C.sub.1-4 alkyl,
oxo, C(O)N(R.sup.A)R.sup.B, C(O)R.sup.A, CO.sub.2R.sup.A, or
SO.sub.2R.sup.A, [0323] and with the proviso that when HetZ is
attached to the rest of the compound via the C(O) moiety, then HetZ
is attached to the C(O) via a ring N atom; or alternatively V.sup.1
and V.sup.2 are respectively located on adjacent carbons in the
phenyl ring and together form methylenedioxy or ethylenedioxy;
V.sup.3 is:
[0323] [0324] (1) H, [0325] (2) C.sub.1-4 alkyl, [0326] (3)
O--C.sub.1-4 alkyl, [0327] (4) C.sub.1-4 haloalkyl, [0328] (5)
O--C.sub.1-4 haloalkyl, or [0329] (6) halogen; W is O, NH,
N--C.sub.1-4 alkyl, NC(O)--C.sub.1-4 alkyl, N--C(O)O--C.sub.1-4
alkyl, or N--SO.sub.2--C.sub.1-4 alkyl; R.sup.2 and R.sup.3 are
each independently H or C.sub.1-4 alkyl; R.sup.6 and R.sup.7 are
each independently H or C.sub.1-4 alkyl; each R.sup.A is
independently H or C.sub.1-4 alkyl; and each R.sup.B is
independently F.sub.1 or C.sub.1-4 alkyl.
[0330] A subclass of the fourth class (Subclass SC4-1) includes
compounds of Formula IIIa' and IIId', and pharmaceutically
acceptable salts thereof, wherein:
bond in the ring is a single bond; n is an integer equal to 1, 2 or
3; V.sup.1 and V.sup.2 are each independently: [0331] (1) H, [0332]
(2) C.sub.1-4 alkyl, [0333] (3) C.sub.1-4 haloalkyl, [0334] (4) OH,
[0335] (5) O--C.sub.1-4 alkyl, [0336] (6) halogen, [0337] (7) CN,
[0338] (8) C(O)NH.sub.2, [0339] (9) C(O)NH(C.sub.1-4 alkyl), [0340]
(10) C(O)N(C.sub.1-4 alkyl).sub.2, or [0341] (11)
SO.sub.2--C.sub.1-4 alkyl; or alternatively V.sup.1 and V.sup.2 are
respectively located on adjacent carbons in the phenyl ring and
together form methylenedioxy or ethylenedioxy; and V.sup.3 is H,
halogen, C.sub.1-4 alkyl, or O--C.sub.1-4 alkyl; and all other
variables are as originally defined in the Class C4.
[0342] A fifth class of the present invention (Class C5) includes
compounds of Formula IIIa' and IIId' and pharmaceutically
acceptable salts thereof, wherein:
bond in the ring is a single bond; n is an integer equal to 1, 2 or
3; V.sup.1 and V.sup.2 are each independently: [0343] (1) H, [0344]
(2) CH.sub.3, [0345] (3) CF.sub.3, [0346] (4) OH, [0347] (5)
OCH.sub.3, [0348] (6) Cl, Br, or F, [0349] (7) CN, [0350] (8)
C(O)NH.sub.2, [0351] (9) C(O)NH(CH.sub.3), [0352] (10)
C(O)N(CH.sub.3).sub.2, or [0353] (11) SO.sub.2CH.sub.3;
V.sup.3 is H, Cl, Br, F, CH.sub.3, or OCH.sub.3;
W is O, NH, or N--CH.sub.3;
[0354] R.sup.2 and R.sup.3 are both H; and R.sup.6 and R.sup.7 are
each independently H or CH.sub.3.
[0355] A sixth class of the present invention (Class C6) includes
compounds of Formula IIIa, IIIb, IIIc and IIId and pharmaceutically
acceptable salts thereof, wherein:
bond in the ring is a single bond; R.sup.2 and R.sup.3 are each
independently H or CH.sub.3;
R.sup.4 is:
[0356] (1) H, [0357] (2) CH.sub.3, [0358] (3) CH.sub.2CH.sub.3,
[0359] (4) CH.sub.2CH.sub.2CH.sub.3, [0360] (5) CH(CH.sub.3).sub.2,
[0361] (3) (CH.sub.2).sub.1-3--OH, or [0362] (4)
(CH.sub.2).sub.1-3--OC(O)R.sup.A;
R.sup.5a is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, OH or -HetR;
R.sup.9a is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, or CH(CH.sub.3).sub.2;
[0363] alternatively, R.sup.5a and R.sup.9a together form oxo;
R.sup.5b is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, or OH;
R.sup.9b is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, or CH(CH.sub.3).sub.2;
R.sup.5c is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2, or
(CH.sub.2).sub.1-3--OH;
R.sup.9c is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, or CH(CH.sub.3).sub.2;
[0364] alternatively, R.sup.5c and R.sup.9c together form
.dbd.CH.sub.2; with the proviso that when one of R.sup.5a, R.sup.5b
and R.sup.5c is other than H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, or CH(CH.sub.3).sub.2, then the other two
of R.sup.5a, R.sup.5b and R.sup.5c is H, CH.sub.3,
CH.sub.2CH.sub.3, CH.sub.2CH.sub.2CH.sub.3, or CH(CH.sub.3).sub.2;
one of R.sup.6 and R.sup.7 is H, CH.sub.3, CH.sub.2CH.sub.3,
CH.sub.2CH.sub.2CH.sub.3, CH(CH.sub.3).sub.2 or
(CH.sub.2).sub.1-3--OH, and the other of R.sup.6 and R.sup.7 is H
or CH.sub.3;
R.sup.8 is:
[0365] (1) H, [0366] (2) CH.sub.3, [0367] (3) CH.sub.2CH.sub.3,
[0368] (4) CH.sub.2CH.sub.2CH.sub.3, [0369] (5) CH(CH.sub.3).sub.2,
[0370] (6) CH.sub.2CH.sub.2CH.sub.2CH.sub.3, [0371] (7)
C(CH.sub.3).sub.3, [0372] (8) CH.sub.2CH(CH.sub.3).sub.2, [0373]
(9) CH(CH.sub.3)CH.sub.2CH.sub.3, [0374] (10) CF.sub.3, [0375] (11)
CH.sub.2CF.sub.3, [0376] (12) (CH.sub.2).sub.2-4--U, wherein U is
OH, OCH.sub.3, N(R.sup.A)R.sup.B, N(R.sup.A)C(O)R.sup.B,
N(R.sup.A)SO.sub.2R.sup.B, or OC(O)R.sup.A, [0377] (13)
(CH.sub.2).sub.1-4--V, wherein V is C(O)N(R.sup.A)R.sup.B,
C(O)R.sup.A, CO.sub.2R.sup.A, S(O)R.sup.A, SO.sub.2R.sup.A, or
SO.sub.2N(R.sup.A)R.sup.B, [0378] (14) (CH.sub.2).sub.2-4-HetC, or
[0379] (15) (CH.sub.2).sub.2-4-HetR; HetC is a 5-membered
heteroaromatic ring selected from the group consisting of:
##STR00011##
[0379] HetR is a 5- or 6-membered saturated heterocyclic ring
selected from the group consisting of:
##STR00012##
the asterisk * in HetC and HetR denotes the point of attachment to
the rest of the molecule; each R.sup.A is independently H or
CH.sub.3; each R.sup.B is independently H or CH.sub.3; V.sup.1 and
V.sup.2 are each independently: [0380] (1) H, [0381] (2) CH.sub.3,
[0382] (3) CF.sub.3, [0383] (4) OH, [0384] (5) OCH.sub.3, [0385]
(6) Cl, Br, or F, [0386] (7) CN, [0387] (8) C(O)NH.sub.2, [0388]
(9) C(O)NH(CH.sub.3), [0389] (10) C(O)N(CH.sub.3).sub.2, or [0390]
(11) SO.sub.2CH.sub.3; and
V.sup.3 is H, Cl, Br, F, CH.sub.3, or OCH.sub.3.
[0391] Another embodiment of the present invention is a compound,
or a pharmaceutically acceptable salt thereof, selected from the
group consisting of the compounds set forth in Examples 1 to 64.
Another embodiment of the present invention is a compound, or a
pharmaceutically acceptable salt thereof, selected from the group
consisting of the compounds set forth in Examples 1 to 9. Another
embodiment of the present invention is a compound, or a
pharmaceutically acceptable salt thereof, selected from the group
consisting of the compounds set forth in Examples 10 to 64.
[0392] Another embodiment of the present invention is a compound of
Formula I, or a pharmaceutically acceptable salt thereof, as
originally defined or as defined in any of the foregoing
embodiments, classes, subclasses, aspects, or features, wherein the
compound or its salt is substantially pure. As used herein
"substantially pure" means that the compound or its salt is present
(e.g., in a product isolated from a chemical reaction or a
metabolic process) in an amount of at least about 90 wt. % (e.g.,
from about 95 wt. % to 100 wt. %), preferably at least about 95 wt.
% (e.g., from about 98 wt. % to 100 wt. %), more preferably at
least about 99 wt. %, and most preferably 100 wt. %. The level of
purity of the compounds and salts can be determined using standard
methods of analysis. A compound or salt of 100% purity can
alternatively be described as one which is free of detectable
impurities as determined by one or more standard methods of
analysis. With respect to a compound of the invention which has one
or more asymmetric centers and can occur as mixtures of
stereoisomers, a substantially pure compound can be either a
substantially pure mixture of the stereoisomers or a substantially
pure individual diastereomer or enantiomer.
[0393] Other embodiments of the present invention include the
following:
[0394] (a) A pharmaceutical composition comprising an effective
amount of a compound of Formula I and a pharmaceutically acceptable
carrier.
[0395] (b) A pharmaceutical composition which comprises the product
prepared by combining (e.g., mixing) an effective amount of a
compound of Formula I and a pharmaceutically acceptable
carrier.
[0396] (c) The pharmaceutical composition of (a) or (b), further
comprising an effective amount of an anti-HIV agent selected from
the group consisting of HIV antiviral agents, immunomodulators, and
anti-infective agents.
[0397] (d) The pharmaceutical composition of (c), wherein the
anti-HIV agent is an antiviral selected from the group consisting
of HIV protease inhibitors, non-nucleoside HIV reverse
transcriptase inhibitors, and nucleoside HIV reverse transcriptase
inhibitors.
[0398] (e) A pharmaceutical combination which is (i) a compound of
Formula I and (ii) an anti-HIV agent selected from the group
consisting of HIV antiviral agents, immunomodulators, and
anti-infective agents; wherein the compound of Formula I and the
anti-HIV agent are each employed in an amount that renders the
combination effective for the inhibition of HIV integrase, for the
treatment or prophylaxis of infection by HIV, or for the treatment,
prophylaxis or delay in the onset of AIDS.
[0399] (f) The combination of (e), wherein the anti-HIV agent is an
antiviral selected from the group consisting of HIV protease
inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and
nucleoside HIV reverse transcriptase inhibitors.
[0400] (g) A method of inhibiting HIV integrase in a subject in
need thereof which comprises administering to the subject an
effective amount of a compound of Formula I.
[0401] (h) A method for the treatment or prophylaxis of infection
by HIV in a subject in need thereof which comprises administering
to the subject an effective amount of a compound of Formula I.
[0402] (i) The method of (h), wherein the compound of Formula I is
administered in combination with an effective amount of at least
one antiviral selected from the group consisting of HIV protease
inhibitors, non-nucleoside HIV reverse transcriptase inhibitors,
and nucleoside HIV reverse transcriptase inhibitors.
[0403] (j) A method for the treatment, prophylaxis, or delay in the
onset of AIDS in a subject in need thereof which comprises
administering to the subject an effective amount of a compound of
Formula I.
[0404] (k) The method of (j), wherein the compound is administered
in combination with an effective amount of at least one antiviral
selected from the group consisting of HIV protease inhibitors,
non-nucleoside HIV reverse transcriptase inhibitors, and nucleoside
HIV reverse transcriptase inhibitors.
[0405] (l) A method of inhibiting HIV integrase in a subject in
need thereof which comprises administering to the subject the
pharmaceutical composition of (a), (b), (c) or (d) or the
combination of (e) or (f).
[0406] (m) A method for the treatment or prophylaxis of infection
by HIV in a subject in need thereof which comprises administering
to the subject the pharmaceutical composition of (a), (b), (c) or
(d) or the combination of (e) or (f).
[0407] (n) A method for the treatment, prophylaxis, or delay in the
onset of AIDS in a subject in need thereof which comprises
administering to the subject the pharmaceutical composition of (a),
(b), (c) or (d) or the combination of (e) or (f).
[0408] The present invention also includes a compound of the
present invention (i) for use in, (ii) for use as a medicament for,
or (iii) for use in the preparation of a medicament for: (a) the
inhibition of HIV integrase, (b) treatment or prophylaxis of
infection by HIV, or (c) treatment, prophylaxis, or delay in the
onset of AIDS. In these uses, the compounds of the present
invention can optionally be employed in combination with one or
more anti-HIV agents selected from HIV antiviral agents,
anti-infective agents, and immunomodulators.
[0409] Additional embodiments of the invention include the
pharmaceutical compositions, combinations and methods set forth in
(a)-(n) above and the uses set forth in the preceding paragraph,
wherein the compound of the present invention employed therein is a
compound of one of the embodiments, aspects, classes, subclasses,
or features of the compounds described above. In all of these
embodiments, the compound may optionally be used in the form of a
pharmaceutically acceptable salt.
[0410] The present invention also includes prodrugs of the
compounds of Formula I. The term "prodrug" refers to a derivative
of a compound of Formula I, or a pharmaceutically acceptable salt
thereof, which is converted in vivo into Compound I. Prodrugs of
compounds of Formula I can exhibit enhanced solubility, absorption,
and/or lipophilicity compared to the compounds per se, thereby
resulting in increased bioavailability and efficacy. The in vivo
conversion of the prodrug can be the result of an enzyme-catalyzed
chemical reaction, a metabolic chemical reaction, and/or a
spontaneous chemical reaction (e.g., solvolysis). The prodrug can
be, for example, a derivative of a hydroxy group such as an ester
(--OC(O)R), a carbonate ester (--OC(O)OR), a phosphate ester
(--O--P(.dbd.O)(OH).sub.2), or an ether (--OR). Other examples
include the following: When the compound of Formula I contains a
carboxylic acid group, the prodrug can be an ester or an amide, and
when the compound of Formula I contains a primary amino group, the
prodrug can be an amide, carbamate, imine, or a Mannich base. One
or more functional groups in Compound I can be derivatized to
provide a prodrug thereof. Conventional procedures for the
selection and preparation of suitable prodrug derivatives are
described, for example, in Design of Prodrugs, edited by H.
Bundgaard, Elsevier, 1985; C. S. Larsen and J. Ostergaard, "Design
and application of prodrugs" in: Textbook of Drug Design and
Discovery, 3.sup.rd edition, edited by C. S. Larsen, 2002, pp.
410-458; and Beaumont et al., Current Drug Metabolism 2003, vol. 4,
pp. 461-458; the disclosures of each of which are incorporated
herein by reference in their entireties. Prodrugs of compounds of
Formula I can also be selected and prepared by application of the
descriptions in WO 2005/070901 and WO 2005/117904, both herein
incorporated by reference in their entireties.
[0411] As used herein, the term "alkyl" refers to any linear or
branched chain alkyl group having a number of carbon atoms in the
specified range. Thus, for example, "C.sub.1-6 alkyl" (or
"C.sub.1-C.sub.6 alkyl") refers to all of the hexyl alkyl and
pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and
isopropyl, ethyl and methyl. As another example, "C.sub.1-4 alkyl"
refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and
methyl.
[0412] The term "alkylene" refers to any divalent linear or
branched chain aliphatic hydrocarbon radical (or alternatively an
"alkanediyl") having a number of carbon atoms in the specified
range. Thus, for example, "--C.sub.1-6 alkylene-" refers to any of
the C.sub.1 to C.sub.6 linear or branched alkylenes. A class of
alkylenes of particular interest with respect to the invention is
--(CH.sub.2).sub.1-6--, and subclasses of particular interest
include --(CH.sub.2).sub.1-4--, --(CH.sub.2).sub.1-3--,
--(CH.sub.2).sub.1-2--, and --CH.sub.2--. Also of interest is the
alkylene --CH(CH.sub.3)--.
[0413] The term "C(O)" refers to carbonyl. The terms "S(O).sub.2"
and "SO.sub.2" each refer to sulfonyl. The term "S(O)" refers to
sulfinyl.
[0414] The symbols "*" and at the end of a bond each refer to the
point of attachment of a functional group or other chemical moiety
to the rest of the molecule of which it is a part.
[0415] The terms "cycloalkyl" refers to any cyclic ring of an
alkane having a number of carbon atoms in the specified range.
Thus, for example, "C.sub.3-8 cycloalkyl" (or "C.sub.3-C.sub.8
cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, cycloheptyl, and cyclooctyl.
[0416] The term "halogen" (or "halo") refers to fluorine, chlorine,
bromine and iodine (alternatively referred to as fluoro, chloro,
bromo, and iodo).
[0417] The term "haloalkyl" refers to an alkyl group as defined
above in which one or more of the hydrogen atoms has been replaced
with a halogen (i.e., F, Cl, Br and/or I). Thus, for example,
"C.sub.1-6 haloalkyl" (or "C.sub.1-C.sub.6 haloalkyl") refers to a
C1 to C6 linear or branched alkyl group as defined above with one
or more halogen substituents. The term "fluoroalkyl" has an
analogous meaning except that the halogen substituents are
restricted to fluoro. Suitable fluoroalkyls include the series
(CH.sub.2).sub.0-4CF.sub.3 (i.e., trifluoromethyl,
2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
[0418] Unless expressly stated to the contrary, all ranges cited
herein are inclusive. For example, a heterocyclic ring described as
containing from "1 to 4 heteroatoms" means the ring can contain 1,
2, 3 or 4 heteroatoms. It is also to be understood that any range
cited herein includes within its scope all of the sub-ranges within
that range. Thus, for example, a heterocyclic ring described as
containing from "1 to 4 heteroatoms" is intended to include as
aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms,
3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2
heteroatoms, 1 heteroatom, 2 heteroatoms, and so forth. As another
example, an aryl or heteroaryl described as optionally substituted
with "from 1 to 5 substituents" is intended to include as aspects
thereof, an aryl or heteroaryl optionally substituted with 1 to 4
substituents, 1 to 3 substituents, 1 to 2 substituents, 2 to 5
substituents, 2 to 4 substituents, 2 to 3 substituents, 3 to 5
substituents, 3 to 4 substituents, 1 substituent, 2 substituents, 3
substituents, 4 substituents, and 5 substituents.
[0419] When any variable (e.g., R.sup.A, R.sup.B, or AryD) occurs
more than one time in any constituent or in Formula I or in any
other formula depicting and describing compounds of the invention,
its definition on each occurrence is independent of its definition
at every other occurrence. Also, combinations of substituents
and/or variables are permissible only if such combinations result
in stable compounds.
[0420] It is understood that the right side of a group Y is
attached to R.sup.K and the left side of a group Y is attached to
the rest of the molecule. Thus, for example, for Y=C.sub.1-6
alkylene-C(O) (e.g., (CH.sub.2).sub.1-2--C(O)), R.sup.K is attached
to the carbonyl; i.e., C.sub.1-6 alkylene-C(O)--R.sup.K (e.g.,
(CH.sub.2).sub.1-2--C(O)--R.sup.K). Similarly, it is understood
that the right side of a group Z is attached to R.sup.L and the
left side of a group Z is attached to ring A. Thus, for example,
for Z=C.sub.1-6 alkylene-C(O) (e.g., (CH.sub.2).sub.1-2--C(O)),
R.sup.L is attached to the carbonyl; i.e., C.sub.1-6
alkylene-C(O)--R.sup.L (e.g.,
(CH.sub.2).sub.1-2--C(O)--R.sup.L).
[0421] The term "substituted" (e.g., as in "is optionally
substituted with from 1 to 5 substituents . . . ") includes mono-
and poly-substitution by a named substituent to the extent such
single and multiple substitution (including multiple substitution
at the same site) is chemically allowed. Unless expressly stated to
the contrary, substitution by a named substituent is permitted on
any atom in a ring (e.g., aryl, a heteroaromatic ring, or a
saturated heterocyclic ring) provided such ring substitution is
chemically allowed and results in a stable compound.
[0422] Any of the various carbocyclic and heterocyclic rings and
ring systems defined herein may be attached to the rest of the
compound at any ring atom (i.e., any carbon atom or any heteroatom)
provided that a stable compound results.
[0423] A "stable" compound is a compound which can be prepared and
isolated and whose structure and properties remain or can be caused
to remain essentially unchanged for a period of time sufficient to
allow use of the compound for the purposes described herein (e.g.,
therapeutic or prophylactic administration to a subject).
[0424] As a result of the selection of substituents and substituent
patterns, certain of the compounds of the present invention can
have asymmetric centers and can occur as mixtures of stereoisomers,
or as individual diastereomers or enantiomers. All isomeric forms
of these compounds, whether isolated or in mixtures, are within the
scope of the present invention.
[0425] As would be recognized by one of ordinary skill in the art,
certain of the compounds of the present invention can exist as
tautomers. All tautomeric forms of these compounds, whether
isolated or in mixtures, are within the scope of the present
invention.
[0426] In instances where a hydroxy (--OH) substituent is permitted
on a heteroaromatic ring and keto-enol tautomerism is possible, it
is understood that the substituent might in fact be present, in
whole or in part, in the keto form, as exemplified here for a
hydroxypyridinyl substituent:
##STR00013##
Compounds of the present invention having a hydroxy substituent on
a carbon atom of a heteroaromatic ring are understood to include
compounds in which only the hydroxy is present, compounds in which
only the tautomeric keto form (i.e., an oxo substitutent) is
present, and compounds in which the keto and enol forms are both
present.
[0427] Certain of the compounds of the present invention can
exhibit a chirality resulting from the presence of bulky
substituents that hinder the otherwise free rotation about a bond.
These rotational enantiomers are named atropisomers, and the
interconversion can be sufficiently slow to allow for their
separation and characterization. See, e.g., J. March, Advanced
Organic Chemistry, 4th Edition, John Wiley & Sons, 1992, pp.
101-102; and Ahmed et al., Tetrahedron 1998, 13277. For example,
certain of the compounds of the present invention as exemplified
with structures A and B below in which there could be sufficient
hindrance to rotation along the bond indicated with an arrow to
permit separation of the enantiomers using, e.g., column
chromatography on a chiral stationary phase. The present invention
includes atropisomers of compounds embraced by Formula I, singly
and in mixtures.
##STR00014##
[0428] The compounds of the present inventions are useful in the
inhibition of HIV integrase (e.g., HIV-1 integrase), the
prophylaxis or treatment of infection by HIV and the prophylaxis,
treatment or the delay in the onset of consequent pathological
conditions such as AIDS. The prophylaxis of AIDS, treating AIDS,
delaying the onset of AIDS, the prophylaxis of infection by HIV, or
treating infection by HIV is defined as including, but not limited
to, treatment of a wide range of states of HIV infection: AIDS, ARC
(AIDS related complex), both symptomatic and asymptomatic, and
actual or potential exposure to HIV. For example, the compounds of
this invention are useful in treating infection by HIV after
suspected past exposure to HIV by such means as blood transfusion,
exchange of body fluids, bites, accidental needle stick, or
exposure to patient blood during surgery.
[0429] The compounds of this invention are useful in the
preparation and execution of screening assays for antiviral
compounds. For example, the compounds of this invention are useful
for isolating enzyme mutants, which are excellent screening tools
for more powerful antiviral compounds. Furthermore, the compounds
of this invention are useful in establishing or determining the
binding site of other antivirals to HIV integrase, e.g., by
competitive inhibition. Thus the compounds of this invention can be
commercial products to be sold for these purposes.
[0430] The compounds of the present invention can be administered
in the form of pharmaceutically acceptable salts. The term
"pharmaceutically acceptable salt" refers to a salt which possesses
the effectiveness of the parent compound and which is not
biologically or otherwise undesirable (e.g., is neither toxic nor
otherwise deleterious to the recipient thereof). Suitable salts
include acid addition salts which may, for example, be formed by
mixing a solution of the compound of the present invention with a
solution of a pharmaceutically acceptable acid such as hydrochloric
acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic
acid. Certain compounds of the invention carry an acidic moiety, in
which case suitable pharmaceutically acceptable salts thereof can
include alkali metal salts (e.g., sodium or potassium salts),
alkaline earth metal salts (e.g., calcium or magnesium salts), and
salts formed with suitable organic ligands such as quaternary
ammonium salts. Also, in the case of an acid (--COOH) or alcohol
group being present, pharmaceutically acceptable esters can be
employed to modify the solubility or hydrolysis characteristics of
the compound.
[0431] The term "administration" and variants thereof (e.g.,
"administered" or "administering") in reference to a compound of
the invention mean providing the compound or a prodrug of the
compound to the individual in need of treatment or prophylaxis.
When a compound of the invention or a prodrug thereof is provided
in combination with one or more other active agents (e.g.,
antiviral agents useful for the prophylaxis or treatment of HIV
infection or AIDS), "administration" and its variants are each
understood to include provision of the compound or prodrug and
other agents at the same time or at different times. When the
agents of a combination are administered at the same time, they can
be administered together in a single composition or they can be
administered separately.
[0432] As used herein, the term "composition" is intended to
encompass a product comprising the specified ingredients, as well
as any product which results, directly or indirectly, from
combining the specified ingredients.
[0433] By "pharmaceutically acceptable" is meant that the
ingredients of the pharmaceutical composition must be compatible
with each other and not deleterious to the recipient thereof.
[0434] The term "subject" (or, alternatively, "patient") as used
herein refers to an animal, preferably a mammal, most preferably a
human, who has been the object of treatment, observation or
experiment.
[0435] The term "effective amount" as used herein means that amount
of active compound or pharmaceutical agent that elicits the
biological or medicinal response in a tissue, system, animal or
human that is being sought by a researcher, veterinarian, medical
doctor or other clinician. In one embodiment, the effective amount
is a "therapeutically effective amount" for the alleviation of the
symptoms of the disease or condition being treated. In another
embodiment, the effective amount is a "prophylactically effective
amount" for prophylaxis of the symptoms of the disease or condition
being prevented. The term also includes herein the amount of active
compound sufficient to inhibit HIV integrase and thereby elicit the
response being sought (i.e., an "inhibition effective amount").
When the active compound (i.e., active ingredient) is administered
as the salt, references to the amount of active ingredient are to
the free acid or free base form of the compound.
[0436] For the purpose of the inhibition of HIV integrase, the
prophylaxis or treatment of HIV infection, or the prophylaxis or
treatment or delay in the onset of AIDS, the compounds of the
present invention, optionally in the form of a salt, can be
administered by any means that produces contact of the active agent
with the agent's site of action. They can be administered by any
conventional means available for use in conjunction with
pharmaceuticals, either as individual therapeutic agents or in a
combination of therapeutic agents. They can be administered alone,
but typically are administered with a pharmaceutical carrier
selected on the basis of the chosen route of administration and
standard pharmaceutical practice. The compounds of the invention
can, for example, be administered orally, parenterally (including
subcutaneous injections, intravenous, intramuscular, intrasternal
injection or infusion techniques), by inhalation spray, or
rectally, in the form of a unit dosage of a pharmaceutical
composition containing an effective amount of the compound and
conventional non-toxic pharmaceutically-acceptable carriers,
adjuvants and vehicles. Liquid preparations suitable for oral
administration (e.g., suspensions, syrups, elixirs and the like)
can be prepared according to techniques known in the art and can
employ any of the usual media such as water, glycols, oils,
alcohols and the like. Solid preparations suitable for oral
administration (e.g., powders, pills, capsules and tablets) can be
prepared according to techniques known in the art and can employ
such solid excipients as starches, sugars, kaolin, lubricants,
binders, disintegrating agents and the like. Parenteral
compositions can be prepared according to techniques known in the
art and typically employ sterile water as a carrier and optionally
other ingredients, such as a solubility aid. Injectable solutions
can be prepared according to methods known in the art wherein the
carrier comprises a saline solution, a glucose solution or a
solution containing a mixture of saline and glucose. Further
description of methods suitable for use in preparing pharmaceutical
compositions of the present invention and of ingredients suitable
for use in said compositions is provided in Remington's
Pharmaceutical Sciences, 18.sup.th edition, edited by A. R.
Gennaro, Mack Publishing Co., 1990 and in Remington--The Science
and Practice of Pharmacy, 21.sup.st edition, Lippincott Williams
& Wilkins, 2005.
[0437] The compounds of this invention can be administered orally
in a dosage range of about 0.001 to about 1000 mg/kg of mammal
(e.g., human) body weight per day in a single dose or in divided
doses. One preferred dosage range is about 0.01 to about 500 mg/kg
body weight per day orally in a single dose or in divided doses.
Another preferred dosage range is about 0.1 to about 100 mg/kg body
weight per day orally in single or divided doses. For oral
administration, the compositions can be provided in the form of
tablets or capsules containing about 1.0 to about 500 milligrams of
the active ingredient, particularly 1, 5, 10, 15, 20, 25, 50, 75,
100, 150, 200, 250, 300, 400, and 500 milligrams of the active
ingredient for the symptomatic adjustment of the dosage to the
patient to be treated. The specific dose level and frequency of
dosage for any particular patient may be varied and will depend
upon a variety of factors including the activity of the specific
compound employed, the metabolic stability and length of action of
that compound, the age, body weight, general health, sex, diet,
mode and time of administration, rate of excretion, drug
combination, the severity of the particular condition, and the host
undergoing therapy.
[0438] As noted above, the present invention is also directed to
use of the HIV integrase inhibitor compounds of the present
invention with one or more anti-HIV agents useful in the treatment
of HIV infection or AIDS. An "anti-HIV agent" is any agent which is
directly or indirectly effective in the inhibition of HIV integrase
or another enzyme required for HIV replication or infection, the
treatment or prophylaxis of HIV infection, and/or the treatment,
prophylaxis or delay in the onset of AIDS. It is understood that an
anti-HIV agent is effective in treating, preventing, or delaying
the onset of HIV infection or AIDS and/or diseases or conditions
arising therefrom or associated therewith. For example, the
compounds of this invention may be effectively administered,
whether at periods of pre-exposure and/or post-exposure, in
combination with effective amounts of one or more HIV antivirals,
immunomodulators, antiinfectives, or vaccines useful for treating
HIV infection or AIDS, such as those disclosed in Table 1 of WO
01/38332 or in the Table in WO 02/30930. Suitable HIV antivirals
for use in combination with the compounds of the present invention
include, for example, HIV protease inhibitors (e.g., indinavir,
atazanavir, lopinavir optionally with ritonavir, saquinavir, or
nelfinavir), nucleoside HIV reverse transcriptase inhibitors (e.g.,
abacavir, lamivudine (3TC), zidovudine (AZT), or tenofovir), and
non-nucleoside HIV reverse transcriptase inhibitors (e.g.,
efavirenz or nevirapine). It will be understood that the scope of
combinations of the compounds of this invention with HIV
antivirals, immunomodulators, anti-infectives or vaccines is not
limited to the foregoing substances or to the list in the
above-referenced Tables in WO 01/38332 and WO 02/30930, but
includes in principle any combination with any pharmaceutical
composition useful for the treatment of HIV infection or AIDS. The
HIV antivirals and other agents will typically be employed in these
combinations in their conventional dosage ranges and regimens as
reported in the art, including, for example, the dosages described
in the Physicians' Desk Reference, 58.sup.th edition, Thomson P D
R, 2004, or the 59.sup.th edition thereof, 2005. The dosage ranges
for a compound of the invention in these combinations are the same
as those set forth above. It is understood that pharmaceutically
acceptable salts of the compounds of the invention and/or the other
agents (e.g., indinavir sulfate) can be used as well.
[0439] Abbreviations employed herein include the following:
AcOH=acetic acid; BOC or Boc=t-butyloxycarbonyl;
BOP=benzotriazol-1-yloxytris-(dimethylamino)phosphonium; Bu=butyl;
DIPEA=diisopropylethylamine (or Hunig's base);
DMF=N,N-dimethylformamide; DMSO=dimethylsulfoxide;
dppa=diphenylphosphoryl azide; EDC or
EDAC=1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; ES
MS=electrospray mass spectroscopy; Et=ethyl; EtOAc=ethyl acetate;
HOAT=1-hydroxy-7-azabenzotriazole; HPLC=high performance liquid
chromatography; LDA=lithium diisopropylamide; LHMDS=lithium
hexamethyldisilazide; Me=methyl; MeOH=methanol; MTBE=methyl
tert-butyl ether; NaHMDS=sodium hexamethyldisilazide; NMR=nuclear
magnetic resonance; TEA=triethylamine; TFA=trifluoroacetic acid;
THF=tetrahydrofuran.
[0440] The compounds of the present invention can be readily
prepared according to the following reaction schemes and examples,
or modifications thereof, using readily available starting
materials, reagents and conventional synthesis procedures. In these
reactions, it is also possible to make use of variants which are
themselves known to those of ordinary skill in this art, but are
not mentioned in greater detail. Furthermore, other methods for
preparing compounds of the invention will be readily apparent to
the person of ordinary skill in the art in light of the following
reaction schemes and examples. Unless otherwise indicated, all
variables are as defined above.
[0441] Scheme 1 depicts a method for preparing
5,6,7,8-tetrahydro-2,6-naphthyridine-1-carboxylate intermediates
useful for making compounds of the present invention. In Part A of
the scheme, lactam 1-1 can be alkylated with an appropriate alkyl
halide in the presence of a deprotonating agent (e.g., NaH, NaHMDS,
or LHMDS) to give 1-2, using methods as described in Jerry March,
Advanced Organic Chemistry, 3rd edition, John Wiley & Sons,
1985, pp. 377-379. Piperidin-2-one 1-2 can be converted to the
corresponding dihydropyridinone compound 1-5 following the two step
procedure set forth in Meyers et al., Tet. Lett. 1995, 36:
7051-7054, wherein the lactam can be treated with base (e.g.,
LHMDS, LDA or Na HMDS) and methyl benzene sulfinate to give
intermediate 1-4, which can then be treated by heating in a high
boiling solvent (e.g., toluene or xylenes) and optionally in the
presence of base (e.g., Na.sub.2CO.sub.3 or K.sub.2CO.sub.3) to
effect the elimination to 1-5. Separately, as shown in Part B of
Scheme 1, oxazoles of the type 1-9 can readily be prepared by
acylating amino acid ester 1-6 with an oxalate ester 1-7 in the
presence of base (e.g., tertiary amines such as TEA, DIPEA, or
pyridine) to afford acylated compound 1-8, which can then be
cyclized and dehydrated (using a dehydrating agent such as
P.sub.2O.sub.5) in the manner described in Krapcho et al. J.
Heterocyclic Chem. 1995, 32, 1693-1702 to afford oxazole 1-9.
Diels-Alder reaction of 1-9 and 1-5, optionally in the presence of
water or an acid (e.g., AcOH or TFA) (preferably in the presence of
water as described in "Catalysis of Diels-Alder Reactions in Water
and in Hydrogen-Bonding Environments", Wittkopp, A. &
Schreiner, P. R. in: Chemistry of Dienes and Polyenes, 2000, Vol.
2, John Wiley & Sons, pp. 1029-1088), will then provide the
desired napthyridine intermediate 1-10.
##STR00015## ##STR00016##
[0442] Scheme 2 depicts a method for preparing naphthyridine
carboxylates and carboxamides embraced by the present invention
from naphthyridine intermediate 1-10, wherein the intermediate 140
can be treated with a suitable oxidizing agent (e.g., hydrogen
peroxide or m-chloroperbenzoic acid) as described in Sharpless et
al., J. Org. Chem. 1998, 1740 and Caron et al., Tet. Letters 2000,
2299 and references cited therein to obtain N-oxide 2-1, which can
then be treated as described in Suzuki et al., J. Med. Chem. 1992,
35, 4045-4053 with acetic anhydride to effect the rearrangement to
the O-acylated intermediate, and then treated with a nucleophile
(e.g., an alkoxide such as NaOMe) to afford the desired
dioxohexahydro-2,6-naphthyridine-1-carboxylate 2-2. In the
preparation of compounds of the present invention that require the
protection of phenolic hydroxyl group on 2-2, the intermediate 1-10
can be treated with trimethylsilyldiazomethane to provide the
O-methyl ether selectively. Chemical transformations similar to
those described in the conversion of 1-10 to 2-2 provided 2-5,
which can be deprotected to give the desired phenol.
##STR00017##
[0443] Scheme 3 depicts a method for preparing
diazocino[2,1-a]-2,6-naphthyridines 3-3 and 3-4 (n=4) and
diazepino[2,1-a]-2,6-naphthyridines 3-3 and 3-4 (n=3) embraced by
the present invention from naphthyridine intermediate 2-2, wherein
the intermediate 2-2 is treated with a suitable base (e.g.,
magnesium alkoxide) and a suitable dihaloalkane (e.g.,
1-bromo-4-chlorobutane or 1-bromo-3-chloropropane) to provide the
alkylated intermediate 3-1. Treatment of halide 3-1 with a primary
amine in the presence or absence of an iodide catalyst such as
potassium iodide or tetra-n-butylammonium iodide provided the
aminoester intermediate 3-2. Base catalyzed hydrolysis of the
amino-ester 3-2 provided the corresponding amino acid which was
treated with an amide coupling reagent such as EDC or BOP to
provide the tricyclic napthyridine products 3-3. The R.sup.Y
substituent on 3-3 can be removed under appropriate conditions to
provide products 3-4.
##STR00018##
[0444] Scheme 4 depicts a method for preparing
pyrazino[2,1-a]-2,6-naphthyridines 4-1 and 4-2 embraced by the
present invention from naphthyridine intermediate 2-2, wherein the
intermediate 2-2 is treated with a suitable base (e.g., magnesium
alkoxide, cesium carbonate, or potassium carbonate) and an
appropriately protected .alpha.-amino-.beta.-haloalkane (e.g., a
protected 1-amino-2-haloethane such as tert-butyl
(2-bromoethyl)carbamate) to provide the tricyclic napthyridine
products 4-1. Treatment of 4-1 with a suitable base and alkylating
reagent (e.g., an alkyl halide) affords 4-2.
##STR00019##
[0445] Scheme 5 depicts a method for preparing
oxazino[2,1-a]-2,6-naphthyridines 5-1 embraced by the present
invention from naphthyridine intermediate 2-2, wherein the
intermediate 2-2 is treated with a suitable base (e.g., magnesium
alkoxide, cesium carbonate, or potassium carbonate) and a suitable
.alpha.,.beta.-dihaloalkane (e.g., a dihaloethane such as
1-bromo-2-chloroethane) to provide the tricyclic napthyridine
products 5-1. Oxazepino and oxazocino analogs can be similarly
prepared using a suitable dihaloalkane such as
Br--CH.sub.2CH.sub.2CH.sub.2--Cl or
Br--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--Cl.
##STR00020##
[0446] Scheme 6 depicts a method for preparing
imidazo[2,1-a]-2,6-naphthyridines 6-4 and 6-5 embraced by the
present invention from naphthyridine intermediate 2-2, wherein the
intermediate 2-2 is treated with a suitable base (e.g., magnesium
alkoxide, cesium carbonate, or potassium carbonate) and a suitable
substituted alkyl haloacetate (e.g., tert-butyl bromoacetate) to
provide the alkylation product 6-1. Selective hydrolysis provides
the naphthyridine carboxylic acid 6-2, which can be converted to
the corresponding tert-butyl carbamate 6-3 via a Curtius
rearrangement in the manner described in J. March, Advanced Organic
Chemistry, 3rd edition, John Wiley& Sons, 1992, p. 1091 (e.g.,
acid 6-2 can be treated with diphenylphosphoryl azide in the
presence of anhydrous tert-butanol to afford carbamate 6-3).
Carbamate 6-3 can then be treated with acid (e.g., HCl or TFA) in a
manner similar to the conditions described in T. W. Greene & P.
G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition,
John Wiley& Sons, 1999, to provide the tricyclic naphthyridine
derivative 6-4. Treatment of 6-4 with a suitable alkylating agent
(e.g., an alkyl halide, an alkyl bromoacetate, or a benzyloxyalkyl
halide) in the presence of base (e.g., NaH, NaHMDS, LHMDS, or LDA)
affords product 6-5. Further conventional functional group
interconversion on the R'' side chain can provide additional
compounds of the present invention.
##STR00021## ##STR00022##
[0447] Scheme 7 depicts a method for preparing
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)-trione 7-3 from naphthyridine intermediate 2-5, wherein the
intermediate 2-5 is treated with a suitable substituted
aminoalcohol and an amide coupling reagent (e.g., EDC or BOP) to
provide the amide product 7-1. Sequential treatment of 7-1 with
alkyl or aryl sulfonic anhydride (e.g., methanesulfonic anhydride)
followed by a suitable base (e.g., cesium carbonate) provides the
tricyclic naphthyridine derivative 7-2. Further standard functional
group interconversion on the side chains R.sup.a to R.sup.g and
removal of the methyl ether protecting group provided the targeted
inhibitors 7-3.
##STR00023##
[0448] Scheme 8 depicts a method for preparing
oxazino[2,1-a]-2,6-naphthyridines from naphthyridine intermediate
2-2, wherein the intermediate 2-2 is treated with a suitable base
(e.g., magnesium alkoxide, cesium carbonate, or potassium
carbonate) and a suitable allyl halide (e.g., allyl bromide) to
provide the allylated napthyridine product 8-1. Osmium
tetroxide-catalyzed dihydroxylation of the terminal olefin
(VanRheenen et. al. Tet. Lett. 1973, 1976) followed by
intramolecular cyclization provides the intermediate
oxazinonaphthyridine 8-2. Deprotection of the methyl ether
protecting group on 8-2 provides the target compound 8-3.
##STR00024##
[0449] In the methods for preparing compounds of the present
invention set forth in the foregoing schemes, functional groups in
various moieties and substituents (in addition to those already
explicitly noted in the foregoing schemes) may be sensitive or
reactive under the reaction conditions employed and/or in the
presence of the reagents employed. Such sensitivity/reactivity can
interfere with the progress of the desired reaction to reduce the
yield of the desired product, or possibly even preclude its
formation. Accordingly, it may be necessary or desirable to protect
sensitive or reactive groups on any of the molecules concerned.
Protection can be achieved by means of conventional protecting
groups, such as those described in Protective Groups in Organic
Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973 and in T. W.
Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis,
John Wiley & Sons, 3.sup.rd edition, 1999, and 2.sup.nd
edition, 1991. The protecting groups may be removed at a convenient
subsequent stage using methods known in the art. Alternatively the
interfering group can be introduced into the molecule subsequent to
the reaction step of concern.
[0450] The following examples serve only to illustrate the
invention and its practice. The examples are not to be construed as
limitations on the scope or spirit of the invention.
Example 1
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H
[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00025##
[0451] Step 1: 1-(3-Chloro-4-fluorobenzyl)piperidin-2-one
[0452] To a cold (0.degree. C.) solution of valerolactam (153.30 g,
1.54 mol) in anhydrous 1-methyl-2-pyrrolidinone (3.5 L), sodium
hydride (67.7 g, 1.69 mol, 60% dispersion in oil) was added over a
period of 5 minutes. The reaction mixture was stirred for 30
minutes, and a solution of 3-chloro-4-fluorobenzylbromide (345.5 g,
1.54 mol) in 1-methyl-2-pyrrolidinone (200 mL) was added over 30
minutes at 0.degree. C. The reaction mixture was stirred at
0.degree. C. for 1 hour, and was allowed to warm up and stirred at
room temperature overnight. The reaction mixture was quenched with
distilled water (5 L), and extracted with dichloromethane (three
times; 2 L, 1 L, 1 L). The organic extracts were combined, washed
with water (3.times.; 4 L each time). The residual oil was
dissolved in ethyl acetate (4 L), and extracted with water
(3.times.; 2 L each time). The organic layer was separated,
concentrated under vacuum to give the title product that solidified
upon standing.
[0453] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.24 (m, 2H), 7.0
(m, 2H), 7.1 (m, 1H), 4.56 (s, 2H), 3.19 (t, J=4.9 Hz, 2H), 2.46
(t, J=6.4 Hz, 2H), 1.8-1.75 (m, 4H).
Step 2:
1-(3-Chloro-4-fluorobenzyl)-5,6-dihydropyridin-2(1H)-one
[0454] To a cold (-20.degree. C.) solution of
1-(3-chloro-4-fluorobenzyl)piperidin-2-one (340 g, 1.41 mol) in
anhydrous tetrahydrofuran (5 L) under an atmosphere of nitrogen, a
solution of lithium bis(trimethylsilyl)amide (3.09 L, 3.09 mol; 1M
in THF) was added over a period of 40 minutes with the temperature
of the reaction maintained at -20.degree. C. After the addition was
complete, the reaction mixture was stirred at -20.degree. C. for
one hour. Methyl benzene sulfonate (231 mL, 1.69 mol) was added to
the reaction mixture over a period of 30 minutes. The reaction
mixture was stirred at -20.degree. C. for 30 minutes. The product
mixture was diluted with ethyl acetate (4 L) and washed with water
(four times; 2 L each time). The organic extract was concentrated
under vacuum. The residue was dissolved in toluene (4 L), treated
with solid sodium carbonate (500 g), and heated at 100.degree. C.
for one hour. The product mixture was diluted with ethyl acetate (4
L) and washed with water (4 times; 2 L each). The organic extract
was concentrated under vacuum. The residue was subjected to column
chromatography on silica gel eluting with a gradient of 0-60% EtOAc
in heptane. Collection and concentration of appropriate fractions
provide the title compound as oil.
[0455] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.3 (m, 1H), 7.15
(m, 1H), 7.1 (t, 1H), 6.6 (m, 1H), 6.0 (m, 1H), 4.55 (s, 2H), 3.33
(t, 2H), 1.38 (m, 2H). ES MS M+1=240.13
Step 3: 2-Butoxy-2-oxoethanaminium chloride
[0456] To a suspension of glycine hydrochloride (400 g, 3.58 mol)
in n-butanol (8 L), thionyl chloride (1.37 L, 18.84 mol) was added
slowly dropwise. After addition was complete, the reaction was
heated at 70.degree. C. overnight. The product mixture was
concentrated under vacuum and the residue was triturated with a
mixture of heptane/ethyl acetate. The white solid precipitated was
filtered and dried under a stream of dry nitrogen to provide the
title compound.
[0457] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.5 (br s, 3H),
4.18 (t, J=6.7 Hz, 2H), 4.0 (br s, 2H), 1.62 (m, 2H), 1.38 (m, 2H),
0.92 (t, J=7.4 Hz, 3H). ES MS M+1=132.
Step 4: Butyl N-[ethoxy(oxo)acetyl]glycinate
[0458] A mixture of 2-butoxy-2-oxoethanaminium chloride (573.5 g,
3.42 mol), triethylamine (415 g, 4.1 mol), and diethyl oxalate (1.0
kg, 6.8 mol) in ethanol (7 L) was heated at 50.degree. C. for 3
hours. The product mixture was cooled and concentrated under
vacuum. The residue was dissolved in methylene chloride and washed
with two 4 L portions of water. The organic fraction was dried over
anhydrous magnesium sulfate, filtered, and concentrated under
vacuum. The residual oil was subjected to column chromatography on
silica gel eluting with heptane/ethyl acetate gradient. Collection
and concentration of appropriate fractions provided the title
material.
[0459] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.56 (br s, 1H),
4.37 (q, J=7.2 Hz, 2H), 4.2 (t, J=6.6 Hz, 2H), 4.12 (d, J=5.5 Hz,
2H), 1.64 (p, J=6.8 Hz, 2H), 1.39 (t, J=7.15 Hz, 3H), 1.37 (m, 2H),
0.94 (t, J=7.4 Hz, 3H). ES MS M+1=232.
Step 5: Ethyl 5-butoxy-1,3-oxazole-2-carboxylate
[0460] To a solution of butyl N-[ethoxy(oxo)acetyl]glycinate (783
g, 3.38 mol) in acetonitrile (8 L) in a 50 L glass reactor with
overhead stirrer, phosphorus pentoxide (415 g, 2.92 mol) was added
in portions. The reaction was heated at 60.degree. C. for 1 hour.
The product mixture was cooled, and water (8 L) was added with the
mixture maintained at 20.degree. C. The resultant mixture was
extracted with dichloromethane (8 L, and 3 times 2 L). The organic
extracts were combined, washed twice with saturated aqueous sodium
bicarbonate (8 L total), dried over anhydrous magnesium sulfate,
filtered and concentrated under vacuum. The residual oil was
subjected to column chromatography on silica gel eluting with 0-30%
heptane/ethyl acetate gradient. Collection and concentration of
appropriate fractions provided the title material.
[0461] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 6.33 (s, 1H), 4.42
(q, J=7.2 Hz, 2H), 4.18 (t, J=6.4 Hz, 2H), 1.8 (p, J=6.4 Hz, 2H),
1.47 (p, J=7.4 Hz, 2H), 1.41 (t, J=7.15 Hz, 3H), 0.97 (t, J=7.4 Hz,
3H). ES MS M+1=214.
Step 6: Ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate
[0462] A mixture of ethyl 5-butoxy-1,3-oxazole-2-carboxylate (44.5
g, 208.6 mmol),
1-(3-chloro-4-fluorobenzyl)-5,6-dihydropyridin-2(1H)-one (25 g,
104.3 mmol), and water (2.82 mL, 156.7 mmol) was heated in a sealed
heavy walled vessel at 130.degree. C. with stirring for 72 hours.
Upon cooling, the product mixture solidified. The solid was
triturated with diethyl ether and collected by filtration. The
product was further purified by crystallization from boiling ethyl
acetate.
[0463] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.79 (s, 1H),
8.42 (s, 1H), 7.4 (dd, J=2, 7 Hz, 1H), 7.2 (m, 1H), 7.15 (t, J=8.6
Hz, 1H), 4.7 (s, 2H), 4.4 (q, J=7 Hz, 2H), 3.5 (m, 4H), 1.4 (t, J=7
Hz, 3H). ES MS M+1=379.0
Step 7: Ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate 2-oxide
[0464] A mixture of ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate (22 g, 58 mmol), glacial acetic acid (500
mL), and hydrogen peroxide (65.8 mL, 30% by weight in water) was
heated at 100.degree. C. for four hours. The resultant solution was
cooled in an ice bath to 25.degree. C. and treated with saturated
aqueous sodium sulfite solution while keeping the reaction mixture
below 40.degree. C. When starch paper test showed complete
consumption of residual perioxide, the solution was concentrated to
two third of its volume, pH was adjusted to .about.3 with aqueous
HCl and the solution was extracted with dichloromethane (3 times).
The organic extracts were combined, dried over anhydrous sodium
sulfate, filtered and concentrated under vacuum to afford the title
product as oil.
[0465] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.65 (s, 1H), 7.9
(s, 1H), 7.38 (dd, J=2, 7 Hz, 1H), 7.27-7.1 (m, 2H), 4.66 (s, 2H),
4.44 (q, J=7 Hz, 2H), 3.52 (t, J=7 Hz, 2H), 2.90 (t, J=7 Hz, 2H),
1.38 (t, J=7 Hz, 3H). ES MS M+1=395.0
Step 8: Ethyl
3,4-bis(acetyloxy)-6-(3-chloro-4-fluorobenzyl)-5-oxo-5,6,7,8-tetrahydro-2-
,6-naphthyridine-1-carboxylate
[0466] A solution of ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate 2-oxide (23 g, 58 mmol) in acetic anhydride
(400 mL) was heated under nitrogen at 100.degree. C. for one hour.
The product mixture was concentrated under vacuum to the title
bisacetate and was used in the following step without further
purification.
[0467] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (m, 1H),
7.2-7.1 (m, 1H), 7.12 (t, J=8 Hz, 1H), 4.68 (br s, 2H), 4.4 (q, J=7
Hz, 2H), 3.48 (m, 2H), 3.35 (m, 2H), 2.38 (br s, 6H), 1.4 (t, J=7
Hz, 3H). ES MS M+1=394.9
Step 9: Methyl
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-na-
phthyridine-1-carboxylate
[0468] A solution of ethyl
3,4-bis(acetyloxy)-6-(3-chloro-4-fluorobenzyl)-5-oxo-5,6,7,8-tetrahydro-2-
,6-naphthyridine-1-carboxylate (27.8 g, 58 mmol) and sodium
methoxide (41.8 mL, 232 mmol; 30% by weight solution of NaOMe in
MeOH) in anhydrous methanol (300 mL) was heated at 40.degree. C.
for 5 hours. The volume of the reaction mixture was reduced by a
half under vacuum, diluted with anhydrous tetrahydrofuran (400 mL),
and treated with an additional solution of sodium methoxide in
methanol (33 mL). The reaction mixture was stirred at room
temperature overnight and then warmed to 50.degree. C. for four
hours. The product mixture was acidified with dilute hydrochloric
acid to pH 3 and extracted with chloroform several times. The
organic extracts were combined, dried over anhydrous sodium
sulfate, filtered, and concentrated under vacuum to provide the
title compound as oil.
[0469] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 10.0-8.2 (br s,
1H), 7.38 (dd, J=6.8.2 Hz, 1H), 7.2 (m, 1H), 7.13 (t, J=8.4 Hz,
1H), 4.68 (s, 2H), 3.92 (s, 3H), 3.46 (t, J=6.4 Hz, 2H), 3.34 (t,
J=6.4 Hz, 2H). ES MS M+1=380.9
Step 10: Methyl
2-(4-chlorobutyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6-
,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
[0470] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (0.80 g, 2.19 mmol) and
magnesium methoxide in methanol (10.6 mL, 6-10% methanol solution
available from Aldrich) in DMSO (22 mL) was heated at 60.degree. C.
for one hour. Methanol was exhaustively removed under vacuum over
45 minutes. The resulting DMSO solution was treated with
1-bromo-4-chlorobutane (1.80 g, 10.50 mmol) and stirred at
60.degree. C. under an atmosphere of nitrogen for one hour. The
reaction mixture was diluted with ethyl acetate and washed with
dilute hydrochloric acid. The organic extract was washed with 10%
aqueous potassium carbonate, dried over anhydrous sodium sulfate,
filtered, and concentrated under vacuum. The residue was triturated
with diethyl ether. The solid precipitated was collected by
filtration to provide the title compound. ES MS M+1=471
Step 11: Methyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
[0471] A mixture of methyl
2-(4-chlorobutyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6-
,7,8-hexahydro-2,6-naphthyridine-1-carboxylate (0.10 g, 0.21 mmol),
methylamine in tetrahydrofuran (1 mL, 2M), and
tetra-n-butylammonium iodide in tetrahydrofuran (5 mL) was heated
at 60.degree. C. for 3 days. The reaction mixture was concentrated
under vacuum. The residue was partitioned between dichloromethane
and saturated aqueous sodium bicarbonate. The organic extract was
washed with brine, dried over anhydrous sodium sulfate, filtered,
and concentrated under vacuum to provide the title compound. This
was used in the following step without further purification. ES MS
M+1=466
Step 12:
6-(3-Chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,-
5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic
acid
[0472] Methyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate (0.18 g, 0.38
mmol) and potassium hydroxide (0.17 g, 2.3 mmol) in a mixture of
1:1:1 v/v/v tetrahydrofuran-methanol-water (4.5 mL) was heated at
50.degree. C. overnight. The reaction mixture was concentrated
under vacuum. The residue was partitioned between dichloromethane
and dilute hydrochloric acid. The aqueous extract was concentrated
under vacuum to provide the title compound as hydrochloride salt.
This was used in the following step without further purification.
ES MS M+1=452
Step 13:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hex-
ahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0473] A solution of
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic acid (0.18 g,
0.40 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (0.08 g, 0.41 mmol), and 1-hydroxy-7-azabenzotriazole
(0.07 g, 0.51 mmol), and N-methylmorpholine (0.35 mL, 3.16 mmol) in
anhydrous DMF (3 mL) was stirred at room temperature overnight. The
reaction mixture was concentrated under vacuum. The residue was
purified by reverse phase high pressure liquid chromatography.
Collection and concentration of appropriate fractions provided the
title compound.
[0474] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (br s, 1H),
7.18 (br s, 1H), 7.13 (m, 1H), 4.80-4.66 (m), 4.55 (d, J=14.7 Hz,
1H), 3.97-2.98 (m), 3.12 (s, 3H), 2.08-1.77 (m, 4H). ES MS exact
mass M+1=434.1282
Example 2
11-(4-Fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H[1,4]diaz-
ocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00026##
[0475] Step 1: Methyl
6-(3-chloro-4-fluorobenzyl)-4-methoxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
[0476] A mixture of methyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate (0.68 g, 1.45
mmol; Example 1, Step 11) and a solution of
trimethylsilyldiazomethane in hexane (2.2 mL, 4.35 mmol; 2M) in
dichloromethane-methanol (1.5 & 4.5 mL) was stirred at room
temperature for one hour. The reaction mixture was concentrated
under vacuum to provide the title compound. This was used in the
following step without further purification. ES MS M+1=480
Step 2:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-methyl-3,4,5,6,12,13-hexa-
hydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0477] The titled compound was prepared in a manner similar to that
described in Example 1, steps 12 and 13, substituting methyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate with methyl
6-(3-chloro-4-fluorobenzyl)-4-methoxy-2-[4-(methylamino)butyl]-3,5-dioxo--
2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate.
Step 3:
11-(4-Fluorobenzyl)-9-methoxy-2-methyl-3,4,5,6,12,13-hexahydro-2H[-
1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0478] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-methyl-3,4,5,6,12,13-hexahydro-2-
H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione (52 mg,
0.12 mmol) and 10% palladium on charcoal (70 mg) in ethanol (6 mL)
was stirred at room temperature under a balloon of hydrogen
overnight. The reaction mixture was filtered and concentrated under
vacuum. ES MS M+1=480
Step 4:
11-(4-Fluorobenzyl)-9-hydroxy-2-methyl-3,4,5,6,12,13-hexahydro-2H[-
1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0479] A solution of
11-(4-fluorobenzyl)-9-methoxy-2-methyl-3,4,5,6,12,13-hexahydro-2H[1,4]dia-
zocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione (27 mg, 0.07
mmol) in 30% hydrobromide in acetic acid was stirred at room
temperature for 30 minutes. The reaction mixture was concentrated
under vacuum. The residue was concentrated from a solution in
toluene twice. The resultant solid was triturated with a mixture of
diethyl ether and dichloromethane to provide the title
compound.
[0480] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.40 (dd, J=8.4,
5.5 Hz, 2H), 7.22 (t, J=8.6 Hz, 2H), 4.77 (d, J=14.7 Hz, 1H), 4.71
(d, J=14.7 Hz, 1H), 3.54-3.27 (m), 3.12 (s, 3H), 2.89 (m, 1H), 2.61
(m, 1H), 2.06 (M, 1H), 1.84 (M, 2H), 1.71 (M, 1H). ES MS exact mass
M+1=400.1652
Example 3
10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2-methyl-2,3,4,5,11,12-hexahydro[1,-
4]diazepino[2,1-a]-2,6-naphthyridine-1,7,9(10H)-triune
##STR00027##
[0482] The title compound was prepared in a manner similar to that
described in Example 1, substituting 1-bromo-4-chlorobutane with
1-bromo-3-chloropropane in Step 10.
[0483] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.40 (br s, 1H),
7.36 (dd, J=6.8, 2.0 Hz, 1H), 7.20 (m, 1H), 7.13 (t, J=8.6, Hz,
1H), 5.28 (m, 1H), 4.73 (d, J=14.5 Hz, 1H), 4.60 (d, 14.5 Hz, 1H),
3.49-3.14 (m), 3.14 (s, 3H), 2.74 (m, 1H), 2.10 (m, 2H). ES MS
exact mass M+1=420.1122
Example 4
10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2,3,4,5,11,12-hexahydro[1,4]diazepi-
no naphthyridine-1,7,9(10H)-trione
##STR00028##
[0484] Step 1:
10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2-(4-methoxybenzyl)-2,3,4,5,11,12--
hexahydro[1,4]diazepino[2,1-a]-2,6-naphthyridine-1,7,9(10H)-trione
[0485] The titled compound was prepared in a manner similar to that
described in Example 1, substituting 1-bromo-4-chlorobutane with
1-bromo-3-chloropropane in Step 10, and replacing methylamine with
4-methoxybenzylamine in Step 11. ES MS M+1=526
Step 2:
10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-2,3,4,5,11,12-hexahydro[1,4-
]diazepino[2,1-a]-2,6-naphthyridine-1,7,9(10H)-trione
[0486] A mixture of
10-(3-chloro-4-fluorobenzyl)-8-hydroxy-2-(4-methoxybenzyl)-2,3,4,5,11,12--
hexahydro[1,4]diazepino[2,1-a]-2,6-naphthyridine-1,7,9(10H)-trione
(18 mg, 30 .mu.mol) and p-toluenesulfonic acid (26 mg, 0.14 mmol)
in toluene (0.5 mL) was heated at 110.degree. C. for 8 hours. The
reaction mixture was concentrated under vacuum. The residue was
purified by reverse phase high pressure liquid chromatography.
Collection and lyophilization of appropriate fractions provided the
title compound.
[0487] .sup.1H NMR (400 MHz, CD.sub.3CD) .delta. 7.50 (dd, J=7.0,
2.2 Hz, 1H), 7.34 (m, 1H), 7.23 (t, J=8.8, Hz, 1H), 5.13 (br s,
1H), 4.85 (br s, 2H), 3.13-2.78 (m), 3.29 (s, 3H), 2.03 (br s, 3H).
ES MS exact mass M+1=406.0980
Example 5
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3,4,10,11-tetrahydro-2-H-pyrazino[2,-
1-a]-2,6-naphthyridine-1,6,8(9H)-trione
##STR00029##
[0489] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (1.00 g, 2.63 mmol; Example
1, Step 9) and magnesium methoxide in methanol (13.1 mL, 6-10%
methanol solution available from Aldrich) in DMSO (26 mL) was
heated at 60.degree. C. for one hour. Methanol was exhaustively
removed under vacuum over 45 minutes. The resulting DMSO solution
was treated with tort-butyl (2-bromoethyl)carbamate (2.94 g, 13.13
mmol) and stirred at 60.degree. C. under an atmosphere of nitrogen
for one hour. The reaction mixture was diluted with ethyl acetate
and washed successively with 10% sodium thiosulfate and brine. The
organic extract was dried over anhydrous sodium sulfate, filtered,
and concentrated under vacuum. The residue was purified by reverse
phase high pressure liquid chromatography. Collection and
lyophilization of appropriate fractions provided the title
compound.
[0490] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 14.00 (s, 1H),
7.36 (dd, J=7.0, 2.2 Hz, 1H), 7.21 (m, 1H), 7.14 (t, J=8.8, Hz,
1H), 6.07 (br s, 1H), 4.68 (s, 2H), 4.35 (t, 2H), 3.25 (t, 2H),
3.43 (t, 2H), 3.46 (t, 2H). ES MS exact mass M+1=392.0789
Example 6
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-2-methyl-3,4,10,11-tetrahydro-2-H-py-
razino[2,1-a]-2,6-naphthyridine-1,6,8(9H)-trione
##STR00030##
[0492] A mixture of
9-(3-chloro-4-fluorobenzyl)-7-hydroxy-3,4,10,11-tetrahydro-2-H-pyrazino[2-
,1-a]-2,6-naphthyridine-1,6,8(9H)-trione (53 mg, 0.14 mmol; Example
5), and sodium hydride (12.3 mg; 60% dispersion in oil) in DMF (2
mL) was stirred at 0.degree. C. for 20 minutes. To the resultant
solution, methyl iodide (96 mg, 0.68 mmol) was added and the
reaction mixture was heated at 40.degree. C. for four hours. The
reaction mixture was quenched with methanol and concentrated under
vacuum. The residue was purified by reverse phase high pressure
liquid chromatography. Collection and lyophilization of appropriate
fractions provided the title compound.
[0493] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (dd, J=6.8,
2.0 Hz, 1H), 7.20 (m, 1H), 7.14 (t, J=8.6, Hz, 1H), 4.68 (s, 2H),
4.35 (t, J=5.3 Hz, 2H), 3.61 (t, J=5.3 Hz, 2H), 3.43 (m, 4H), 3.14
(s, 3H). ES MS exact mass M+1=406.0963
Example 7
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3,4,10,11-tetrahydro[1,4]oxazino[3,4-
-a]-2,6-naphthyridine-1,6,8(9H)-trione
##STR00031##
[0495] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (0.15 g, 0.39 mmol; Example
1, Step 9) and magnesium methoxide in methanol (2 mL, 6-10%
methanol solution available from Aldrich) in DMSO (4 mL) was heated
at 60.degree. C. for 30 minutes. Methanol was exhaustively removed
under vacuum over 45 minutes. The resultant DMSO solution was
treated with 1-bromo-2-chloroethane (0.28 g, 1.97 mmol) and stirred
at 60.degree. C. under an atmosphere of nitrogen overnight. The
reaction mixture was diluted with ethyl acetate and dilute
hydrochloric acid. The organic extract was washed with aqueous
sodium sulfite, brine, dried over anhydrous sodium sulfate,
filtered, and concentrated under vacuum. The residue was purified
by reverse phase high pressure liquid chromatography. Collection
and lyophilization of appropriate fractions provided the title
compound, which was recrystallized from a mixture of ethyl acetate
and hexane
[0496] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.38 (dd, J=6.5,
2.5 Hz, 1H), 7.21 (m, 1H), 7.15 (t, J=8.8, Hz, 1H), 4.69 (s, 2H),
4.55 (br s), 4.36 (br s), 3.96 (br s), 3.52 (t, 2H), 3.48 (t, 2H).
ES MS exact mass M+1=393.0652
Example 8
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3-dimethyl-1,8,9,10-tetrahydroimid-
azo naphthyridine-2,5,7(3H)-trione
##STR00032##
[0497] Step 1: Methyl
2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-di-
oxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
[0498] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (0.50 g, 131 mmol; Example
1, Step 9) and magnesium methoxide in methanol (6.6 mL, 6-10%
methanol solution available from Aldrich) in DMSO (13 mL) was
heated at 60.degree. C. for one hour. Methanol was exhaustively
removed under vacuum over 45 minutes. The resultant DMSO solution
was treated with tert-butyl bromoacetate (1.80 g, 10.50 mmol) and
stirred at 50.degree. C. under an atmosphere of nitrogen for one
hour. The reaction mixture was diluted with ethyl acetate and
washed with ice cold dilute hydrochloric acid. The organic extract
was washed with aqueous sodium thiosulfate, brine, dried over
anhydrous sodium sulfate, filtered, and concentrated under vacuum.
The residue was triturated with a mixture of diethyl ether and
ethyl acetate. The solid precipitated was collected by filtration
to provide the title compound. ES MS M+1=495
Step 2: Methyl
2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-di-
oxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
[0499] A mixture of methyl
2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-di-
oxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate (0.70 g,
1.41 mmol) and a solution of trimethylsilyldiazomethane in hexane
(1.0 mL, 2.0 mmol; 2M) in dichloromethane-methanol (4 & 2 mL)
was stirred at room temperature overnight. The reaction mixture was
concentrated under vacuum. The residue was subject to column
chromatography on silica gel eluting with 2% methanol in
dichloromethane. Collection and concentration of appropriate
fractions provided the title compound. ES MS M+1=509
Step 3:
2-(2-tert-Butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-
-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic
acid
[0500] A mixture of methyl
2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-di-
oxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate (0.49 g,
0.96 mmol) and lithium hydroxide monohydrate (0.12 g, 2.9 mmol) in
a mixture of tetrahydrofuran (3 mL) and water (2 mL) was stirred at
room temperature for one hour. The reaction mixture was
concentrated under vacuum. The residue was partitioned between
dichloromethane and dilute hydrochloric acid. The organic extract
was dried over anhydrous sodium sulfate, filtered, and concentrated
under vacuum to provide the title compound. This was used in the
following step without further purification. ES MS M+1=495
Step 4:
1-[(tert-Butyloxycarbonyl)amino]-2-(2-tert-butoxy-2-oxoethyl)-6-(3-
-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naph-
thyridine
[0501] A mixture of
2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-di-
oxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic acid (0.31
g, 0.62 mmol), triethylamine (0.10 mL, 0.74 mmol), and
diphenylphosphoryl azide (0.19 g, 0.69 mmol) in a mixture of
anhydrous dioxane (6 mL) and anhydrous tert-butanol (6 mL) was
heated at 90.degree. C. overnight. The reaction mixture was
concentrated under vacuum. The residue was subject to column
chromatography on silica gel. Collection and concentration of
appropriate fractions provided the title compound. ES MS
M+1=566
Step 5:
8-(3-Chloro-4-fluorobenzyl)-6-methoxy-1,8,9,10-tetrahydroimidazo[2-
,1-a]-2,6-naphthyridine-2,5,6(3H)-trione
[0502] A mixture of
1-[(tert-butylcarbonyl)amino]-2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4--
fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine
(0.11 g, 0.96 mmol) and hydrogen chloride in dioxane (5 mL, 4 M)
was stirred at room temperature for four hours. The reaction
mixture was concentrated under vacuum to provide the title
compound. This was used in the following step without further
purification. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 7.60 (dd,
J=7.0, 2.0 Hz, 1H), 7.30 (m, 1H), 7.19 (t, J=8.6, Hz, 1H), 5.44 (s,
1H), 4.83 (s, 2H), 4.72 (s, 2H), 3.90 (s, 3H), 3.51 (t, J=5.8 Hz,
2H), 2.63 (t, J=5.8 Hz, 2H) ES MS M+1=392
Step 6:
8-(3-Chloro-4-fluorobenzyl)-6-methoxy-1,3-dimethyl-1,8,9,10-tetrah-
ydroimidazo[2,1-a]-2,6-naphthyridine-2,5,6(3H)-trione
[0503] A mixture of
8-(3-chloro-4-fluorobenzyl)-6-methoxy-1,8,9,10-tetrahydroimidazo[2,1-a]-2-
,6-naphthyridine-2,5,6(3H)-trione (67 mg, 0.17 mmol), sodium
hydride (17 mg, 60% dispersion; 0.42 mmol), iodomethane (49 mg,
0.35 mmol) in anhydrous DMF (8 mL) was stirred at room temperature
overnight. The reaction mixture was concentrated under vacuum. The
residue was subject to column chromatography on silica gel.
Collection and concentration of appropriate fractions provided the
title compound. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.39 (dd,
J=6.8, 2.0 Hz, 1H), 7.23 (m, 1H), 7.12 (t, J=8.6, Hz, 1H), 4.74 (t,
J=14.8 Hz, 1H), 4.72 (q, J=6.9 Hz, 1H), 4.63 (t, J=14.8 Hz, 1H),
4.05 (s, 3H), 3.41 (m, 2H), 3.39 (s, 3H), 2.92 (m, 2H), 1.74 (d,
J=6.9 Hz, 3H). ES MS M+1=420
Step 7:
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3-dimethyl-1,8,9,10-tetrah-
ydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione
[0504] A mixture of
8-(3-chloro-4-fluorobenzyl)-6-methoxy-1,3-dimethyl-1,8,9,10-tetrahydroimi-
dazo[2,1-a]-2,6-naphthyridine-2,5,6(3H)-trione (10 mg, 23 .mu.mol)
and 33% hydrogen bromide in acetic acid (1 mL) was stirred at room
temperature for two hours. The reaction mixture was concentrated
under vacuum. The residue was triturated with diethyl ether and
filtered to provide the title compound. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.38 (dd, J=6.8, 2.0 Hz, 1H), 7.23 (m, 1H),
7.12 (t, J=8.6, Hz, 1H), 4.71 (br signals, 3H), 3.47 (br signals,
2H), 3.40 (br, s, 3H), 3.12 (br s, 2H), 1.76 (br signals, 3H) ES MS
exact mass M+1=406.0969
Example 9
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1,3,3-trimethyl-1,8,9,10-tetrahydroi-
midazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione
##STR00033##
[0506] The titled compound was prepared in a manner similar to that
described in Example 8. In Step 6, additional sodium hydride and
methyl iodide were added for trimethylation. .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.36 (dd, J=6.8, 2.0 Hz, 1H), 7.23 (m, 1H),
7.16 (t, J=8.6, Hz, 1H), 4.69 (br s, 3H), 3.48 (br signals, 2H),
3.40 (s, 3H), 3.10 (br s, 2H), 1.79 (br s, 6H) ES MS exact mass
M+1=420.1112
Example 10
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(acetyloxy)ethyl]-3,4,5,6,12,1-
3-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00034##
[0507] Step 1: Ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate
[0508] A mixture of ethyl 5-butoxy-1,3-oxazole-2-carboxylate (248
g, 1.16 mol; Example 1, step 5),
1-(3-chloro-4-fluorobenzyl)-5,6-dihydropyridin-2(1H)-one (199.2 g,
0.83 mol; Example 1, step 2), and deionized water (22.5 mL, 1.25
mol) in a glass lined stainless steel high pressure reactor (with
the interstitial space between the liner and the pressure vessel
was filled with water) was heated at 135.degree. C. with stirring
for 72 hours. The product mixture was cooled in an ice-water bath
and the gaseous by-product was carefully vented. The orange solid
product was triturated with methyl tert-butyl ether (300 mL) and
collected by filtration. The product recrystallized from boiling
ethanol-water (.about.500 mL, 9:1 v/v), collected by filtration,
washed successively with a small quantity of ethanol, methyl
tert-butyl ether (300 mL), and heptane (200 mL), and air dried to
afford the title compound.
[0509] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 12.79 (s, 1H),
8.42 (s, 1H), 7.4 (dd, J=2, 7 Hz, 1H), 7.2 (m, 1H), 7.15 (t, J=8.6
Hz, 1H), 4.7 (s, 2H), 4.4 (q, J=7 Hz, 2H), 3.5 (m, 4H), 1.4 (t, J=7
Hz, 31-1). (ES MS M+1=379.0)
Step 2: Ethyl
6-(3-chloro-4-fluorobenzyl)-4-methoxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate
[0510] To a stirred solution of ethyl
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate (208 g, 0.55 mol) in a mixture of
dichloromethane (830 mL) and methanol (410 mL) at 10.degree. C., a
solution of (trimethyl-silyl)diazomethane (600 mL, 1.2 mol; 2M) in
hexanes was added over a period of 1 hour with the reaction
temperature maintained below 15.degree. C. The reaction mixture
(unstirred) was allowed to stand at 10.degree. C. overnight, and
then at 20.degree. C. for additional 4 hours. The reaction mixture
was cooled back to 10.degree. C. and quenched with acetic acid
(.about.75 mL). The product mixture was concentrated under vacuum
and the residue recrystallized from boiling methyl tert-butyl ether
and heptane. The solid recrystallized was collected by filtration,
washed with a mixture of methyl tort-butyl ether and heptane (1:1,
v/v), and air dried to afford the title compound.
[0511] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.42 (s, 1H), 7.41
(dd, J=2, 7 Hz, 1H), 7.24 (m, 1H), 7.11 (t, J=8.6 Hz, 1H), 4.70 (s,
2H), 4.42 (q, J=7 Hz, 2H), 4.12 (s, 3H), 3.4 (m, 4H), 1.42 (t, J=7
Hz, 3H). (ES MS M+1=392.9)
Step 3: Ethyl
3-(acetyloxy)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-5-oxo-5,6,7,8-tetrahy-
dro-2,6-naphthyridine-1-carboxylate
[0512] To a cold (5.degree. C.) mixture of ethyl
6-(3-chloro-4-fluorobenzyl)-4-methoxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphth-
yridine-1-carboxylate (199 g, 0.51 mol) and urea hydrogen peroxide
(100 g, 1.06 mol) in dichloromethane (1.5 L), trifluoroacetic
anhydride was added dropwise over a period of 45 minutes. The
resultant homogeneous solution was stirred at 20.degree. C. for 30
minutes and cooled back to 5.degree. C. The reaction mixture was
treated with aqueous potassium hydrogen phosphate (pH of aqueous
extract increased to .about.8), followed by slow addition of
freshly prepared aqueous sodium bisulfite solution with the
temperature of the product mixture maintained below 25.degree. C.
The organic extract was separated and the aqueous fraction
extracted with toluene (2.times.). The organic extracts were
combined, dried over anhydrous sodium sulfate, filtered, and
concentrated under vacuum. Without further purification, a solution
of this intermediate N-oxide (.about.280 g) and acetic anhydride
(239 mL, 2.5 mol) in toluene (2 L) was heated at 110.degree. C. for
16 hours. The product mixture was concentrated under vacuum. The
resultant oil was concentrated from toluene (300 mL, twice) and
stored under vacuum overnight. The acetate product was used in the
following step without further purification.
[0513] (ES MS M+1=408.9)
Step 4:
6-(3-Chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahy-
dro-2,6-naphthyridine-1-carboxylic acid
[0514] A mixture of ethyl
3-(acetyloxy)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-5-oxo-5,6,7,8-tetrahy-
dro-2,6-naphthyridine-1-carboxylate (217 g, 0.48 mol), lithium
hydroxide monohydrate (70.7 g, 1.67 mol), and water (320 mL) in
ethanol (1.8 L) was sonicated for 20 minutes. The reaction mixture
was cooled in an ice-water bath and treated with hydrochloric acid
(425 mL, 3 M). The resultant light yellow solid was filtered,
washed successively with water (1 L), a 3:2 v/v mixture of water
and ethanol (500 mL), MTBE (750 mL), and air dried. The yellow
solid was dissolved in anhydrous DMF (700 mL) and concentrated
under vacuum. The procedure was repeated twice to remove residual
water. The yellow solid was triturated with MTBE, filtered, and
stored under vacuum overnight to afford the title acid.
[0515] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.54 (dd, J=2, 7
Hz, 1H), 7.3 (m, 2H), 4.65 (s, 2H), 3.89 (s, 3H), 3.43 (t, J=5.5
Hz, 2H), 3.00 (t, J=5.5 Hz, 2H). (ES MS M+1=380.9)
Step 5:
N-[2-(Benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)silyl]oxy}butan-1-a-
mine
[0516] A mixture of 4-hydroxybutylamine (4.0 g, 44.9 mmol),
tert-butyldimethyl-silyl chloride (7.4 g, 49.3 mmol) and imidazole
(6.7 g, 98.7 mmol) in dichloromethane (150 mL) was stirred at room
temperature for 2 hours. The product mixture was washed
successively with aqueous NaHCO.sub.3, water, and brine. The
organic extract was dried over anhydrous sodium sulfate, filtered,
and concentrated under vacuum. This intermediate silylated
aminoalcohol was used without further purification. To a mixture of
the amine (1.0 g, 4.9 mmol) and benzyloxyacetaldehyde (0.74 g, 4.9
mmol) in dichloroethane (15 mL) at room temperature, sodium
triacetoxyborohydride (1.3 g, 6.3 mmol) was added. The reaction
mixture was concentrated under vacuum. The residue was partitioned
between ethyl acetate and aqueous sodium carbonate. The organic
extract was dried over anhydrous sodium sulfate, filtered, and
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel eluting with 2% methanol in
dichloromethane. Collection and concentration of appropriate
fractions afforded the title silyloxybutyl-amine.
[0517] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.33-7.25 (m, 5H),
4.51 (s, 2H), 3.60 (m, 4H), 2.79 (br t, J=4.9 Hz, 2H), 2.60 (br t,
2H), 1.52 (br signal, 5H), 0.87 (s, 9H), 0.03 (s, 6H).
Step 6:
N-[2-(Benzyloxy)ethyl]-N-(4-{[tert-butyl(dimethyl)silyl]oxy}butyl)-
-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-
-naphthyridine-1-carboxamide
[0518] A mixture of
6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-
-naphthyridine-1-carboxylic acid (0.19 g, 0.49 mmol),
N-[2-(benzyloxy)-ethyl]-4-{[tert-butyl(dimethyl)silyl]oxy}butan-1-amine
(0.19 g, 0.55 mmol), EDC (0.10 g, 0.55 mmol), HOAt (75 mg, 0.55
mmol) and diisopropylethylamine (0.35 mL, 1.99 mmol) in DMF (2 mL)
was stirred at room temperature overnight. The product mixture was
concentrated under vacuum. The residue was partitioned between
methylene chloride and water. The organic extract was dried over
anhydrous sodium sulfate, filtered, and concentrated under vacuum
to afford the title compound. This material was used in the
following step without further purification.
Step 7:
N-[2-(Benzyloxy)ethyl]-N-(4-hydroxybutyl)-6-(3-chloro-4-fluorobenz-
yl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxam-
ide
[0519] To a solution of
N-[2-(benzyloxy)ethyl]-N-(4-{[tert-butyl(dimethyl)silyl]-oxy}butyl)-6-(3--
chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-napht-
hyridine-1-carboxamide (0.41 g, 0.59 mmol) in THF, a solution of
tetra-n-butyl-ammonium fluoride (0.65 mL, 1M) in THF was added. The
reaction mixture was stirred at room temperature overnight, and
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel eluting with 3% methanol in
dichloromethane. Collection and concentration of appropriate
fractions afforded the title compound.
Step 8:
N-[2-(Benzyloxy)ethyl]-N-(4-methanesulfonyloxybutyl)-6-(3-chloro-4-
-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-
-1-carboxamide
[0520] To a solution of
N-[2-(benzyloxy)ethyl]-N-(4-hydroxybutyl)-6-(3-chloro-4-fluorobenzyl)-4-m-
ethoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide
(0.20 g, 0.34 mmol) and diisopropylethylamine (0.07 mL, 0.41 mmol)
in dichloromethane, methanesulfonic anhydride (71 mg, 0.41 mmol)
was added. The reaction mixture was stirred at room temperature for
30 minutes. The product mixture was washed with water. The organic
extract was dried over anhydrous sodium sulfate, filtered, and
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel eluting with 0.5% methanol in
dichloromethane. Collection and concentration of appropriate
fractions afforded the title compound.
[0521] .sup.1H NMR (400 MHz, CDCl.sub.3) mixture of rotamers
.delta. 7.36-7.08 (m, 8H), 4.64 (s, 1H), 4.57 (s, 1H), 4.50 (s,
1H), 4.33 (s, 1H). 4.06 (s, 3H), 3.75 (s, 2H), 3.69 (q, J=5.7 Hz,
1H), 3.58 (t, J=7.3 Hz, 1H), 3.49 (br m, 3H), 3.44 (s, 1.5H), 3.52
(s, 1.5H), 3.25 (q, J=6.8 Hz, 2H), 2.97 (t, 6.4 Hz, 1H), 2.69 (q,
6.7 Hz, 2H), 1.78-1.36 (m). (ES MS M+1=664.2)
Step 9:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-[2-(benzyloxy)ethyl]-3,4,-
5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)--
trione
[0522] To a mixture of
N-[2-(benzyloxy)ethyl]-N-(4-methanesulfonyloxybutyl)-6-(3-chloro-4-fluoro-
benzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carb-
oxamide (90 mg, 0.14 mmol) and cesium carbonate (53 mg, 0.16 mmol)
in DMF was heated at 75.degree. C. for 90 minutes. The product
mixture was concentrated under vacuum. The residue was subjected to
column chromatography on silica gel eluting with 5% methanol in
dichloromethane. Collection and concentration of appropriate
fractions afforded the title compound.
[0523] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (dd, J=2.0,
6.8 Hz, 1H), 7.27-7.08 (m), 7.09 (t, J=8.6 Hz, 1H), 5.28 (s), 4.74
(dd, J=6.2, 13.9 Hz, 1H), 4.67 (d, J=14.8 Hz, 1H), 4.57 (d, 14.8
Hz, 1H), 4.48 (s, 2H), 4.18 (m, 1H), 4.09 (s, 3H), 3.78-3.66 (m,
2H), 3.46-3.16 (m, 6H), 2.70-2.63 (m, 1H), 2.25-2.00 (m, 1H),
1.85-1.72 (m, 1H). (ES MS M+1=569.0)
Step 10:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(acetyloxy)ethyl]-3,4-
,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-
-trione
[0524] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-[2-(benzyl-oxy)ethyl]-3,4,5,6,12-
,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
(120 mg, 0.21 mmol) and 33% hydrogen bromide in acetic acid (1 mL)
in dioxane (1 mL) was stirred at room temperature for 1 hour. The
product mixture was concentrated under vacuum. The residue was
subjected to reverse phase column chromatography on C-18 stationary
phase eluted with a 95-5% water-acetonitrile gradient. Collection
and lyophilization of appropriate fractions afforded the title
compound.
[0525] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (dd, 6.7, 1.6
Hz, 1H), 7.18 (br signal, 1H), 7.12 (t, J=8.6 Hz, 1H), 4.79 (br
signal), 4.76 (d, J=14.7 Hz, 1H), 4.54 (d, J=14.7 Hz, 1H), 4.46 (br
signal), 4.18 (m, 2H), 3.48-3.25 (m), 3.00-2.93 (m), 2.61-2.57 (m),
2.03 (s, 3H), 2.09-1.75 (m). (ES MS M+1=506.2)
Example 11
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-hydroxyethyl)-3,4,5,6,12,13-he-
xahydro-2H
[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00035##
[0527] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(acetyloxy)ethyl]-3,4,5,6,12,-
13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
(50 mg, 0.1 mmol) and aqueous lithium hydroxide (0.5 mL, 1M) in THF
was stirred at room temperature for 1 hour. The product mixture was
concentrated under vacuum. The residue was subjected to reverse
phase column chromatography on C-18 stationary phase eluted with a
95-5% water-acetonitrile gradient. Collection and lyophilization of
appropriate fractions afforded the title compound.
[0528] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.17 (br s, 1H),
7.35 (dd, J=6.9, 2.2 Hz, 1H), 7.18 (br signal, 1H), 7.13 (t, J=8.4
Hz, 1H), 4.82 (m, 1H), 4.79 (d, J=15.0 Hz, 1H), 4.54 (d, J=15.0 Hz,
1H), 4.19-4.13 (m, 1H), 3.95-3.82 (m, 2H), 3.49-3.35 (in),
3.29-3.24 (m, 1H), 3.03-2.96 (m, 1H), 2.64-2.57 (m, 1H), 2.13-0.09
(m). (ES MS M+1=464.1378)
Example 12
[11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-1,8,10-trioxo-1,3,4,5,6,8,10,11,12-
,13-deca-hydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]acetic
acid
##STR00036##
[0529] Step 1: tert-Butyl [(4-hydroxybutyl)amino]acetate
[0530] To a cold (0.degree. C.) solution of 4-hydroxybutylamine
(9.1 g, 101.8 mmol) in diethyl ether (100 mL), a solution of
tert-butyl bromoacetate (7.4 g, 49.3 mmol) in diethyl ether (25 mL)
was added dropwise over a period of 2 hours. The reaction mixture
was allowed to warm up slowly to room temperature and stirred at
the temperature overnight. The product mixture was washed
successively with aqueous NaHCO.sub.3, water, and brine. The
organic extract was dried over anhydrous sodium sulfate, filtered,
and concentrated under vacuum. This intermediate was used in the
following reaction without further purification.
[0531] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 3.58 (t, J=5.3 Hz,
2H), 3.26 (s, 2H), 2.63 (t, J=6.1 Hz, 2H), 1.67-1.58 (m, 4H), 1.45
(s, 9H).
Step 2: tert-Butyl
[11-(3-chloro-4-fluorobenzyl)-9-methoxy-1,8,10-trioxo-1,3,4,5,6,8,10,11,1-
2,13-decahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]acetate
[0532] The title compound was prepared in a manner similar to that
described in Example 10, steps 6 to 8, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with tert-butyl [(4-hydroxybutyl)amino]acetate in step 6.
[0533] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.45 (dd, J=6.7,
1.6 Hz, 1H), 7.18 (br signal, 1H), 7.08 (t, J=8.6 Hz, 1H), 4.75
(dd, J=13.9, 6.0 Hz, 1H), 4.67 (d, J=14.7 Hz, 1H), 4.63 (d, 14.7
Hz, 1H), 4.25 (d, J=16.8 Hz, 1H), 4.11 (s, 3H), 3.91 (d, J=16.8 Hz,
1H), 3.68 (dd, J=10.8, 13.7 Hz, 1H), 3.48-3.34 (m), 3.19 (dd,
J=4.15 Hz, 1H), 2.86-2.79 (m), 2.55-2.48 (m, 1H), 2.11-2.08 (m),
1.89-1.74 (m). (ES MS M+1=549)
Step 3:
[11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-1,8,10-trioxo-1,3,4,5,6,8,-
10,11,12,13-deca-hydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]acet-
ic acid
[0534] A mixture of tert-butyl
[11-(3-chloro-4-fluorobenzyl)-9-methoxy-1,8,10-trioxo-1,3,4,5,6,8,10,11,1-
2,13-decahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]acetate
(50 mg, 0.09 mmol) and 33% hydrogen bromide in acetic acid (1 mL)
in dioxane (1 mL) was stirred at room temperature for 1 hour. The
product mixture was concentrated under vacuum. The residue was
subjected to reverse phase column chromatography on C-18 stationary
phase eluted with a 95-5% water-acetonitrile gradient. Collection
and lyophilization of appropriate fractions afforded the title
compound.
[0535] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (dd, J=6.6,
2.1 Hz, 1H), 7.18 (br signal, 1H), 7.11 (t, J=8.4 Hz, 1H), 4.78 (d,
J=14.8 Hz, 1H), 4.52 (d, J=14.8 Hz, 1H), 4.41 (d, J=17.8 Hz, 1H),
4.07 (d, J=17.8 Hz, 1H), 3.67 (m, 1H), 3.51-3.36 (m), 3.23 (br d,
1H), 2.96 (m), 2.60 (m, 1H), 2.08 (m), 1.96 (m), 1.76 (m). (ES MS
M+1=478.2)
Example 13
2-[11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-1,8,10-trioxo-1,3,4,5,6,8,10,11,-
12,13-d
ma-hydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]-N,N-dimet-
hylacetamide
##STR00037##
[0536] Step 1:
2-[11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-1,8,10-trioxo-1,3,4,5,6,8,10,11-
,12,13-deca-hydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]-N,N-dime-
thylacetamide
[0537] A solution of
[11-(3-chloro-4-fluorobenzyl)-9-hydroxy-1,8,10-trioxo-1,3,4,5,6,8,10,11,1-
2,13-deca-hydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridin-2-yl]acetic
acid (25 mg, 0.05 mmol), BOP (28 mg, 0.06 mmol),
diisopropylethylamine (7 mg, 0.07 mmol) and dimethylamine (0.11 mL,
2M in THF) in DMF (0.5 mL) was stirred at room temperature
overnight. The product mixture was concentrated under vacuum. The
residue was subjected to reverse phase column chromatography on
C-18 stationary phase eluted with a 95-5% water-acetonitrile
gradient. Collection and lyophilization of appropriate fractions
afforded the title compound.
[0538] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.2 (br s, 1H),
7.35 (d, J=6.8 Hz, 1H), 7.18 (br signal, 1H), 7.12 (t, J=8.4 Hz,
1H), 4.84 (m, 1H), 4.80 (d, J=14.8 Hz, 1H), 4.66 (d, J=16.1 Hz,
1H), 4.52 (d, J=14.8 Hz, 1H), 3.89 (d, J=15.9 Hz, 1H), 3.68 (app t,
J=12.2 Hz, 1H), 3.50-3.15 (br m, 4H), 3.07 (s, 3H), 3.01-2.92 (br
m, 4H), 2.77 (dt, J=5.3, 15.9 Hz, 1H), 2.14-2.08 (m, 1H), 1.96-1.74
m, 3H). (ES MS M+1=505.3)
Examples 14-15
[0539] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 13 using the
appropriate amine in place of dimethylamine.
TABLE-US-00001 Example Compound Data 14
2-[11-(3-Chloro-4-fluorobenzyl)-9- ES MS M + 1 = 491.3
hydroxy-1,8,10-trioxo- 1,3,4,5,6,8,10,11,12,13-
deca-hydro-2H-[1,4]diazocino[2,1-a]-
2,6-naphthyridin-2-yl]-N-methylacetamide ##STR00038## 15
2-[11-(3-Chloro-4-fluorobenzyl)-9- HRMS (APCI, M + 1):
hydroxy-1,8,10-trioxo- found 477.1334 1,3,4,5,6,8,10,11,12,13-
deca-hydro-2H-[1,4]diazocino[2,1-a]-
2,6-naphthyridin-2-yl]acetamide ##STR00039##
Example 16
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-morpholin-4-ylethyl)-3,4,5,6,1-
2,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trion-
e
##STR00040##
[0540] Step 1:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-(2-hydroxyethyl)-3,4,5,6,12,13-h-
exahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0541] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-[2-(benzyloxy)ethyl]-3,4,5,6,12,-
13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
(0.55 g, 0.97 mmol) and 5% rhodium on carbon (1.10 g) in ethyl
acetate (22 mL) was stirred under a balloon of hydrogen at room
temperature overnight. The product mixture was filtered through a
pad of Celite. The filtrate was concentrated under vacuum to afford
the title compound. This material was used in the following
reaction without further purification.
[0542] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (m, 1H),
7.22-7.19 (m, 1H), 7.10 (t, J=8.6 Hz, 1H), 4.83-4.61 (m, 3 H),
4.19-4.00 (m, 4H), 3.93-3.80 (m, 2H), 3.72-3.55 (m, 1H), 3.49-3.14
(br m, 5H), 2.96-2.81 (m, 1H), 2.48-2.34 (m, 1H), 1.95-1.43 (br
signal), 1.21-1.13 (br m, 1H), 0.93-0.84 (br m, 1H). (ES MS
M+1=478.1)
Step 2:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-[2-(methanesulfonyloxy)et-
hyl]-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8-
,10(11H)-trione
[0543] To a cold (0.degree. C.) solution of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-(2-hydroxyethyl)-3,4,5,6,12,13-h-
exahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
(250 mg, 0.52 mmol) and diisopropylethylamine (0.19 mL, 1.05 mmol)
in dichloromethane (5 mL), methanesulfonic anhydride (0.1 g, 0.63
mmol) was added. The reaction mixture was allowed to warm up to
room temperature and was stirred at room temperature for 2 hour.
The product mixture was diluted with dichloromethane and washed
with aq ammonium chloride. The organic extract was dried over
anhydrous magnesium sulfate, filtered, and concentrated under
vacuum to afford the title compound. This material was used in the
following reaction without further purification. (ES MS
M+1=556.3)
Step 3:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-(2-morpholin-4-ylethyl)-3-
,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11-
H)-trione
[0544] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-(2-methane-sulfonylethyl)-3,4,5,-
6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-tr-
ione (97 mg, 0.17 mmol), morpholine (30 mg, 0.35 mmol), and
diisopropylethylamine (006 mL, 0.355 mmol) in THF (1.7 mL) was
stirred at 40.degree. C. overnight. The product mixture was
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel eluting with gradient mixture of
methanol in dichloromethane. Collection and concentration of
appropriate fractions afforded the title compound.
[0545] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (dd, J=2.0,
7.0 Hz, 1H), 7.21 (m, 1H), 7.12 (t, J=8.8 Hz, 1H), 4.80 (dd, J=6.2,
13.9 Hz, 1H), 4.74 (d, J=15.0 Hz, 1H), 4.62 (d, J=14.8 Hz, 1H),
4.12-4.07 (m, 4H), 3.69-3.64 (m, 4H), 3.45-3.30 (m, 5H), 3.20-3.13
(m, 1H), 2.90-2.83 (m, 1H), 2.66-2.42 (m, 7H), 2.08 (br m, 1H),
1.91-1.72 (br m, 3H). (ES MS M+1=547.4)
Step 4:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-morpholin-4-ylethyl)-3-
,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11-
H)-trione
[0546] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-(2-morpholin-4-ylethyl)-3,4,5,6,-
12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trio-
ne (30 mg, 0.06 mmol) and 33% hydrogen bromide in acetic acid (0.4
mL) in dioxane (2 mL) was stirred at room temperature for 30
minutes. The product mixture was concentrated under vacuum. The
residue was subjected to reverse phase column chromatography on
C-18 stationary phase eluted with a 95-5% water-acetonitrile
gradient. Collection and lyophilization of appropriate fractions
afforded the title compound.
[0547] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.3 (s, 1H), 7.35
(dd, J=2.0, 7.0 Hz, 1H), 7.22-7.17 (m, 1H), 7.13 (t, J=8.7 Hz, 1H),
4.84-4.76 (m, 1H), 4.67 (app q, J=14.5 Hz, 2H), 4.43-4.36 (m, 1H),
4.02-2.85 (br signal, 17H), 2.66-2.60 (m, 1H), 2.11-2.01 (br m,
1H), 1.94 (br m, 1H), 1.78-1.69 (br m, 2H). (ES MS M+1=533.3)
Examples 17-22
[0548] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 16 using the
appropriate amines or sodium alkoxide in place of morpholine in
Examples 17-19 and 22. Acetylation and methanesulfonylation of the
intermediate leading to the preparation of 19 provided Examples 20
and 21.
TABLE-US-00002 Example Compound Data 17
11-(3-Chloro-4-fluorobenzyl)-9- ES MS M +1 = 517.3
hydroxy-2-(2-pyrrolidinyl-1- ylethyl)-3,4,5,6,12,13-hexahydro-
2H[1,4]diazocino[2,1-a]-2,6- naphthyridine-1,8,10(11H)-trione
##STR00041## 18 11-(3-Chloro-4-fluorobenzyl)-9- ES MS M +1 = 531.2
hydroxy-2-(2-piperidinyl-1- ylethyl)-3,4,5,6,12,13-hexahydro-
2H[1,4]diazocino[2,1-a]-2,6- naphthyridine-1,8,10(11H)-trione
##STR00042## 19 11-(3-Chloro-4-fluorobenzyl)-9- ES MS M +1 = 463.2
hydroxy-2-(2-aminoethyl)- 3,4,5,6,12,13-hexahydro-2H[1,4]
diazocino[2,1-a]-2,6- naphthyridine-1,8,10(11H)-trione ##STR00043##
20 11-(3-Chloro-4-fluorohenzyl)-9- ES MS M +1 = 505.3 hydroxy-2-[2-
(acetylamino)ethyl]-3,4,5,6,12,13-hexahydro-
2H[1,4]diazocino[2,1-a]-2,6- naphthyridine-1,8,10(11H)-trione
##STR00044## 21 11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2- ES MS
M + 1 = 541.3 (methanesulfonylamino)ethyl]-
3,4,5,6,12,13-hexahydro- 2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-
1,8,10(11H)-trione ##STR00045## 22 11-(3-Ch1oro-4-flnorobenzyl)-9-
ES MS M +1 = 478.2 hydroxy-2-[2-methoxy)ethyl]-
3,4,5,6,12,13-hexahydro-2H[1,4] diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00046##
Examples 23-24
11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2-methyl-3,4,5,6,12,13-hexahydr-
o-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00047##
[0550] The title compound was prepared in a manner similar to that
described in Example 10, steps 6 to 10, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with 4-{[tert-butyl(diphenyl)silyl]oxy}-1-(methylamino)butan-2-ol
(Romeril, S. P. et al, Tet. Lett. 2003, 7757) in step 6.
Isomer A:
[0551] .sup.1H NMR (600 MHz, CDCl.sub.3) .delta. 13.09 (s, 1H),
7.35 (dd, J=1.6, 6.7 Hz, 1H), 7.20-7.15 (m, 1H), 7.14-7.09 (m, 1H),
4.78 and 4.71 (d, J=14.2 Hz, second d overlaps with broad
multiplet, 2H), 4.60 and 4.55 (d, J=14.9 Hz, 1H), 4.16 and 3.96 (m,
1H), 3.77 and 3.62 (dd, J=10.8, 14.4 Hz, 1H), 3.52-3.36 (m, 2H),
3.34-3.22 (m, 2H), 3.17 (s, 3H), 3.06-2.98 (m, 1H), 2.67-2.48 (m,
2H), 1.94 (m).
Isomer B:
[0552] .sup.1H NMR (600 MHz, CDCl.sub.3) .delta. 13.13 (s, 1H),
7.35 (d, J=6.6 Hz, 1H), 7.18 (m, 1H), 7.13 (t, J=8.5 Hz, 1H), 4.79
and 4.74 (d, J=15 Hz, 1H), 4.68 (m, 1H), 4.59 and 4.54 (d, J=15 Hz,
1H), 4.16 and 3.96 (br signal, 1H), 3.79 (m), 3.56-3.17 (m),
3.06-2.98 (m, 1H), 2.62-2.54 (m), 2.48 (br m), 2.12 (br m), 1.90
(br m).
[0553] (ES MS M+1=450.21)
Example 25
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-5,6,12,13-tetrahydro-2H[1,-
4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone
##STR00048##
[0554] Step 1:
11-(3-Chloro-4-fluorobenzyl)-4-hydroxy-9-methoxy-2-methyl-3,4,5,6,12,13-h-
exahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0555] The title compound was prepared in a manner similar to that
described in Example 10, steps 6 to 9, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with 4-{[tert-butyl(diphenyl)silyl]oxy}-1-(methylamino)butan-2-ol
(Romeril, S. P. et al, Tet. Lett. 2003, 7757) in step 6.
Early Isomer on Normal Phase Silica (2:1 Mixture of
Conformers):
[0556] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (d, J=6.8 Hz,
1H), 7.17 (m, 1H), 7.10-7.07 (m, 1H), 4.89 and 4.71 (d, J=15 Hz,
1H), 4.67-4.63 (m, 1H), 4.58 and 4.41 (d, J=15 Hz, 1H), 4.14 (br
m), 4.08 and 3.96 (s, 3H), 3.90 (in), 3.76-3.70 (m), 3.67-3.52 (m),
3.38 (br s), 3.42-3.21 (m), 3.16 (s), 2.86-2.73 (m, 2H), 2.48-2.33
(m, 2H), 2.06 (m), 1.86-1.77 (m, 1H).
Late Isomer on Normal Phase Silica (5:2 Mixture of Conformers):
[0557] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (d, J=6.8 Hz,
1H), 7.17 (m, 1H), 7.13-7.09 (m, 1H), 4.91 and 4.73 (d, J=14.7 Hz,
1H), 4.70-4.64 (m, 1H), 4.61 and 4.44 (d, J=14.9 Hz, 1H), 4.17 (br
s), 4.10 and 3.99 (s, 3H), 3.92 (br m), 3.79-3.74 (m), 3.69-3.54
(m), 3.51 (br s), 3.42-3.24 (m), 3.18 (s), 2.89-2.75 (m, 2H),
2.50-2.38 (m, 2H), 2.08 (br m), 1.88-1.73 (m, 1H).
[0558] (ES MS M+1=464.2)
Step 2:
11-(3-Chloro-4-fluorobenzyl)-9-methoxy-2-methyl-5,6,12,13-tetrahyd-
ro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone
[0559] A mixture of
11-(3-chloro-4-fluorobenzyl)-4-hydroxy-9-methoxy-2-methyl-3,4,5,6,12,13-h-
exahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
(50 mg, 0.11 mmol), molecular sieves (4A), N-methylmorpholine
N-oxide (19 mg, 0.16 mmol), and tetra-n-propylammonium ruthenium
tetroxide in dichloromethane was stirred at room temperature for
two hrs. The mixture was filtered, and the filtrate concentrated
under vacuum. The residue was subjected to column chromatography on
silica gel eluting with 0-15% methanol in dichloromethane gradient.
Collection and concentration of appropriate fractions provided the
title compound.
[0560] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (d, J=6.2 Hz,
1H), 7.19 (m, 1H), 7.11 (t, J=8.5 Hz, 1H), 4.80 (d, J=14.1 Hz, 1H),
4.74 (d, J=15.2 Hz, 1H), 4.62 (d, J=14.6 Hz, 1H), 4.15 (s, 3H),
4.10 (d, J=15.4 Hz, 1H), 3.66 (t, J=13.2 Hz, 1H), 3.52 (d, J=15.0
Hz, 1H), 3.45-3.36 (m, 2H), 3.11-3.04 (m, 4H), 2.94-2.90 (m, 1H),
2.79 (d, J=18.9 Hz, 1H), 2.48-2.45 (m, 1H). (ES MS M+1=462.20)
Step 3:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-5,6,12,13-tetrahyd-
ro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone
[0561] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-methyl-5,6,12,13-tetrahydro-2H[1-
,4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone (25
mg, 0.05 mmol) and 33% hydrogen bromide in acetic acid (0.5 mL) in
dioxane (1 mL) was stirred at room temperature for 1.5 hour. The
product mixture was concentrated under vacuum. The residue was
dissolved in DMSO and subjected to reverse phase column
chromatography on C-18 stationary phase eluted with a 95-5%
water-acetonitrile gradient. Collection and lyophilization of
appropriate fractions afforded the title compound.
[0562] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.47 (s, 1H),
7.38 (d, J=6.0 Hz, 1H), 7.19 (m, 1H), 7.12 (t, J=8.2 Hz, 1H), 5.56
(br s, 1H), 4.94 (br m, 1H), 4.23 (br m, 2H), 4.16-3.98 (m, 2H),
3.60 (br d, J=8.1 Hz, 1H), 3.51 (br d, J=10.2 Hz, 1H), 3.24 (br
signal, 1H), 2.89 (s, 3H), 2.59 (br signal, 1H). (ES MS
M+1=448.0)
Example 26
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-4-pyrrolidin-1-yl-3,4,5,6,-
12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trio-
ne
##STR00049##
[0563] Step 1:
11-(3-Chloro-4-fluorobenzyl)-4-pyrrolidin-1-yl-9-methoxy-2-methyl-3,4,5,6-
,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-tri-
one
[0564] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-methyl-5,6,12,13-tetrahydro-2H[1-
,4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone (30
mg, 0.06 mmol), molecular sieves (4A), pyrrolidine (23 mg, 0.32
mmol), and acetic acid (4 mg) in dichloroethane (1 mL) was heated
at 80.degree. C. for four hrs. The mixture was cooled to room
temperature, treated with sodium borohydride (12 mg, 0.19 mmol),
and stirred at room temperature for 30 minutes. The product mixture
was diluted with dichloromethane, washed successively with aq
sodium carbonate and brine. The organic extract was dried over
anhydrous magnesium sulfate, filtered, and concentrated under
vacuum to provide the title compound. This material was used in the
following step without further purification.
[0565] ES MS M+1=517.3
Step 2:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-5,6,12,13-tetrahyd-
ro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,4,8,10(3H,11H)-tetrone
[0566] A mixture of
11-(3-chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-4-pyrrolidin-1-yl-3,4,5,6-
,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-tri-
one (40 mg, 0.08 mmol) and 33% hydrogen bromide in acetic acid (0.5
mL) in dioxane (1 mL) was stirred at room temperature for 1.5 hour.
The product mixture was concentrated under vacuum. The residue was
dissolved in DMSO and subjected to reverse phase column
chromatography on C-18 stationary phase eluted with a 95-5%
water-acetonitrile gradient. Collection and lyophilization of
appropriate fractions afforded the title compound.
[0567] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (d, J=7.1 Hz,
1H), 7.17 (m, 1H), 7.13 (t, J=8.4 Hz, 1H), 4.84 (m, 1H), 4.70 (d,
J=14.9 Hz, 1H), 4.63 (d, J=15.1 Hz, 1H), 3.83 (m, 1H), 3.74 (m,
2H), 3.58 (dd, J=10 Hz, 1H), 3.48-3.43 (m, 4H), 3.14 (s, 2H),
3.05-2.94 (br m, 2H), 2.63-2.58 (m, 1H), 2.40 (m, 1H), 2.29-2.24
(m, 1H), 2.07 (br m, 3H). (ES MS M+1=503.2)
Example 27
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-4-morpholin-4-yl-3,4,5,6,1-
2,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trion-
e
##STR00050##
[0569] The title compound was prepared in a manner similar to that
described in Example 26, substituting pyrrolidine with morpholine.
ES MS M+1=518.99.
Examples 28-29
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,6-dimethyl-3,4,5,6,12,13-hexahydr-
o-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00051##
[0570] Step 1: 5-(Methylamino)pentan-2-ol
[0571] A mixture of .gamma.-valerolactone (5.0 g, 49.9 mmol) and
methylamine (75 mL, 2 M in methanol) in methanol (50 mL) was
stirred at room temperature overnight. The product mixture was
concentrated under vacuum. This intermediate methylamide was
concentrated from benzene to remove residual methanol and was used
in the following step without further purification. To a cold
(0.degree. C.) solution of the above amide (2.0 g, 15.3 mmol) in
anhydrous THF, a solution of lithium aluminum hydride (15.2 mL, 2M)
in THF was added. The reaction mixture was stirred at room
temperature for 30 minutes, and heated at 65.degree. C. overnight.
The product mixture was cooled to 0.degree. C. and treated
successively with water (1.2 mL), 15% aq sodium hydroxide (1.2 mL),
and water (3.6 mL). The resultant suspension was diluted with
ether, and filtered with a pad of Celite. The solid filtered was
washed with methylene chloride. The organic filtrates were combined
and concentrated under vacuum to provide the title compound.
Step 2:
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,6-dimethyl-3,4,5,6,12,13--
hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
[0572] The title compounds were prepared in a manner similar to
that described in Example 10, steps 5 to 10, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with 5-(methylamino)pentan-2-ol, and tert-butyldimethylsily
chloride with tert-butyldiphenylsily chloride in step 5. Two sets
of enantiomeric mixtures (atropisomeric at the exocyclic amide
moiety and enantiomeric at the 6-methyl position) were obtained
with reverse phase HPLC on C-18 stationary phase after hydrogen
bromide deprotection in step 10.
Early Isomer on Reverse Phase:
[0573] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (d, J=6.3 Hz,
1H), 7.18 (br signal, 1H), 7.13 (t, J=8.6 Hz, 1H), 4.78 (d, J=14.7
Hz, 1H), 4.55 (d, J=14.7 Hz, 1H), 3.49-2.97 (m), 3.10 (s, 3H),
2.59-2.55 (m, 1H), 2.03 (br signal), 1.74 (br signal), 1.36 (d,
J=7.1 Hz, 3H). (ES MS exact mass M+1=448.1466)
Late Isomer on Reverse Phase:
[0574] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (d, J=6.5 Hz,
1H), 7.18 (br signal, 1H), 7.13 (t, J=8.6 Hz, 1H), 4.78 (d, J=14.7
Hz, 1H), 4.55 (d, J=14.7 Hz, 1H), 4.05 (br t, J=6.6 Hz, 1H),
3.49-2.57 (m), 3.11 (s, 3H), 1.81 (br signal), 1.72 (d, J=6.6 Hz,
3H). (ES MS exact mass M+1=448.1457)
Examples 30-36
[0575] The compounds in the following table were prepared in
accordance with the procedures set forth in Examples 11 and 29
using the appropriate aminoalcohol in place of
5-(methylamino)pentan-2-ol in Example 29. The amino heterocycles
were incorporated in the manner described in Examples 16.
TABLE-US-00003 Example Compound 30 & 31
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-hydroxyethyl)-6-methyl-
-3,4,5,6,12,13-
hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00052## Early isomer on reverse phase: .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.35 (dd, J = 6.8, 1.8 Hz, 1H), 7.198 (br
signal, 1H), 7.13 (t, J = 8.6 Hz, 1H), 5.72 (m, 1H), 4.77 (d, J =
14.6 Hz, 1H), 4.54 (d, J = 14.6 Hz, 1H), 4.18 (m, 1H), 3.92-3.78
(m, 2H), 3.50-2.92 (m), 2.55 (m, 1H), 2.01-1.75 (br signals), 1.34
(d, J = 7.2 Hz, 3H). (ES MS exact mass M + 1 = 478.1548) Late
isomer on reverse phase: .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.35 (dd, J = 6.8, 1.6 Hz, 1H), 7.19 (br signal, 1H), 7.12 (t, J =
8.6 Hz, 1H), 4.78 (d, J = 14.6 Hz, 1H), 4.54 (d, J = 14.6 Hz, 1H),
4.18- 4.06 (m, 2H), 4.04-3.78 (m, 2H), 3.51-3.00 (m), 2.78-2.56
(m), 1.83-1.77 (br signals), 1.71 (d, J = 6.7 Hz, 3H).. (ES MS
exact mass M + 1 = 478.1551) 32
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-morpholin-4-ylethyl)-6-meth-
yl-
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)- trione ##STR00053## (ES MS M + 1 = 547.2) 33
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-piperidinyl-1-ylethyl)-6-me-
thyl-
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)- trione ##STR00054## ES MS M + 1 = 545.2 34
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-(2-pyrrolidinyl-1-ylethyl)-6-m-
ethyl-
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)- trione ##STR00055## (ES MS M + 1 = 531.2) 35
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(1H-pyrazol-1-yl)ethyl]-6-m-
ethyl-
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)- trione ##STR00056## (ES MS M + 1 = 528.2) 36
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2-[2-(1H-imidazol-1-yl)ethyl]-6--
methyl-
3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(-
11H)- trione ##STR00057## ES MS M + 1 = 528.2
Example 37
11-(3-Chloro-4-fluorobenzyl)-5,9-dihydroxy-2-methyl-3,4,5,6,12,13-hexahydr-
o-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00058##
[0577] The title compound was prepared in a manner similar to that
described in Example 10, steps 6 to 10, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with N-methyl-3-benzyloxy-4-hydroxybutan-1-amine in step 6.
[0578] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.34 (d, J=6.8 Hz,
1H), 7.18 (m, 1H), 7.12 (t, J=8.4 Hz, 1H), 5.30 (s), 4.78 (d,
J=14.7 Hz, 1H), 4.71 (br d, 1H), 4.54 (d, J=14.7 Hz, 1H), 4.08 (br
signal, 1H), 3.54-3.34 (m) 3.20-2.98 (m), 3.13 (s, 3H). (ES MS
M+1=450.2)
Example 38
(4R)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl-3,4,5,6,12-
,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00059##
[0579] Step 1:
(3R)-3-(Benzyloxy)-4,4-dimethyldihydrofuran-2(3H)-one
[0580] A mixture of D(-)-pantolactone (20.0 g, 153.7 mmol) and
sodium hydride (4.4 g, 184.4 mmol) in anhydrous THF was stirred
under an atmosphere of nitrogen at room temperature for 1 hour. The
resultant mixture was treated with benzyl bromide (31.5 g, 184.4
mmol) and stirred at room temperature overnight. The product
mixture was treated with water and diluted with dichloromethane.
The organic extract was washed with brine, dried over anhydrous
magnesium sulfate, filtered, and concentrated under vacuum. The
residue was subjected to purification on silica gel eluting with
0-5% methanol in dichloromethane gradient. Collection and
concentration of appropriate fractions provided the title
compound.
[0581] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 739-7.29 (m, 5H),
5.03 (d, J=12.1 Hz, 1H), 4.75 (d, J=12.1 Hz, 1H), 4.00 (d, J=8.8
Hz, 1H), 3.86 (d, J=8.8 Hz, 1H), 3.74 (s, 1H), 1.14 (s, 3H), 1.10
(s, 3H).
Step 2:
(3R)-3-(Benzyloxy)-2,2-dimethyl-4-(methylamino)butan-1-ol
[0582] The title compounds were prepared in a manner similar to
that described in Examples 28-29, step 1, substituting
.gamma.-valerolactone with
(3R)-3-(benzyloxy)-4,4-dimethyldihydrofuran-2(3H)-one.
[0583] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.41-7.32 (m, 5H),
6.63 (br s, 1H), 4.55 (d, J=11.4 Hz, 1H), 4.47 (d, J=11.4 Hz, 1H),
3.79 (s, 1H), 3.48 (s, 1H), 3.43 (d, J=11.8 Hz, 1H), 3.37 (d,
J=11.8 Hz, 1H), 2.84 (d, J=5.0 Hz, 3H), 1.06 (s, 3H), 0.85 (s,
3H).
Step 3:
(4R)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl-3,-
4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H-
)-trione
[0584] The title compound was prepared in a manner similar to that
described in Example 10, steps 6, 8 to 10, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with (3R)-3-(benzyloxy)-2,2-dimethyl-4-(methylamino)butan-1-ol in
step 6.
[0585] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.4 (dd, J=1.6,
5.4 Hz, 1H), 7.2 (m, 1H), 7.13 (t, J=8.4 Hz, 1H), 4.84 (d, J=14.6
Hz, 1H), 4.75 (d, J=14.8 Hz, 1H), 4.58 (d, J=14.8 Hz, 1H), 3.71
(dd, J=15.0, 9.7 Hz, 1H), 3.44 (m), 3.19 (s, 3H), 3.19 (m), 3.03
(d, J=15.0 Hz, 1H), 2.94 (m, 1H), 2.54 (m, 1H), 1.22 (s, 3H), 0.93
(s, 3H). (ES MS M+1=478.2)
Examples 39-44
[0586] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 38 using the
appropriate lactone in place of D(-)-pantolactone.
TABLE-US-00004 Example Compound Data 39
(4S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5- (ES MS M + 1
= 4782)
trimethyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00060## L-(-)-pantolactone 40
& 41 (4R/S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,5,5-
(ES MS M + 1 = 478.2)
trimethyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00061## (racemic D/L pantoyl
lactone 42
(4R/S)-11-(4-Fluorobenzyl)-4,9-dihydroxy-2,5,5-trimethyl- (ES MS M
+ 1 = 448.2) 3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00062## 43 (4R,
6S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,6- (ES MS M + 1 =
464.1)
dimethyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00063## 44 (4S,
6S)-11-(3-Chloro-4-fluorobenzyl)-4,9-dihydroxy-2,6- (ES MS M + 1 =
464.1)
dimethyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-
naphthyridine-1,8,10(11H)-trione ##STR00064##
Example 45
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,4,4-trimethyl-3,4,5,6,12,13-hexah-
ydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00065##
[0588] The title compound was prepared in a manner similar to that
described in Example 10, steps 6 to 10, substituting
N-[2-(benzyloxy)ethyl]-4-{[tert-butyl(dimethyl)-silyl]oxy}butan-1-amine
with
4-{[tert-butyl(diphenyl)-silyl]oxy}-N,2,2-trimethylbutan-1-amine in
step 6.
[0589] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (dd, J=1.6,
6.8 Hz, 1H), 7.2 (m, 1H), 7.13 (t, J=8.6 Hz, 1H), 4.79 (d, J=14.9
Hz, 1H), 4.70 (m, 4H), 4.54 (d, J=14.9 Hz, 1H), 3.53 (m), 3.18 (s,
3H), 3.05-2.93 (m), 2.84 (d, J=15.2 Hz, 1H), 2.56-2.48 (m),
1.85-1.66 (m), 1.12 (s, 3H), 0.89 (s, 3H). (ES MS exact mass
M+1=462.1600)
Example 46
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-2,4-dimethyl-3,4,5,6,12,13-hexahydr-
o-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(1H)-trione
##STR00066##
[0591] The title compounds were prepared in a manner similar to
that described in Examples 28-29, substituting
.gamma.-valerolactone with
.alpha.-methyl-.gamma.-butyrolactone.
[0592] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36-7.30 (m, 1H),
7.21-7.18 (br signal, 1H), 7.13 (t, J=8.6 Hz, 1H), 4.80 (d, J=14.6
Hz, 1H), 4.80 (m), 4.53 (d, J=14.6 Hz, 1H), 3.50-2.53 (m), 3.11 (s,
3H), 2.18-1.53 (m), 0.90 (d, J=7.0 Hz, 3H). (ES-MS M+1=448.17)
Example 47
(6R)-11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,4-
,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H-
)-trione
##STR00067##
[0593] Step 1: (2S)-1-(Benzyloxy)-5-(methylamino)pentan-2-ol
[0594] The title compound was prepared in a manner similar to that
described in Examples 28-29, step 1, substituting
.gamma.-valerolactone with
(5S)-5-[(benzyloxy)methyl]dihydrofuran-2(3H)-one. (ES MS
M+1=224.0).
Step 2:
6-(3-Chloro-4-fluorobenzyl)-N-[(45)-4,5-dihydroxypentyl]-4-methoxy-
-N-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide
[0595] The title compound was prepared in a manner similar to that
described in Example 10, step 6, substituting
N-[2-(benzyloxy)-ethyl]-4-{[tert-butyl(dimethyl)silyl]oxy}butan-1-amine
with (25)-1-(benzyloxy)-5-(methylamino)pentan-2-ol. (ES MS
M+1=586.33)
Step 3:
(6R)-6-[(Benzyloxy)methyl]-11-(3-chloro-4-fluorobenzyl)-9-methoxy--
2-methyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-
-1,8,10(11H)-trione
[0596] The title compound was prepared in a manner similar to that
described in Example 10, steps 8 and 9, substituting
N-[2-(benzyloxy)ethyl]-N-(4-hydroxybutyl)-6-(3-chloro-4-fluorobenzyl)-4-m-
ethoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide
with
6-(3-chloro-4-fluorobenzyl)-N-[(4S)-4,5-dihydroxypentyl]-4-methoxy-N-
-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide
in step 8. (ES MS M+1=568.3)
Step 4:
(6R)-11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-me-
thyl-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8-
,10(11H)-trione
[0597] A solution of
(6R)-6-[(benzyloxy)methyl]-11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-methy-
l-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,1-
0(11H)-trione (167 mg, 0.29 mmol) in dichloromethane (2.9 mL) was
cooled to 0.degree. C. and treated with boron tribromide (295 mg,
1.18 mmol). The cooling bath was removed and the mixture stirred at
room temperature for 30 minutes. The reaction was quenched by the
addition of MeOH followed by 1 N aqueous HCl. The mixture was
diluted with dichloromethane and washed with water. The organic
layer was dried over anhydrous magnesium sulfate, filtered and
concentrated under vacuum. The residue was subjected to reverse
phase column chromatography on C-18 stationary phase eluted with a
95-5% water-acetonitrile gradient. Collection and concentration of
appropriate fractions afforded the title compound.
[0598] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.15 (br s, 1H),
7.35 (d, J=6.8 Hz, 1H), 7.19 (m, 1H), 7.13 (t, J=8.5 Hz, 1H), 4.80
(d, J=14.6 Hz, 1H), 4.54 (d, J=14.6 Hz, 1H), 4.40-4.10 (br signal),
4.04-3.92 (m, 3H), 3.8-3.6 (br m), 3.54-3.47 (m), 3.41-3.31 (m),
3.22-3.16 (m), 3.10 (s, 3H), 3.06-2.99 (m, 1H), 2.61-2.54 (m, 1H),
2.25-2.15 (m, 2H), 1.85-1.80 (m, 2H), 1.26-1.14 (m). (ES MS
M+1=464.3)
Example 48
(6R)-11-(4-Fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,4,5,6,12,1-
3-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00068##
[0600] A mixture of
(6R)-11-(3-chloro-4-fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,-
4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11-
H)-trione (109 mg, 0.24 mmol), 20% Pd(OH).sub.2 on carbon (40 mg)
and diisopropylethylamine (0.1 mL) in EtOH (2.4 mL) was stirred
under hydrogen atmosphere for 20 hours. The reaction mixture was
filtered through a Celite pad and the filtrate concentrated under
vacuum to afford the title compound.
[0601] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.30-7.28 (m),
7.04 (t, J=8.5 Hz, 2H), 4.80 (d, J=14.6 Hz, 1H), 4.59 (d, J=14.6
Hz, 1H), 4.06-4.04 (m, 2H), 3.95-3.92 (m, 1H), 3.53-3.45 (m, 1H),
3.40-3.28 (m, 2H), 3.22-3.17 (m, 1H), 3.04-2.97 (m, 1H), 2.59-2.52
(m, 1H), 2.23-2.21 (m, 2H), 1.81 (m, 2H). (ES MS M+1=430.2)
Example 49
(6S)-11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-6-(hydroxymethyl)-2-methyl-3,4-
,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H-
)-trione
##STR00069##
[0603] The title compound was prepared in a manner similar to that
described in Example 46 and was isolated as a mixture of
atropisomers. Further purification by reverse phase column
chromatography on a C18 column (gradient elution with 70%
H.sub.2O--CH.sub.3CN to 65% H.sub.2O--CH.sub.3CN over 30 minutes,
then isocratic elution with 65% H.sub.2O--CH.sub.3CN for 10
minutes) afforded the title compound as the less polar
atropisomer.
[0604] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.11 (s, 1H),
7.36-7.34 (m, 1H), 7.21-7.10 (m, 2H), 4.78 (d, J=14.7 Hz, 1H), 4.55
(d, J=14.7 Hz, 1H), 4.01-3.90 (m, 3H), 3.54-3.42 (m, 1H), 3.40-3.30
(m, 2H), 3.21-3.17 (m, 1H), 3.09 (s, 3H), 3.06-3.00 (m, 1H),
2.60-2.53 (m, 1H), 2.23-2.15 (m, 2H), 1.84-1.80 (m, 2H). HRMS (ES
M+1): found 464.1400; calculated 464.1383.
[0605] The more polar isomer was also isolated from the
mixture:
[0606] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.09 (s, 1H),
7.36 (dd, J=1.9, 6.8 Hz, 1H), 7.22-7.10 (m, 2H), 5.68 (br s, 1H),
4.82 (d, J=14.8 Hz, 1H), 4.52 (d, J=14.8 Hz, 1H), 3.72-3.66 (m,
2H), 3.53-3.46 (m, 1H), 3.38-3.32 (m, 2H), 3.16-2.82 (m, 5H),
2.53-2.45 (m, 1H), 2.05-2.01 (m, 2H), 1.78-1.69 (m, 2H). HRMS (ES
M+1): found 464.1402; calculated 464.1383.
Example 50
11-(3-chloro-4-fluorobenzyl)-9-hydroxy-2-methyl-6-methylene-3,4,5,6,12,13--
hexahydro-2H-[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00070##
[0608] The title compound was generated during the boron
tribromide-mediated deprotection of
(6S)-6-[(benzyloxy)methyl]-11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-methy-
l-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10-
(11H)-trione following the method described in Example 47, step 4
for deprotection of the corresponding (6R)-isomer, and was isolated
by reverse phase column chromatography on C-18 stationary phase
eluted with a 95-5% water-acetonitrile gradient. HRMS (ES M+1):
found 446.1264; calculated 446.1277.
Example 51
2-[8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-2,3,7,8-
,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]-N,N-dimethylaceta-
mide
##STR00071##
[0609] Step 1: tert-Butyl
[8-(3-Chloro-4-fluorobenzyl)-6-methoxy-3,3-dimethyl-2,5,7-trioxo-2,3,7,8,-
9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]acetate
[0610] A mixture of
8-(3-chloro-4-fluorobenzyl)-6-methoxy-1,8,9,10-tetrahydroimidazo[2,1-a]-2-
,6-naphthyridine-2,5,6(3H)-trione (1.00 g, 2.55 mmol; Example 8,
step 5), sodium hydride (112 mg, 60% dispersion; 2.81 mmol),
tert-butyl bromoacetate (0.55 g, 2.81 mmol) in anhydrous DMF (10
mL) was stirred at room temperature overnight. The reaction mixture
was concentrated under vacuum. The residue was subject to column
chromatography on silica gel. Collection and concentration of
appropriate fractions provided the required alkylated intermediate.
A mixture of the above material (0.49 g, 0.99 mmol), sodium hydride
(71 mg, 60% dispersion; 2.96 mmol), iodomethane (0.42 g, 2.96 mmol)
in anhydrous DMF (10 mL) was stirred at room temperature overnight.
The reaction mixture was concentrated under vacuum. The residue was
subject to column chromatography on silica gel. Collection and
concentration of appropriate fractions afforded the title compound.
ES MS M+1=534.2
Step 2:
2-[8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7-trioxo-
-2,3,7,8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]-N,N-dimet-
hylacetamide
[0611] A mixture of tert-butyl
[8-(3-Chloro-4-fluorobenzyl)-6-methoxy-3,3-dimethyl-2,5,7-trioxo-2,3,7,8,-
9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin-1(5H)-yl]acetate
(0.30 g, 0.56 mmol) and hydrogen chloride (2.8 mL, 4 M in dioxane)
in dioxane (5 mL) was stirred at room temperature overnight. The
reaction mixture was concentrated under vacuum. The residue was
triturated with diethyl ether and filtered to provide the title
compound. This intermediate acid was used in the following step
without further purification. A solution of the acid (40 mg, 0.08
mmol), BOP (48 mg, 0.11 mmol), diisopropylethylamine (12 mg, 0.12
mmol) and dimethylamine (0.04 mL, 2M in THF) in DMF (0.5 mL) was
stirred at room temperature overnight. The product mixture was
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel. Collection and concentration of
appropriate fractions afforded the penultimate product. This
material (28 mg, 0.06 mmol) was treated with 33% hydrogen bromide
in acetic acid (44 mg) in dioxane (1 mL) at room temperature for
1.5 hour. The product mixture was concentrated under vacuum. The
residue was dissolved in DMSO and subjected to reverse phase column
chromatography on C-18 stationary phase eluted with a 95-5%
water-acetonitrile gradient. Collection and lyophilization of
appropriate fractions afforded the title compound.
[0612] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.33 (br d, J=6.8
Hz, 1H), 7.18 (br signal, 1H), 7.13 (t, J=8.4 Hz, 1H), 4.65 (s,
3H), 4.63 (s, 3H), 3.40 (br signal, 2H), 3.08 (s, 3H), 2.98 (s,
3H), 2.73 (br signal, 2H), 1.84 (s, 6H) (ES MS exact mass
M+1=491.1570)
Examples 52-53
[0613] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 51 using the
appropriate amine in place of dimethylamine.
TABLE-US-00005 Example Compound Data 52
2-[8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7- (ES MS
exact mass
trioxo-2,3,7,8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin- M + 1
= 477.1343) 1(5H)-yl]-N-methylacetamide ##STR00072## 53
2-[8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-3,3-dimethyl-2,5,7- (ES MS
exact mass
trioxo-2,3,7,8,9,10-hexahydroimidazo[2,1-a]-2,6-naphthyridin- M + 1
= 463.1179) 1(5H)-yl]acetamide ##STR00073##
Example 54
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(2-hydroxyethyl)-3,3-dimethyl-1,8,-
9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione
##STR00074##
[0615] The title compound was prepared in a manner similar to that
described in Example 50, substituting tert-butyl bromoacetate with
2-benzyloxyethylbromide in step 1.
[0616] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.36 (dd, J=6.8,
1.8 Hz, 1H), 7.20 (br signal, 1H), 7.13 (t, J=8.6 Hz, 1H), 5.30 (s,
1H), 4.68 (s, 2H), 4.02 (t, J=5.5 Hz, 2H), 3.87 (t, J=5.5 Hz, 2H),
3.44 (t, J=6.2 Hz, 2H), 3.04 (t, J=6.2 Hz, 2H), 1.79 (s, 6H) (ES MS
exact mass M+1=450.1225)
Examples 55-56
[0617] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 55 using the
appropriate benzyloxyalkyl bromide in place of
2-benzyloxyethylbromide.
TABLE-US-00006 Example Compound Data 55
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(3-hydroxypropyl)-3,3- (ES
MS exact mass
dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine- M + 1
= 464.1408) 2,5,7(3H)-trione ##STR00075## 56
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(4-hydroxybutyl)-3,3- (ES
MS exact mass
dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine- M + 1
= 478.1548) 2,5,7(3H)-trione ##STR00076##
Example 57
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(2-acetyloxyethyl)-3,3-dimethyl-1,-
8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine-2,5,7(3H)-trione
##STR00077##
[0619] The title compound was prepared in a manner similar to that
described in Example 54, except 33% hydrogen bromide in acetic acid
was used in the final demethylation step.
[0620] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.35 (br d, J=6.8
Hz, 1H), 7.20 (Iv signal, 1H), 7.14 (t, J=8.4 Hz, 1H), 4.68 (s,
2H), 4.27 (t, J=5.5 Hz, 2H), 4.12 (t, J=5.5 Hz, 2H), 3.49 (t, J=6.2
Hz, 2H), 3.02 (t, J=6.2 Hz, 2H), 2.02 (s, 3H), 1.80 (s, 61-1) (ES
MS exact mass M+1=492.1342)
Examples 58-60
[0621] The compounds in the following table were prepared in
accordance with the procedure set forth in Example 57 using the
appropriate benzyloxyalkyl bromide in place of
2-benzyloxyethylbromide.
TABLE-US-00007 Example Compound Data 58
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(3-acetyloxypropyl)- (ES MS
exact mass 3,3-dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6- M +
1 = 506.1480) naphthyridine-2,5,7(3H)-trione ##STR00078## 59
8-(3-Chloro-4-fluorobenzyl)-6-hydroxy-1-(4-acetyloxybutyl)-3,3- (ES
MS exact mass
dimethyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine- M + 1
= 520.1645) 2,5,7(3H)-trione ##STR00079## 60
8-(3-Chloro-4-fluorohenzyl)-6-hydroxy-1,3-bis(2-hydroxyethyl)- (ES
MS exact mass
3-methyl-1,8,9,10-tetrahydroimidazo[2,1-a]-2,6-naphthyridine- M + 1
= 480.1350) 2,5,7(3H)-trione ##STR00080##
Example 61
11-(3-Chloro-4-fluorobenzyl)-9-hydroxy-3,4,5,6,12,13-hexahydro-[1,4]oxazoc-
ino[3,4-a]-2,6-naphthyridine-1,8,10(11H)-trione
##STR00081##
[0623] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (0.80 g, 2.19 mmol; Example
1, step 9) and magnesium methoxide in methanol (10.6 mL, 6-10%
methanol solution available from Aldrich) in DMSO (22 mL) was
heated at 60.degree. C. for 30 minutes. Methanol was exhaustively
removed under vacuum over 45 minutes. The residual DMSO solution
was treated with 1-bromo-4-chlorobutane (1.80 g, 10.50 mmol) and
stirred at 60.degree. C. under an atmosphere of nitrogen overnight.
The reaction mixture was heated at 100.degree. C. for 3 hrs. The
reaction mixture was treated with dilute HCl. The solid
precipitated was filtered, dissolved in DMSO, and subjected to
reverse phase HPLC purification. Collection and lyophilzation of
appropriate fractions provided the title compound.
[0624] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.4 (br s, 1H),
7.38 (dd, J=1.6, 6.6 Hz, 1H), 7.20 (m, 1H), 7.14 (t, J=8.6 Hz, 1H),
4.68 (s, 2H), 4.26 (br signal, 2H), 3.46 (t, J=6.4 Hz, 2H), 2.83
(br signal, 2H), 2.00 (br signal, 4H). (ES MS exact mass
M+1=421.0966)
Example 62
10-(3-Chloro-4-fluorobenzyl)-8-hydroxy-4,5,11,12-tetrahydro-3H-[1,4]oxazep-
ino[3,4-a]-2,6-naphthyridine-1,7,9(10H)-trione
##STR00082##
[0626] The title compound was prepared in a manner similar to that
described in Example 61, substituting 1-bromo-4-chlorobutane with
1-bromo-3-chloropropane.
[0627] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 13.78 (s, 1H),
7.38 (dd, J=2, 7 Hz, 1H), 7.18 (m, 1H), 7.14 (t, J=8.6 Hz, 1H),
4.68 (s, 2H), 4.23 (t, J=6 Hz, 2H), 3.45 (t, J=6 Hz, 2H), 2.97 (t,
J=6 Hz, 2H), 2.23 (t, J=6 Hz, 2H). (ES MS exact mass
M+1=407.0819)
Example 63
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3-(acetyloxymethyl)-3,4,10,11-tetrah-
ydro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione
##STR00083##
[0628] Step 1: Methyl
2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hex-
ahydro-2,6-naphthyridine-1-carboxylate
[0629] A mixture of
6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-N,N-dimethyl-5-oxo-5,6,7,8-tetr-
ahydro-2,6-naphthyridine-1-carboxamide (3.99 g, 10.51 mmol; Example
1, step 9) and magnesium methoxide in methanol (52.4 mL, 6-10%
methanol solution available from Aldrich) in DMSO (100 mL) was
heated at 60.degree. C. for 30 minutes. Methanol was exhaustively
removed under vacuum over 45 minutes. The residual DMSO solution
was treated with allyl bromide (3.810 g, 31.52 mmol) and stirred at
room temperature under an atmosphere of nitrogen for overnight. The
reaction mixture was treated dilute hydrochloric acid. The solid
precipitated was filtered to provide the title compound. (ES MS
M+1=421.2)
Step 2: Methyl
2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hex-
ahydro-2,6-naphthyridine-1-carboxylate
[0630] A mixture of methyl
2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hex-
ahydro-2,6-naphthyridine-1-carboxylate (6.08 g, 14.92 mmol), cesium
carbonate (6.08 g, 18.65 mmol), and iodomethane (2.79 mL, 44.77
mmol) in DMF (20 mL) was heated at 40.degree. C. overnight. The
reaction mixture was filtered and concentrated under vacuum. The
residue was subjected to column chromatography on silica gel.
Collection and concentration of appropriate fractions provided the
title compound. (ES MS M+1=435.2)
Step 3:
9-(3-Chloro-4-fluorobenzyl)-3-(hydroxymethyl)-7-methoxy-3,4,10,11--
tetrahydro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione
[0631] A mixture of methyl
2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hex-
ahydro-2,6-naphthyridine-1-carboxylate (0.20 g, 0.46 mmol),
N-methylmorpholine N-oxide (67 mg, 0.58 mmol), water (0.2 mL), and
osmium tetroxide (0.75 mL, 0.08 M in t-butanol) in acetone (1 mL)
was stirred at room temperature overnight. The product mixture was
concentrated under vacuum. The residue was subjected to column
chromatography on silica gel. Collection and concentration of
appropriate fractions provided the title compound.
[0632] (ES MS M+1=437.2)
Step 4:
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3-(acetyloxymethyl)-3,4,10,1-
1-tetrahydro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione
[0633] A mixture of
9-(3-chloro-4-fluorobenzyl)-3-(hydroxymethyl)-7-methoxy-3,4,10,11-tetrahy-
dro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione (50 mg,
0.11 mmol) and 33% hydrogen bromide in acetic acid (0.1 g) in
acetic acid (1 mL) was stirred at room temperature for 30 minutes.
The product mixture was concentrated under vacuum. The residue was
dissolved in DMSO and subjected to reverse phase column
chromatography on C-18 stationary phase eluted with a 95-5%
water-acetonitrile gradient. Collection and lyophilization of
appropriate fractions afforded the title compound.
[0634] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.60 (1H), 7.42
(1H), 7.38 (1H), 4.86 (1H), 4.71 (2H), 4.68 (1H), 4.34 (2H), 3.82
(1H), 3.50 (2H), 3.20 (2H), 2.07 (3H). (ES MS exact mass
M+1=465.0851)
Example 64
9-(3-Chloro-4-fluorobenzyl)-7-hydroxy-3-(hydroxymethyl)-3,4,10,11-tetrahyd-
ro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione
##STR00084##
[0636] A mixture of
9-(3-chloro-4-fluorobenzyl)-7-hydroxy-3-(acetyloxymethyl)-3,4,10,11-tetra-
hydro[1,4]oxazino[3,4-a]-2,6-naphthyridine-1,6,8(9H)-trione (46 mg,
0.10 mmol) and 30% sodium methoxide in methanol (39 mg) in dioxane
(1.5 mL) was stirred at room temperature for 2 hours. The product
mixture was concentrated under vacuum. The residue was dissolved in
DMSO and subjected to reverse phase column chromatography on C-18
stationary phase eluted with a 95-5% water-acetonitrile gradient.
Collection and lyophilization of appropriate fractions afforded the
title compound.
[0637] .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.37 (dd, J=6.8,
1.8 Hz, 1H), 7.21 (br signal, 1H), 7.15 (t, J=8.6 Hz, 1H), 4.89 (d,
J=14.6 Hz, 1H), 4.69 (s, 2H), 4.03-3.82 (m, 4H), 3.47-3.30 (m, 5H),
2.29 (br s, 3H). (ES MS exact mass M+1=423.0754)
Example 65
Oral Compositions
[0638] As a specific embodiment of an oral composition of a
compound of this invention, 50 mg of compound of Example 1 is
formulated with sufficient finely divided lactose to provide a
total amount of 580 to 590 mg to fill a size 0 hard gelatin
capsule. Encapsulated oral compositions containing any one of the
compounds of Examples 2 to 64 can be similarly prepared.
Example 66
HIV Integrase Assay
Strand Transfer Catalyzed by Recombinant Integrase
[0639] Assays for the strand transfer activity of integrase were
conducted in accordance with WO 02/30930 for recombinant integrase.
Representative compounds of the present invention exhibit
inhibition of strand transfer activity in this assay. For example,
the compounds of Examples 1 to 64 were tested in the integrase
assay and found to have IC.sub.50 values of less than about 1
micromolar.
[0640] Further description on conducting the assay using
preassembled complexes is found in Wolfe, A. L. et al., J. Virol.
1996, 70: 1424-1432, Hazuda et al., J. Virol. 1997, 71: 7005-7011;
Hazuda et al., Drug Design and Discovery 1997, 15: 17-24; and
Hazuda et al., Science 2000, 287: 646-650.
Example 67
Assay for Inhibition of HIV Replication
[0641] Assays for the inhibition of acute HIV infection of
T-lymphoid cells were conducted in accordance with Vacca, J. P. et
al., Proc. Natl. Acad. Sci. USA 1994, 91: 4096. Representative
compounds of the present invention exhibit inhibition of HIV
replication in this assay (also referred to herein as the "spread
assay"). For example, the compounds of Examples 1 to 64 were tested
in this assay and found to have 1095 values of less than about 10
micromolar.
Example 68
Cytotoxicity
[0642] Cytotoxicity was determined by microscopic examination of
the cells in each well in the spread assay, wherein a trained
analyst observed each culture for any of the following
morphological changes as compared to the control cultures: pH
imbalance, cell abnormality, cytostatic, cytopathic, or
crystallization (i.e., the compound is not soluble or forms
crystals in the well). The toxicity value assigned to a given
compound is the lowest concentration of the compound at which one
of the above changes is observed. Representative compounds of the
present invention that were tested in the spread assay (see Example
67) were examined for cytotoxicity up to a concentration of 10
micromolar, and no cytotoxicity was exhibited. In particular, the
compounds set forth in Examples 1 to 64 exhibited no cytotoxicity
at concentrations up to 10 micromolar.
[0643] While the foregoing specification teaches the principles of
the present invention, with examples provided for the purpose of
illustration, the practice of the invention encompasses all of the
usual variations, adaptations and/or modifications that come within
the scope of the following claims.
* * * * *